var title_f30_60_31680="Elbow x-ray adult fat pad";
var content_f30_60_31680=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Adult elbow with fat pad sign",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 434px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this radiograph, the anterior and posterior fat-pads are elevated away from the humeral surface as a result of joint effusion or hemarthrosis (white arrows). This \"fat pad sign\" is associated with a subtle impaction fracture of the radial neck, manifested only by a sharp, angular change in the contour of the ventral cortex (black arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yochum, TR, Rowe, LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_60_31680=[""].join("\n");
var outline_f30_60_31680=null;
var title_f30_60_31681="Male LGV";
var content_f30_60_31681=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Male lymphogranuloma venereum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwC/dQl0OO/Sufu7dkLvhiwHHtXXeUChBXv+VZt1BncG+6eK42j1Iy6Mw7G48s7WyScGt+CYAnkZAyKwZ7d4jlMj0x3qXT7vC7M5cHDDH8qBtXOusnyUBIVv51sQMp2iY4APeuWtrhTtVj838Ldq3rWY7Qsoyf73XFaxdzCSsagdXDBQDhhjNXo8jaQo98isv9425lHBHOeM1ajeaSUcBMcMDVkM0EClgDkfQVYkjQIVCqxGMmo7ZDt+chvfFWCHRuqk4x04oJbJkbCjKgL/AHQOtRGBkViWVVc5C919qYZPKRmmB3kYHGfyqbccL5a44xz2pAUANj7QuVweCKhmm+zo8fmBmKnYPWtKBBCjuzAq55D9aqXEaMUYxgZz+AqWjRO7HafLJtQGNctwAG68etaRkG/5eCeMnvVW3MkWFPzIen+NXgFY543YzkUiXuQguHYIAS3IJ5xTo4ZWXDlDz6Yp8RLBgw5zwwNPQtgsy4xz160ANeE7TtYhhzn/AOvSqSx2yID268GpGlJ+bI2HnFJGyLkbhgdj0zQCB4l+YKpx7HiiLeX4YYHTdR5ieWSgZVPoeKfCoZ2ChsDpmgB+G3BQQrEEnHFCxNuy7jB6Lt6U1IRJcnls7c7SetPkEqOuxgd3QE4xQIcsK+f8ruD/ALPGalXIch9xXsc1WleVSMryegqVJQigvu/DrQBOF8skjlMfl70/zlCknnPpyaiVo8qcHLevBpHEavuHA6c0gWu4glLMXwzH36VKbiNk7bvTFIjB+AMAc1E+Y33Ko29fpQFritMBGDkZ9KmX7uG49MdQaqJMC2QMt2FPa4BOD8pPUZoCzJ/Lk3cNkDqPSmyDOcHA71G8zLgEBgOcr6UguVAGCOe2OlAWYg2oMKQfc03ei9qawYtuIGaa/cY46c0DsKGMh+QEgd6YwY/xEAdxxTC2GC7cn2o85gcAHaf0NAwUqBwc+560hdQMDj0OKRhzk9RUW7kknp1xQFiOcEqSMlupwKijUuvOd2M9askgr9OlV3YgMOp7UWGEa/OAT16n0qOUKGIyc5prSHPck9xUbrlvnJ/CmFheq4UfMTyfWkCkoSRk9h6U/BRt20HinR884J465oAg3MWw/wCeKnhUKckHHpTo0LOS3A75p7pwAgyO2TQFyPDMyNwMdc1LCOSWGD2ojjJGOjHoKkWN8HJwaBMB0Vu3TmkZyJMNgrjrjvT4wdp34yaSXbwY8nA6mgRBczrGBlu3SqfmlxmMYyepFTFPNOWGasCFY0G/AHpQN2SOAkjLYAPPvVeaEPnjAHFaWFB9T1xTZY/lOO9OxfNY526tFK+mKyWhVGIAAHbsRXUSR4Ur6ms3UbYNAT0J9OtQ11LUipabQdjc8Z5rbsZQrAN+ZPaub2ywur4G1Rg561ds7n5gJFG0njmlF2HNXR2MN0HAj3Df/Sr9s43IXOM9a5q0ljE25WA56eorcs5lclZGBPUY9K2Tuc7TRtRyBRjqM9alNy45OGH+yKoIobIDsuPQ08SunDM3HcCmJF83AdSDkuen+FO+1Oyncm0dPUiqv7vZy2HPINHmLkqzD1BHQ0h2LFwFaNFCMc9zVeTc0gUszKBycVKjl8LncoHJz0qpLhg/loMAYBbocetJlR0NGFvN2hA2QMHmpplZF37zt/UVmw8AGRWBXptbAFXRIWUxEuR0z1yKkCSGH94drMpByvOeDU43A8vkg9e49qF5AUcY64pELRsSzR7Scgj0oEMeR42Y4LD9cVPbMkozhcgdKg8wkM4TnORn+VKiLlj5ZQnk0AXtikAxgbu2ec0m9d+/vjB9qrLdxodo3ZA5HUVES7yg/dJG5M/yNArGjLuIWRTnHPy+nelEyv8AcBYleOeo+tU4mLArI+WH8A4H/wBen+Z5DDhfLbrgY2mgGrkhkcE5/DHJ+lPi+WTcfmA7k/1qJn5U7VHpk02QOTzhVJzxxigC9LtmULyrdQ3vUTQ7lGXbIPPNQRl0bKuSO2eakPnMwYMig8EYzmgAZSowpOAeueaerIVGMkL602XYrDL5ye/FIULkBcgdc9B1osMsq/HO3aBxxUUiqQGIIOOtRhGViWORTt+FyQSFpCGq4xhSfcmmvsYrjn0Peldi3IRlpqjCcBiTxz1oGIWkzkOen3SM01nZiDIcL32jmnD5M45pjM3ABAA6mgaE+6o9P880CUBc7QGNDDcPmK4zwaglGeUb2zQCHM5K7gpwT1psjY5Ixn9aD5jBWyGApHcngqcA+lACZ2DcevrUB3O3XOf5VMBx09yTS7Du5HXoBTAr4YrgIdpPX2pzR5yR2/lU/lkAkkA9cGgMenDd6BEIQo2Cc8/THtUhT5yE+h9aDEWK88DkjFTrjIONv+FAEcXX5VyOmTTmXggfe7YqYhQQADg8DNNcSbsKN3bntQIjCHgn0pY1YHaAd3tUojO0BmDH096WT5EIyRxzt5oE2Rog4JJJPqaQ7eRng9cCkVSjZU7i3XNP3DnPGORigLlcoQQyAgGnSMoOBjI9eacz5z3bpjtVdskdMZ7UWGccp4Hp61Io5yc4qrZyBkAc89xVpOc8g1ZRBJCNzZ9egqheQhJAxUmM8fjW4qbk6dRVO4hIV+OT29aTQXOeuLTIYpu574rK8s2rH5S2z7uP5V1bxkxkdQOMVk3lvk4P8Q4PvUNGkZPqV7ebeEY4KgYIHUVowyuFDrKxCEDbWIMRtuHyuOD/ALQrVsp0kOGYIxIyKSfQprS51WnXiyR7gfmHUd60RKGVcrnPX2rlbUJ5zhXCtnIx0Na1tc3AYB1UrjjmtE+hi0uhqFMSb92QOCoNTKVIDRtu7Fcc49qrxSK7fOAGPFS+V02nafUVRI1tkbMroxB6YHWopblpeI8LtGBnjdzTXMiDNxIAnTOMH8agkdLdwVZpowRj5entUMtI1baVJcq2QR2K9auRRjfvD7CO6isq1vIBnY6D/Z9KlF2zSAqQAT6ZzSE7mujROhMjnPXlqY6MpymAhAG088+oNVFIBUgbjnJyOn/1quKhbqEB6470CHF5GXEYGO6mkjaaQBVAwOGOOlPjDLHhe5zmkEjFiWwAeNwoAe0Q244Xp+NHlgspYMSP5U15dybUCnPTn9acsgCEswBPfNAEc8a71IfaBwC2evtSYd/lZio/2jUqOG28lW7ew+lPEoYHcpC+u3OaAGRoyg4bIHBB5BpxJx8kgPcg81IBHJyoyw7D+tGQsYG0rjsaAEVlc4jwB3xT1mCkrnGOvFUlmYEHY2D1Cjg+9TST4U4Vzn0HWkOxZWZGZmPQD070/c+CSAue3ce1Ut7iReTgc4P6UCSSdlVQQvU+9MOUvLIpUliVBHSkeRAcAHOOwqOOLs9OUKG2q+73zSEOQ7Thuh796YZBuIx+PWlkODhcZ+vWotvVsBjn8qAHbtzDac/hSMgBI4z6ZpoOMn5vp2FOVtxAUFse2M0AMcHnAHHHHWo1Tdl8Z7YqwULnlCAfzo2YbbkBegA6YoGnYiRWKL0A9/SlCqNx3H6YqZlAHAx7UmzlSoOcck0CK7qcnCgnHFPiUheB71NtAyTJnHQAU3YSPlUj3amJsj8sMdzEHFGQc7VJPoalWAY+ds49OBSiNNwxnigEQrlfTnk4qQoACW4xTwx/hA9jTTvPJACnrnrQA3aWYfKDjHT1qUrjBboe2aQPsG1QT2zTTmTjP09qaEwZu2OBzTQwYjGeevenuuAA/pjIpp2xZZRnd+VAiF03n5eCOppDGqKdzBj2Hepd3XccY7AdapzH5mYqc+1CFqyrPcFXKrkZPJFHmHklgB6Gkdd75wKc0YbsB9e1DLOBtn3SfKccc5HWtSA9MdD39K56wuAJAOvv6VtxS7lGORRF3NJKxoAY4znmn7Acn071CsgZf1qRCRgj7vpVmZSnh25IwB1qrLGHQ5Ge9bBUuHVQM+4qmU2sQR06UnEaZy9/asxLbcHOee9Z9pOI5zHIpUtyprtZIwwBI79KwdU09RIwxhScqx/lWco21NIT6MS0uvnYP8gBHIro7KVWI2uB3HeuRBlVdpTcAOlaOnzGMhxgZ/hpQepVSOh10R5Kt827nirUUzbyrDO0Zx6Vi297G4GWww6D1q/DcLLgMNsgHBra6MLGojRup3AEHqGFVri1jaMjHyjlR/dqGKVhKVJC4PpTpZVO5NzbhwdppBaxHDbQkZZMHOd2OlWYkjZvuqSx4I4qrOrEBySvQgD+KpLaRQyBzg5ySP8APFRsXvqaSDYNhbYR04zmpQJ1zhgvrxmqc9xtB8vDDGODSpLKkYBYsPUnrQKxaMrDKF2XPPamlwI22tz6nmqqSs7HcvAH1qWR4ggZgoHpjigCeBJBks4GRkn1pC0bsAxyAeSetZA1AiWSFmYoDw3IIFTJtlH7s5AOdwOTQVymktxCjFUBLdQccVYS5Lr9yTjgkjArOiaPdtO9W7gf0qTzUVR8+4njb3zQJmiLuGIMQuXPBwaWF9zjdnOPu56Vnjh1AbhuqipUlIByFHr9KBWLcnKgqfl9qagIX73A655qr5hfiNiuRjHWiFJmVcnjNA9bE77j1PHXpViIqv3mYk8YzUIVt/zkjtwOlS4z0IGOCSKBEgA7KOnrShhtUhscdajEbdVIwTjOcZqVLZ34IQe5NAWRHlwPn2N6c4IpyOHGNpA9xirCWhAAdlHHQCrC26BCWZs/XpSFcqKqDncpY9j2pwA5Gc4PGKsRxwnO8bu4PWpC0K8hR+AxQFyqycZI2jPepI0VBjaygdscVKGDEqOgwelMdgCQSc9+eaAIZVZuEG0jnPrTdh53OOnpTshT8o69eaAduC2N/bvQAiEDPlrkepPFJliwBbjsAP60SuWX5VPFKBxl3yM8D0piDaQST69M5zSYbnAUZ5yTwKVpDnEa89iKZIWKgbsc54FACAOxOOvrTtuRwx4PccUijaoD8/jSFtwx056GgGEu0NjGd3UCmgnIwuB2zTt/zEZAU+gpMgOSQfpQguAJbBc8j1qNicE8nHakeROQWAbrioWkZl46+g54piSAzZAzwGPFV5MseMhOnPenbchiThh+FKjrsAHC+vWkO1hkMW0ZZhn2qCeQKxwOfU1MxB3EdDVSQjzOefrTGtzyOyuSkgDkbgcf/XroNOn3uVJ47Vyuof6O3mljkcGrOk3nmIH3/P29qyTsdTjzI7e2faxVgCT0q4pGCPesG3uGMYPUgc471pWsrSNt4Axmt0znasXUbGcHvUc4Bwe4psDYDE54pxYSjOdvoKZJGAFdt33evXpVPUYPtULKG2MvpVufiXbgEgc0SlBKpwDng0t9A2ZzF1ZToDtkO7+YqOGQK+yYYboM966GeESF9jAHGKo3lj5hjAjG5ed3pUOPY1U+jHW2GwjYDj7o7GrschXIO5XHO3sazdvlBUdWZQc1YjQzyIHJwPuk8H8aBWNC3vhPuwcE4Vieo9xWg0ce7cWySMMc9axJrRIIt7gNt5Ddc02K2u41zASVP8OSOKYrJ7M17i1QQERyOoI4YNyD6D61PasIFCgb8dT1NYZuriFhH9nkLEj5sZB/GrNvds+5XWSPB5I4zRdDs7GwLiJBuJbJ9BSS3LyDEXQ9c8VBBtG0MGfI42irRHmjAQKuMnnmluJNIfbFyPkUf7TN/hT25I3lmI9eaiRAsnG5V7DPQ1LHuKggkEnNAuojKpdAdvAPWoTEmWMalO57c+1STfMw4UYzznNNmyWj55z0I60D1JLRHDMepIxz2FSsFIDBetNWYZGE4qaFJHRt4Hy9DntQD0CBdp3SEDPQk4Ap8qRngkAnjIFAg8zJdm2+nUUnkAgrG3I/IUDtccAsW0IfxJ6+lXIJ3ZggUY9TwarRxSdGLvH32oM5qcKrH5J9uOoJwR/9ekhMsbzliNxI5xjrT4CJPmYYA5AzmkSJWDGSaVjx8xbgUqRBSTCpxnnJzmmTYnB3EFVA+i5qaIMCQxfB4GMU2HcSQ2ce3GKm29iygdznmkDEJAPXHb60qjjcF3Z9+lOG0KPlZ+4x3NAVgWzhAewNAIaAQ3rk/SnRxnJwAB9aURFWOfmOflJqR9xXgqG9hSAi8piCM5JPWmhY0U5OSe/enfLuZXck+pPFNleNDuLDH86YDZPLxnbuxzhv50yIYKkKM+tI94h6dvamPKXI7479KBWZJI/cLnPcdqgZQHLMSx9GPSlLgLlnC9sVXlnROEO7FMaj2JoxtGB29zxSTSBEOwkkdSapm5JZunPYCo2m24xx9aVylBl7cwwWYnAzjPX8KSSTA5OAcVWacfe3DI647VUkuw3JIyDmi9g5GzUEq7ccs1QPK25uM4I6HpVWKYsoYg5xUnnDhQMj+VFx8hIB5gy5GM0gcxoSvyt7d6r4O5gBgd6YWB+XLFulNEyiPMikbI/XPPrQ7BUCjAH1qIR7BnOT2zSOd7gAA8daBAWOMAkg1C/JqTymH3iff2psinbhAu4evSgrQ8mu4VlhlR+SAa522l+wygs3yg4AzXXXVuu5kDgMep9a5vVtIKrvByAehrM6Y7HRaTfguobhT2z+tb0UwilIXJBPBrzC0vHtnw8nK/dNdXpuqCeJJU+cg4x61UZWInDqjrY23O3qasxqoUgE1jW115y5YlGJyK0I7gblRxz2rRMwa6C3DENmInceDnsKsoisAp5LDrVZHAml6c4Bp6ymPaDwCMD1oATASVS33W4NOl6BQM0s7+Zbtj5dvJHemxOJItyHGaLgxkSk5YDKjr6CpvLV1w2QMZBxS2+IkEbg7cnJzVqOPeNwPQcEelMV2mVViMmEkcGPPGe/1q3B8jbVbcp5xntSNG2HAj3Dtjp9aryOLderbTgbvT2oDcnMiBzlQU6EAZxUJUTTq0JX25/SrCXCugWEASA7Rim3NtJJCQTGcnsMUmUnbchzKh+Qqx3ZZR2q/CXKYDjL/nVWytJrZCyndHkfL3H0q00qNLygUnkkUth+g1XnUZlRmIOATzUvmFmAzhuhBGMU9Y0CByzKe3OcVDGQ28EBsZwxPNADgWkcqvzAcHNSRW8pdvMwwPAHICioreJllJ3MB1OT1rUiYOdqLz3BPIFIdyCKGdnDFNyjI6cVaihdfnYFcdjxxVmBlVD5knHoDTnhUkNIxAx0PpT6EN3ZFGiFc7sZ5xjrVq3tRs3KeT+lRP5cWTI4ZcDGBk/lT45YpQCxMQ9D1pBfTQsJCHIO5gp4x0/Gl8uB2AdVfBxkjNORY3Xd5sjZ4+XvUimJWG0c9t1DFcQQxAjZFgY5IWrKsoXCgkjt6VCWA4BIxgjFO/1bsT8oP3ST19qAJ9ysvKgY5xnOacAhGFC7h36YquZMkFOfr3pru20liN3U44pBYtJvK9VY+oFNb5QPnBI74qOFj5YyQARnNMkxuG45296AS7k3mNwdxIz1qJn+bjk9s96iaUlcxJkZxk03IGTIwz1Ge1JFcorTFiVCjPQA1A4IG4nLZ4yOahe6iDsevYc4wKqXF7lcKT8p4xSui1Fss+ay5yRgHoetQy3ZAcIRt9R1qj5ztuLEetVJpGHAIb+VK5pGn3L8koIOGyO+aia6XCgMfpVITBgN7LnHOKY1wu4Y+UdDSuaqCL32jdjsvbNMeYYBBJwckelUnnzgY3D36U5ZRuP3iO+KdxcupYaUPk79oUfnT8LkDOMg5PtVKSUFVOO3THOKDKScqM98elBLRcDMG2ryPY1MxYHB/IVSjfI6471ZVgexI/WmiJEwkGOeV74pBwP3f86jjAJyBwOtSEDA2kepqzJkiDKksSPpTht3ZXAPf3pi9OWyB6U59gO5CSfftQQwLAJgct2zUJBJP16UO2CGxgnv6U45bjdgmgLHnmoWw80cjDDPvWdd2m+IIvPHWt+5sSxaQvkg8YqE2BVS6nn27UnHU3jI8r8R2cyPiPoxGT6VDo90+nuBJIQyNjH9a9BvtPWb5JhuUAnJridZ0G4ku90R+6v3f7wqLGyaZ0cPiGMx7FwQMEv6VpWWspdCLykZHHdjw1ecorQ2zDJEeeh6g1uadqsS6dHGoPmxyYHFK7QOCPVrbaUXAByAaJFQPtPC561heGL53jVJDlsHrW55mWw4GW6itou6OWceWVh4WQhgGxjgN6j0qsUa0YYYjeQBxx1q9uCuM8Ky49qbdKk7xoW3BDkexqnoJMkg2jcrnr3Papo0CHAk+XPHvUMCnaRKNzZz16e1StIXGP8AVup49cUIRbibcuGPtzUUqo4EUgIy2RxTmC7FwmGx0B/nU0EUIi54Yc+9MRVjs1jPKAvtyB0x70+KRijLsOTxwOlSklQ5fJ4+97Uk85REaLAHAPu1S11LWokt2CCsjGMAYBxUYSIxfM4Vcdc81HukbdypB+U1FcWbeaWSVgABlG5/KpbLUUTQWyOx2Sv5Y5Bbv9atLxuW3kVh/F7VPbn90iSRoxxx3zQ1rFK7Mpxg4wBwKBdRiPHE4V3EjkdFOf16VOgWQb8jcP4VOfz9aSOJWd0KhWOACD0/Cp0jVQBGoR14zmgQ5UJIACKO4bPJqR4UYATl89ev9KV0Z49rvtJ5DdMUkKmNUVz5j92PFMiw6O3O8qAqDHXuav29uSFbdkgd+1RM7MgY4DkcYXqaTzVSQB2KtjjHWkPcuMrIpA2cjnmmGKPZubCgDrnBNQKN5yyFB2ycmpYI2+QMQRg5z6UA0JM3y4jaTaCMN2NPdwWzIW+rdqlIUc8nAzyeQKRnhAzuXBHFISZDuIblWfI604xShCdygnjBOaEdc8YVT1J7/hTF3Kp2tgHuRQUSbpECj5d2OvaneZEAC7lvUZ/Oq6W8sgDO+0ZwRjip0gWJV24c9Cc9/QelMBqsrD93vOO1RGIybt7BRjpU8jsWwFOMZwp5qjIJW6FlyeATggUWGkQsgjch9qE8qW7+1Zd7KIXIyCOo29Dmrd3bELuTe4AHzZ5rLnj38nG4cHvmpaZvG3VlVrwvIBkqp44NNYPIrYLe2a2dG0L7fMFXp/KtvWNFttNsC3LSgArjjNCpNrUJYmMXyrc4YI6sVLHnoSaew45JJ9PenXt0qkEYwDx6VnTXRJ4YqM9QKhxUTaLlIvNOoUr3Jpkc3zZz7YrO84tn9QT1qWOTCqGIzjvUXKcbIvvOQx6MxOODUkIZRgk7up9qogkgg8EjHFaMEW1gSSRirWplLQsJhjg81chC7Rg/N0HFV48RR7sfMe1TKG3Dj5evNaI55MmBxjtnqKMkAOfwK0mwgbnPNLKyhPQdhTIG+ZnkZ/Kk3kkDsO9JHycryMVIqsDgfMAPTpQAgB6HJPapFXKgjrjj2p8cTM2WIGecCrNvDGAxOQMcE96CdEccVdoyCKNoZcAYPeraY2M+M+gqJ2wqjGD2rQVzJuol87aF6561l3lqDhjjK/KCBWxKS7ZIwwPFVZQDbkSZTDVmzSL6HnGsW32XUkDLlH59s1l3MxtYo/syDe0nGRx9c12Xigx29i00o+XcB9K4W6uC8J2Z+VsjJ+9WR1w2udpo2oFiCcJPFgtjpiurlviTHJwG+6fevH9K1UtdS7g29flJ/vV2thdyi2QuN75yfYelCfKTOFztLW+DMqzj5M4B9KmtpQm4AhlbIGeuayFmBjUrHlTwRnp71HPcI9wu1yoUYweK05tDHk6HVwMJSfNPzEYwOMVHdIYpgTIdu3qfWuduJJYZAUkfaVA3dfoabaX9xdwusw2svTPHT/Gjn6MXsnujrI5fL2lyQCATj+lTmePzFSNgF6nP8qwrC9aa12Y3SZwGbjAqVW2QHemZHYtlBkLiqUhOC2N4gPERuBLHgDis5mH2hBM4ODjJwOO9RpctcQJskB7MWGCv0FYUqGSfy4t20tksxxx6VMpdioQ6GzFNlZ1ilVEB+oP0p2nl2aZmbdIHwNx+6PWsy2nhS5khjBZV4Zh0H09a2Vg3gzxBQ+M7QuM0ty2rG3EyLDu3kjviq5nDM/l7lx1yeM1QUs20YII/5Z5q/bR5QzBBtHJHp/jVLXYjlsTQnIYkkher4wc0SyvJwJEBA+9tyaiurkRAvFgsy/cxgVXgIeTMpMa43D6UrhbqWoLh1XErlgGxx2rQikhCFl47Fs5596yikbDasjANyc9KT7JAsWd8nHX5qolpM12uy5A83gdMVAJY4iSrbgPTk/hVKO3CmMofmJ6EZBFWlVwyh0UKO23rSBJInWdpUYKWJPTtz71Kl1K65DhVxkDPPpiqrGQ7gq7T6Nx+IqutsjyeaUHmAYLk44oHym15y4IlJYnAAB61LCsfl5Zcg9uy1hk7SckJ3DA96sRvNE3OZUPXPGKQcpqs+XG1gCRyc9KeZUgi3nAVemfX0qs0spjxFCB2GD1qSK2kKMz7Nx7daaJasWBiWEOWcqeSETk/SjyZgpZYpGYn5M85q7BdRwAOrFumVA6cU1dchkLSEsEU8KR94iqsjO8uiHzW5Fn50+eAMbB0+opsqWn2YNKdreXuUk5Lf4Vmz+I5kg2xNGpYnoeRWHc6iZJGBYZ6k55NF0Eac3uS6jKq5EeFXGO+T9azBOzN5ch5HI47VFPdKWwWLHp15NZ9xeANls8dGNTc64waVjpNP1abTs+WVAPfGapavrtzfBmnct6Z4/ICsN9RUrtDfP8A3RVOa4RXBOST1oc9NAVFc17C3EoZi7YCnt6Gqk0i5PPA565qO6n+f5doB5FVXk3PgcDHT1rmnM64Qsi9CQSCchT09atRsGOFBZj0xzVO0gaXaBnB6mt2C2WJQEAx6nqTRFN6inJIltotiDed0hPUdMVaULtAbGD2B6U1UWQ/KgAXg5qzFCGJLLhc8H1rZI5JSHxhQByC3ap42IHXIAqnlI2OMDuMd6IpGZQoJ+Ynr2qzNq5aMh4yeeuPalXDgbup6CodwAG3lumT3qaIZfjqRjJ6UEvQmI2kc/h61OgZVO1WIPXimpHkL0DA9T/SpogCuSSSD3P86BbjhLChdZJUWRF3MAeVX1IpbPc8IkWSOZXJKMg4Knp+NUsTWF1cMkMUyzt5gYyqjA4xgg9vSrOmIbe0O5otzyM5EZyqknoPpQZnNo+VwBgDtTrja0BGBu7e1V1LDBJIFSljkY/GtLjsZErOHVWHzZzzRcqJYWLblIOMgdqsXw/FxyKpO8hBGeD6VBotTkfGtvt0t5FUug5Yf1rgJEVdP85D+8+6R6n2r0/Vcz2NxbPjnivN7yzks7uOKViVDZyOfxrJ2OmF7WZT02OOdW+8so+Z2A/Cuut5iltEA+1mG3k+lcFrE8+lXbLFIXRiCSPT0rRstW3MyzOVwhK9+aC1rod/ot5m4iG9tzZDBjnNXL66gJYbwMN5YX+LPeuJsZw6WzwTMsquGbb1xWskGPMmaR5U3gc8nJ6mkmDjrc67TrtnVoroD5UwoHQjsaSKWKGXyyyksPlBPf0rkbnWZkv0VifL27QQOw7H3rRtLK71CcOCAGBKv347UXvohcttWdTp05huEiaQkYI3+3pW3b3iwnarKzMcbccY9RWHbWJjhiZ8EqMnnitWNYsrvhdEYH6k+taRvYxlZjIbdp4Zfn2sXJzu+8BTbSOXczp5fOQCx5+tWoRmEyFNsaA5Hr71Gt1EWCqUhiJD4Ydfw9KNOo1foaelwRtAu8IuBj6+9WvLjT/VSHC88YrOtJ4lZ1SVXixwqL+uakkZ2bbCAh4YMe/4U01YTjdmiRGU3CRVdhwwwTn0qt9rXypAzncnUE4X6D1rMdI0lDzu28DjB6e2Ku29vPIfMm2I5G7a2Tx6/Wle+w7JDYeWNxOQQemTwoqWSMgq3mksRkYwMUy5tC6NvVmYDpn+VRwRPgbSgz6noO1CQXL8FyFGXRB65Iz+BpY5xLJuVDgcfN0qpukiK7vKI7YBPNXYjgq+53Jb5lCYAHt7VWxDJY5GeTIBG4gDB4Aq07S+Ywwp+pNRjzUVQgyN24KVwB70rLKrq7uCR8pX0/GjQRIkxXKzcYGDjkfnU0MsZyAhYkdhTEfdhUbtggioxOoDRrJjnIOOfz/pRYaLCoChDhQSeV9fxpTJnEKgHd/G/b1qo0r5K7st2bHb3phlPlKpJZMffPBP0ouhpNmj5yQkxmRsAHYc1WubxCc5fKng81nvOMZdnYerDJJ9DUE8qudmSQ3GCe4pN2HyFt9SdWYorYHHvVafU3ceUdoUcjmqrTbIsN9APWqjYkDlyAuRjA6GpbNVAtSXDADoT32rVSSYu3GQTnOOtMLO75LhlHrVeZ/3jHOAQMk1LkaqKJnJHA49xWfdSsckDB9qfJPu3KPmwOoPAqB3ZUBY/L7VPMOxAXwwO3BJxxUc8rBW3A5qWZUYjkbTk5HWoY8OxRBk4we9Q5GiSWrK4WRlG4YIwMCr1vbOu0Mhyx5x1NWbWHbIAPnfoB6e9X7W3nmmUwruKtjd0A980RgTOp2Hxp5KLgIpIyVByR7GtG2gkkGWVgp/ibrT7TTktyrTOJGU5XHT6+9WZJwu5TtHOAPUVvY5XK+wYVVLIqjYdvr+FQTzNjDnA7dqbJKR1O1OwPes52WbJYsq5wCDyaTYlHqy60mCS+QMZ3Z7+1IkrbdwyBjOR/KqLHchZ3JcA4HaprdiCC3XrtouKxqRPg7pMDjCjrmrkDHaH4A6Y71nxEE7mOQTwcVdhbdtVAee5q0zJ6FrJfBBUqD3FXIk3kE8EnoKr20WH+bp6e9XDCbiF1O5FIx8h2kfjRYzlIyfJiW/vBdaVcXId9yy+Xu4wOBk9BWnpyxfZyI7Q2yAn926bTn1xUI0mIn/AF95wOf35qxbRraDyEaVuuDI25ufeq2MzkUMbKy981HIjIOGO05+tNVw7lSMH1qWMEMAxyBTLWhVmw5Abt3NUJEkBbYMjNajJuYgdjmqNzmNjjgEY4qWaJmXdwEuWwM/xEGue1rT4HhZzESy8jFdXKxAII4bvVaSDzo3jzkN2rKSNoPuebahonmRpcKFYKMEdsVxmrTJaX6tGqALwVzk/WvWdYjSC1eIjawzuWvGdetJjqHmzghRzu9eeDRHsavujoNG3XU/7lyrtGcMON2O1ddotw48uKWbKfekDDgEe9eb2l55IiuIpNrx5DLjA69q6/Srp7mIuRksRwvYHtStYtO6O1sraFp5ppkDRyNuBxkmrUay6fdHacRcyL9PSsO11iS32wOnzZz8x4q7qF9m8tRJ9x85Ab7o9KEQ0zYkvxG6xTbl8w7gT91q2Y78G3fMi+YF65zXNzLFLsZzlSPm56egqrcE2U4ZHYI5zjHPuKd2hKKZuPqBlWXyiZOMnbxxUPn3Nx5byJ83YsQMfWqmnXsVvfCIt5nmrkk8D6Vo3F9DbwN9okU5PBBAyKjfcq3LsjRtVMEQMjZZuDzwfap5dQ24KrvGPLBBx+QrEW6U2wnk2eUOcE4OanFzbOEEJHlqMj1zTvoDj3LS3k8itIYF35A+boB2P1rWtLmcjbcZYdPlHOa56K4mjl2Iu7B3HccDGK04pZd4bLKeC2BkZqosmSVjXUfaAC5kJU8J3qTZEpAU4k6L3GahglI25wJsHLZzUNxMkgBTzAhbaG6D61psYl8MVYLuWRu4x/WhZxAX3sdnA49KrwCRDsyN2M7vWpkkijjYMSGzkHPemwLVtdyO+5GiIAwoPIpxuH85SRwowO//AOuqcMILttXOT94cc1aQMB85UkDk+v1o6C2ZK7gMXPOeS5qlNu4LF9hOdvrUsjsSN2AM8KO/1pJWyp24HYAjikzSKEPIxvYA+9ICQCS7MvsKru+1eQG9hSPJlvlUhcfdznFRcuwyWcpIHDZGOBjg0ySUsGHlgAchgcnPrmq80cu7LAJEegJz+VU2ZvM4A2KcbtxxU3LUUXBKrSRmUnPT61LJIpViAMdBWHc3Esi7NgaJW4BOCfc1Cbx1UK/KHge3tSciuQ1JJEAK/wCIqHeApZgN/f3rMa4kcgRhQo7k0SO2QJHBB56VDlc0SLjyr0UY5+6BUEh3KwByw7D1pTFI0Y8pAM/dXOT9auWukzzAB1EYGMnPWjlchOcUZio7nLlVBxkAf1rbttOuLhsELBGMAgDGKu2umBdpyhZfQfzq/ZxLb4JYADkHGe9awp23MJ1b7EFtpaW+PMBHPK55Naixts2ttiUDkDjA/wAPeqM1+sc6pGjMSc8c5/8ArVFfX4EQPmKXI4A5OKq6Rnyye5dkdBGqRYG3jPWs2eVVDMTls8cVVN8zL5cSs0jHkgdaYGEYAODIRlz2FTzXNVC24txISyhssSc4B6CqlxLgsSeAOBUc02zc+4ED9aqbSzJLKcZ6A9h61LlYdjRgJdDt3c4JA9K0I5AXRUQMTyxrP05JruQxwAqucM9dHY6XFbhQg3M33jmrjG+pzzmkOtLKSUKxUhSOlasFtt8pVQEZ5JNWoVkWNRGE47d6dAQ0mG4xxjbzmtbWRzOTZZhjRAcD8PelZ1xlQd1MUKS2eTnk0oU5ygxxnB70rk2I5bmOBZfMmjRYwDJk5Kg9PzqnaEyTeYbkXEL/ADIQoAA7DP8AjUFxbtHqYSSa12STfaQjNiSRgvC49ARnNXtLjEdkWkkikkldpj5fKAsc4U07CvqcTcECTPJ3fpUibsEY5qN2Dy79uCBjNWFfCcd+vtT8zTZWIGkKyrkfeHaoZsSZU8DGQcVNcIGGBx6AVEMhtvU44pMqJnzI2AvOB1qq8jI2F7dyK03fK7sE+oNZNzN5UhDjg9wKzkax1ZieIE86KRwR5hX864HxIIv7N2zIfMXA44+XvXpOoQfaICU5Udcda5zWrCK5gIGCR90EdqhM3XY8dlgJnAt8vBuyHPoa7rRbuODTHQgYUY3KecjvXPatZGGJ2QYMTdB359Kj03USqSxPFgbs5HHHcCq3BaaM6u4kEk4dpsy7dyDPAbHSoP7SZpYrc5eduCXP+rFVXiFxZRTRKGEjdm+b9KrQ3MNnd+e8bOjcOzdRSZaep3Gj6gZNNdJh+93YP4HrUsl86T72SRigy2ecH1FctDeiYPJbHYHcgL/KuiRGFqHZRuD5dieOn649KkZZW9TyllnRlCjduxV/T57S6PllRIcBsYztJ/rWXZ7J4Ps6MofnO4E5q9ZWLLKWUor7s4TgAUWDQ1NSfyI0LKVUggLt754NMVmWIIpXzeCxC9fapNT3IiyFzJ5Yy27upH9KqJqZW4JEYk+UYAPGPSoeg4vQ0beeSFx5cgkXGSWGPw5rWtdSEi7JGYgjbgLmsWyf7RNNujKjG/ZnnPvVmeWS3kWNMg7d24fwmqTa1JlFN6mvHfk3KM0bgEEYx+Rpxu1zhZDhWzs29/aslYpJQsiMVXGPm/jFWrKTh41iKkcHaueapSuQ4pGpbzBoiziUOezZ/AVfghQMDLln688gfSqVl5Z4nJEi4YIAeK0BGVOUwD29hWkdiJWuXE+VPl2kddo4pRKDIM5xjJ9c1TaZuRtDH1VqVXJGWi/BT0/GncnlLJkRt3Bx71XOWZlCDjk8012c5wuTjOCaasnLfJggDB9aTZSQpXaCdw+ijOKjlkCn5ST7Y/rTi69WGFP86hkckkqj4Xpk4FToVr1Itsr5ym8dif6Vn3LShyoUhVPIJ6Vbkmk5BRR3A3VnP5pz5cZB5zuPJGO9RJItMimlPOzcB0OeuaryfvJRCAGY49h+daKW0UfzTu7PjJ2jv7Ui25LA+QQhXOSfm/KhRC/YjitooozuIdiOAozz/KlhsTK+8REBD1PP4+/0rXtlibDbm2KvG/GAe1OEgWNvvEsOVx1z3+lXyoz5pEcMMVvIBIm4n7xJwfyqaa5ihPyrgDJ28jj2qoZghcRBGwOSQSV/GqUjyzK2/HzLu468fypOdti1TuaQ1K4QAeWuxz8rA8Z9/So/trNGIg6mTGWB4/OqxdZEUMxy/DAVR8weY292Xjbgc8CpcmWoJGql9tVRGATg7nA4/OooleUB5CSh6HGOPp6VXi2OFJ3bfVjx9MUs7qF+RxjoAO1HqGi0Rba4jTeLf5iRgnHQegqhdXGwA/ef0Hp6U0zhI9q9T6cZquxCqXdd/UUm7oFoDPxmQEd8UyESXU6beEB5znBqMlyfu5UDJHrW/osEhAZYw6kdSenpRCPMZVJ8q0NPSYVjZmQgHIBGK2rYYYlnGfcdKoRxusoZ1AbI6dK0UfynYFc9yRXVscTdy7CjOd2/qMYHHNShWQFtxZ1GCQKq20pLqdpGeSMda0d6tGDnHpSuQxI9zgsSEJPP4VI0yxK3zAcfXNJIcKdwDDHJpEZfLycA/wAqkFqY06zRX/mraSzK1yJxJEAWK7cbfXj8q09HtjBYlZVWF3keQRKc7ATnbWRNHZDULx9UaWJ2YGP5nClcDlcdTTtHT7Nd2yxfaMyCRnWTJzHn5GOejVZJgyoAgKjBHUUxkZlyAB+PWnythj6GljkBj9yOKDXoUpmkAGeP14qQgMUZOw5FOuQNmAMnGT71UgZgowSCOCDxxU7F7jt+JCOuBn2rPneNidy81pvGS+VwazrqIKzmQfd71Mtiobme03lBgoBwOc1m3kfnOrDGw9R/KtC4KyAiNRkdDVOTDKM5V+hFYts6YrU4/WtPAKlY0IDfMPrXFazayWa7vKyGznHb0r1G+iZFdJIywcfeFcBqdteNNLAwjwOhY8YpxZUldGRpczom5FkXAzjFbdtFFqDZwwLDdjOawNTuJNP8gxzMQFwQcEVNpM1wjxzCUCORd2Acf56VbXUiMrHUQWTWU6sNrRhfMbnpjrU5u5bqYhB+5IJyOgNU4XM8hW5YRpIoYc8D6H3q1DiORmiAaMKOB1zSNF2N+2dnACpmXGOT7VZtpZQxBVgd2DjkciqtgsVyhEzKqoQM8g/QitMLItw0kTKIx/s8EVDVwv3NqWBHhj5BfbsKkZyKxG0u7jkElvAroc4wcsB7VowF3aMTgFx2HBH1raWV4IgyoABx607J7k8zjsYUP24Zd7UkjoehHrWnDs2AyHABGSTnrxSSXDMxL4SPGMZ7mo1MawHHVuq+p9aS30G9tTYiELSbdqsEIClTgH6VKrxiSNlGxtx+YH3rPtXXJLKFBPOf4atxRRNJlinXg55rRMye5qAbHBUnc3XNS7SQxLAgjtWdbhzMCxzhiqg9+KsPKSSAdwBxheBTuImAGNsZzg46cD8aVAwJG7POOlNikHTbznBPaneao5KjA96BjdhDsS+1vcU1sbCS7H60gdVYbjw5yM1VeZQr7ivyn17UNjJbi4HlcoduPvdqqrcuRhAxA+YZqIyrLL82Co/WtBMsi87T0/yKkexnyJM24/MXOCcjAxTnTypTkrID1HPJ9q0nk2x7UC9OpHU1QAwrKxyScfL2z71MkOLuPtnCIS4BIGQdvenSzrOATjjpzwPY1RZZRnCu6gc89D6023ZoZB+6Lt975ug98UczL5UXnmjit3GxlwMcdORVKS+jjt1QPIHUBV+bginyu9wwEgPlg42jnJ96ozhdjFQAQdp9sUpNjjFdSdZ2DsCMEnLcdR6U15RIAq4Bz0zjNVog7SbVztXgAVOYwCPNIBHvzUJuxo0kSG7EK7ozlj1JHaqkW770g2hmJyfSpWkWP5UG8t6dqbMzMBlRt9O9V6ksne4QIQjYQ9T3qs8m5TsBAHGaicY5PHooommWKFfMbCrztB65pt33Fog3gLuc4xkZJ6/SqslwJASGOxTwM8n2FVmuGunIBBiIIBHJz7VoWdmfMiwjlc9xk496lJsicktC5pMDSKCwOH6ZrsNJtVjLBgSgGQRxg1S0/T2+82dvTC9hWnGht5BjJAHyjrmuqKSRwzlzFudVYqw+TaOgHX3qSNHYqxGD6npRFvYEOo+bqBU6NsQZX5j6DrQ2QSRLgA5J5yalRS0udvydfSo4cZIbIUcg1Y3Z24PQ9hSEKFUv1Oe+OlPVRkc5GeRjrSM3U4zjsOtETjYWOcgZxTQjEvprn7XMTeyW8UdykJRAo2Kw4fn379Kv6M7NZP5kzzusrxtKTnfg9R7VDMZ7q6u0MtrboMR7JYgxkXGckk9KsWMbQ2iozRyKpOGhUKo9BgUMSOSmjBQ5PXsO1QplSAuMelKJv4SR+XWmTAbgwYA45wabZpEkYYU5zjqPas2VCrlwpK5q60oKAMaQbTtUZIpNFJ2KiTyAZwSOme9Urx5HJ4xntV6Zdk2EJJ+8Mdqhk2v948H3qX2NE+pjCJgSuMH1qKZOVJAIHcGtOaEgMSeBWVcSFRwCVzz7Vk1Y3i+ZlS+RpS21tqg459K4rxLGI45HZsM3Rh2rrpVaUsVfb2471yfiC0mRXcuJFjIyD70luabI4WaBVnK3f7yNujdulVII2gBkjnTYrYHPTPUitG5I+0FFdSgO4A/drn76Forh/LU7BzxyBW8Uc0nbU63RL6OSdfnZs/fz04rRM809wyqrZTJXZx0NcXa6kIIRGFIDdWHX/wDVXQ28774pFcgLjK9MjsamUTWE7nWW99K1tvjYlW5aU/xD0P0q9avMZIfMkcwZwWDZB9K5X+0kFkyxt8kjEBSOM+oq3pN9IsaIXCFV3HHc1FjVNM9OsZE2uud0hJyWbkmpIbowCSKckkAsSp6iue0S5LbfN2jOGBU9TVrWZoiqSKw3qdjHPap5hct3Y2VvPMYTGN2jbjaRjPoaHnLFUZcfxbR2rJuL+RraMIEjjjX74bOM1e0eW3e2lcvuk/ikJ6+/NTqOySuXLdZHmkRmYcZ2gYxWna24twu7LkgEEdeKowTwkKyv6jdn73oKv2zZIZ5ArY+X0Ud60ikZtlyCISIWYNuySRnipNnlwqYwCQcge9VEnVDITJ0OFHqKjiu3YMxkOBx9aq6I3LqXZVWDIA4ODnpmnztGu0luewFUYMAsSpEjHcPTFEk4V8RID6k8mlcPQSWcyOyRgnjBc8flTEjCsTNIuRwO+fwotlyjeZgsT0PUCpikYjGB36461JdxbOMuS7LGyHuRyamBEQcMoKn0bpUe7AKjAP14qNzJtAxlR0AINVcnclnuRtKx8EAHBOfxqnNMFPzFi/HU8U9mCAM4y4GB7VC86ENlQoPt0qXr1LjoSLcMxGGwRxn1qGa62yFlVsjjJOeKrvcIem/69Ki89SxAUq2AS3apv0LSLL3dyw2xLhW9R1+lQrDJ/EVRR2Y0x5+MM+R/npTUVmbIWU/Wla5d7EyMwBWEjI9BSvuAw7gN9c/lR5cnG792nfnmoZrqK3iaTBVB/wAtcZ5otbcnm7EyCTsNqnqzHmmXUyJJtTOBhfUk+1YU2qySkGFjj1btTJ4i8EOzdvkPJLdf8KavYluxfuL/AAzxxKX9e9ZkkdxeTATHIzzGpwPxrT0/THRWIOHHbFblppOwqdhJJ+hNCg2RKokUdN0yWRUUAqAeABwMeldPbaU0cbeYRuIwcVctYAm1Cu0Y4Na8KqV6/Tjmt4RSOWdRtjYEKRgIwwBg5FToBn5fnbHJ9amWFCM4GD6VLHGikkKT6kdqtmVxsR2qwXBbjjvVhQMAF8fQU1ERAG29eTUjBRtKjr1JqQIZSwICfjUqHOCxwOn40wzKTyu0gYHvTkY7lYYGexoC5JI+zuOR3pIMHac89OtN7FmUlmOMe1JOnnW8kfzJu43IcMPoe1AjMkgAvrx5tJkulZxslO08YHHJ6elaVkuy1AW0+yKWP7nAGPfiqA01GJH2y9Pr++NaNvAbeMRiaR0BJ3Snc30zVbk7HFSQEjke4OelVVjYZcqy7zyGrR3AhQxHoPek42EN97pVSRUWZ5jUMy87qjaJlZcE1alUoxOB0poYKp3HIPArM1WxXZmD7s/LjGKruVK9sZ78VekRTEeD9B1qnOMkAj5h1PTP0oaHcpygBSOGB9Kz7yVnG0IPcetaTDPsBVaeNW52jP5Vk1c3izmpklRm2rhT1Ge1c5rDkiRZT8r9h2NdxcBYh+8Oc9M9q5++to2V3fPTHFQbI86v9MMbI0WTkZAHQ1SlkVI5E2KshHOR94en1rqdVhkRgE5Ujg1zt9bFwGMhAPPNaqRlKJzS/M+ODu4wf4a1LTUCrQRSk4RTEAR2zxzVjT7VE1QAEbHQ7g44qS6kjDSxtapJ33YxzV6WIs0TW84icRzLiNOADzjNXdOWN51k3kIHOzIzn/61Yeoec8CSRgpkYeMjuO4NWdEuXjQbiQhHHOSlJx7FRl0Z29jqDrM6o8e1Rk7jjH0rVtZjfZjVFVehHUn3rgUuS7AsjHeMrJ7981u2NxLHKjiYENgEAY49aykjeMjqrq2ceWpDLHuIAB4/OlXY8DMxRFXknOOfpWYurEyLGrKYyfmUnG3/APXU93PHcMUcRpuwVxwcY7++ahlbG1pt7bIqEqSMfM+Mj61vqqyKpWQ7c5HNczpMsz25hSPYOm7GcVq2knlReVO/yqeCO31prsS0XfKQF1ZjuOcN3IqzZwqIgxJc4ydxql9qLCNsLtzheetXllXyvlYbh3qlYiV7FiW5CrknHYelVo5Ni9eT09aoyssRPnOeuQMe9OguQxDSAKg7dwKObUOXQvu5VgXGFbHX1przHbtDVDJdxTjEZGOo9cVVN3lwq4Vfz59KOYSRf88Ih3MD2C9aYLjndhkbsG4qOFgSeQSOc02a4SMAvjqcHrRfQAkk+bEeAzHJ3DvTDK2/5iJCvbFQyXil8BMsBg4Oc1Xm1JI0Py4f061JaTLkjYk5LKBzjt+HrUrQocl2A3c8cAVhXetrFG0hQDjGTz+lc1c+I7u5UrbgIn8Td8ULUD0J7u0s1IJQY4JJzWHqfiyGFC0EgcjI4FcFm6vbjM8rMhP3c4Aq6tnJIwXaMY4HanZvcEorUtXWvatfqCjeRGewHzVYtV1Ca3jilnke3RsrF1I9zU8GlMGiaM5z8oB9a6jTtNnjGw7WDDp0P501HUmc9DKtbJmRRGhVejgjpWzpmmOSrEjB+6McCteHT5VRMAAZ4zWpDA8YJ2qB1wBVqHcwdTsVIbVbZNxHTOR6itS1MYxI/QcD6UsIEyEMrYIx04q9Bp/lRIsYGMdScmrStsZN9yXKSBMYwe2KuRKqKuF6cmmQ23y+9WVXB2vz9KozY5SGBUoF9M81JFGixAspIzk5qMEswBHHT6UPIIwwEnzN+NK4WJfNjCnceOoz6VXedcbULbR1xUQiLAGV+e2BViNAGXbkY7f1pXG0kNiGXB2kD1brVkgIpB+91pwA69SOaaWUxF9wLZ5z1qttCR8RXlzxgACoZQZI5EDvGG4DrjIPtTjtQJg59KdGMAkjnORSSuIwZJhbyNC2oai8oYKwjiDDd1xnHXFaumzedp6OGmkQsSHlADnn27VVkhVJrsxXMYkjdLsIVOUYdmx2IH1q5pK/6JvEsUpmdpsx52fMeg+lUScijMOM49xT3OZAx7dac4GB03CmuAcHPI9KopO5BKd7EY475qnMGVBjkZqxcBxkE4HrTcb0IIrJmyHRPlQT1xUFy+D82PY+lLGpVCGPI6GopxvTd/F1pMqxBLIrIQcD3qqyhgck4H61I8e7gnn+dU2JjO0tk9qzkzWKK96m7DA/T/GsG+kJ/d4LqOM1vXTZjz0IrLMKuhA+8evOKhrU2ic/eIrxlEOSP0rDuIcRMhCkDoD1zWpeo8csixH5euPSse5WSSRSz8HnINUgaIba2EkhZQvyjB45rQWzVtuUG48EYqjZb4ppZHyST8oX1qaK5eYqxQ5z82O9NhFIdcWCT3Ea52Rk4Y+/b8KrRWaWsjhokc7sNg8CtNDs5UAhjwGpBbNLG4TK8/MKEwcTFki2StHKEEbYAK/w1ZbybEYMpY8Al+h+lPMKxgoc5PQMOnrVOWCS4ONoKA4Ix3p3uTsX7K4jnuSJBlW6sT0rorOzhnKyLP8Ad/ibn8K4iJpIJmHlyKCvQDAPuK1LW/aKNGh3Oq53g8UmrlKXc7eOaa3AMZDOx9KSLUJowyzBFLf6wdcmsBddjZFTliQD7rVr7YHnSV/ulcksKloo2rW6+0MVLOjDldox+Nacc4ywzlf4iD0Nck2pwNIv7wBgMLtJA/GrC6gRJ94YY8kdKVgept3MgkZQWLKeR6/WqC3twJZMuWAGTkf0qu96VkUBvmxlcd6qC/MhYhWWYnDMOp/wpNBzHRNfCSEEIAccnpUUeolWXCghQcc+lc7NeO68uE2jHIPze1VlvisvlK3AOMH1p2EdTNqUjYzJsHQBTn8Kq3F8Xs8mUJnKEs3WsKa9t4LeZt8bzZwMMcZ/xrnNT1eU24lijaWNSd7Dop96pRE5I6ltXjQ5lmPlp8p2jOT7VjX+rtI5SN8Fjwyvzj+lc2mq3EEDlQkskqEgjrGPTHb61VtJPlWSRMyBtzIehHYU+TQn2l2ba3oa88tpS4Uc/NwD6Z71uxO12saKqxIOgVcfn61yOlwyTXgd14ySOPzNemaJYSSR/MigEccUAn3ILTTnC/cJ9Djqa37DTVkhU9T6txV/T4cKqTL0HbtWtBaonBH+FFricrFWztYsAEBVQ9D3rVijG4FZCCB1HPFPtrVCpVhw3QntTIbOcMArjZnmqs0Ytp7mxCXZQNucd8daniQgAOAPWnWwZYwGyT159KsorHBwa0tcy0uEMTKBzhewqeNyXAJxTgNwAORT/KDLknGOlFrCdtiVH28D7zelWIwcgAZz3qoGVCqjjPJq0k6rgDIPbApE2JXBJXJxjqailiUDKqCT3PJpTcq2B6mkdlCcNzQItQxKAWwAe/FREqmN4HHOfSollO47ST6DPenHD8zA5H5CgAkZmysb7gfbHFQpGIhtBLE+oqbeFBG3BPANIqElWJ56E0wHY2oSuGfHU9qkzGEZ2cKi9yeBTSAgwjZY9utRr5boYtokQ8bW5B59KNgKZdrG6uBD9lmWZvMxJOI2RsDg+o9Kt6XCI7YkyRys0jSMYjlFYnkD6VTEdxd3t2YrbT2jjfy980RLM2B1/wAam0i6lUxRywW8UcjSIPIBG106gjoc+oqiDmCfkyc0q42nJ4/Woo2OcdVNPbjG04p3KEkIaPBGTVSMsCRgH0NPlLKCw601SHbJPI9KlmsdgaQMASuD0qsylgQByOc1POrbSapncck5PqBUMuIyb7oHVh6VRn2yow+6w6e1XZdwHJJ/pVKYYAJzWbNoFEhlfazde3bNZ14QJMDoetaV2y+X3B7YrKkyT/DkdvWoehsjAvbdgruGPPp2FZEluVVt56/dHpXS3haIcfx9c9qxb5AuwEfI/XJ6U07sbVzKlEkMKFVyCMMR1HvUdn5jjHKkc56U3UrsxxBDkMp6Acmr2moZrePBwGznHGDVkrexds1eSZS4BOOcdAK2/KW3twHIAPKsO9V4YxGI4xx/eIPSrcgSOPEY3jqQece9Z3Ltcxp4lcyOsWW68DpTDbRRxRmYtg/dA7GtGWKQo2MKWHGOpqpJasioN7MOOnammFrmNfWamaQOCV/hweh71X3RRWssSrskfBXB6/WtCRm+2bVQ4Xo2Op96rSws8nKZxwDjrVGbiU4Tu25bIXOT0q5LfMiAiQBF/hPP50x4kXaqJns22lVIERyFdlL7SW7UxXaLMTL5aStEmZW+XaeuO4qCS53T7d+IhyAD1Pei9vIprWNFQZhXYjKPu1liF8rIxVXPtwp9KfKLnNiO/SDa8n7zJ5RT1FMuNSV5PNCDyjzsU4IxWbMXEYaMoZJBjew+6fpVV1BgQ7iUxgnOOfpRyicrmkbz5yshaJhjBJzj2xTZ55La6upJlJRPlQA8knoa5+/lYqkIkAOSVJ/rTH1Fo7FrVjG0uPvbuWPY5qlG5EqlhzXsCs7SuzzA/Mme/tWZDeM00m52SIoylQeMdqzSW3FnHJPOac0oEZROS33ie/sK1UEjjde5eku/NhhQDDINpIPLD3rf0C0abaecnqa5mxRJbpEXKg+vc16d4Usdqr8nzd8DFZz00OrDvmV2a2i6QBLGdgAz3HSvQ9Ptk8sJtwB+ZrN0u2AOe+Oa6GKIKQR06Gs0aTY4WgQhx+Q4NWgBGRtAOBwDUkWDuKoQE4ye9NwdxO0Fc8n1qzIl3llCgD1qxCpVgRj1NVAu47wcA8AVZjkZGUOOD39aLg0a8Odox6d6sKcjn1rORhuDKzD0wasI5ZcDIBq7mXKy0u1p1bA3IMA/WppSXOTwB6VRjkkaT5SMDrxUvmJ/GTkHp60mwsWFwUzjJ96dkhRxhj6VV3szHbwSOgqZDtAUdcflSE7k20MMY6HmkGBvGBuxxn+VKBkAAtj3o2BpOv1FVYklgZeuAPYf0qZdsvzYKk9KbGgAxjGeBSSOyAAg8+nalswFmZYlIPIxVfeRgKSCR9alWTcCp5A7UlvGyOWPLHp7U2gGrHM+Tz/KrUMB25YAeuOpp6PtCluR04pS4cZRcE8fhQK5izwvPdztZwOpVtk0i3BhDtjOMDOcDvVnT4oZooZ4IHgMJaHymbOw5+b8T696ebGZ7p5rS7aDedzLsDLnGNwB6GpdKWNbR1g3gLI6u8hyWcHk0NCOCkZ0JweOmPWnx3Ctw2RmoQS4wcgBupp/lgoQQCCc5HY0zREjyqQQCDk9O5psSkfOORSRoBjfjdjg1IjZPAG7OKmxV7C7lIywI9h3qG5jyu5DgdxU8/K5AAPTNVS4YFQePX0pMpFZ1dQOevT6Vn3SsDkdAa08OMg8+4qtPgZzjB61DWhrGVjNkZHzu6qKyLrYpDKRz1rTvEjbODWDKDvbByB2NZNnREZcHzMAjK4x0rKvrXfIpJyo42mtVjlcE4qhqTLwODniiO5ZyOoxma/YRYUEc5GePaug0O22WyHyyAKz4kC35V1zF/nkV0AmCNFsYGM8e1U3oSo2Zctk+ZQUyW6Vr/Z4VhVSu085zVMIwKYO0DoSOauIZJo8YGVPGT1rNlleSFNyEENjgcdKhvbRTEVB3ADI2jpWlChA8zHA4Kd6bJeRJu+UAkYIIqUN6nOJpnLsflcjis26tXgi53785HtXRK4kEgUlTn5R1/KsS7M7lhL8wH4kCtIy6EtGKIJmcyoSGYfMAOlNSIiOTcNob72ehrTgPkysmVLY6k9afbyI+6SRF2ZO44q9iLXRlW0cNopdoWIPQP1PvVOaR5JcoiqpOef4av6nGpugy5KEZUjpiqCxFZT5ZLgnowp3J5bDliBG0527hhzVaS3+cpKMKAcDHTmtu2sriSMAxERg55GKiltucyKMk96aJZ5zrVyzXUiZwFO3AFZeTWl4iUJq06j1rNrqjseTWbc3cTJpaKKZkaGiJ5l6gOOOa9t8OQBYYyq4wOR17V4loTFdShx3Ne7+HHH2eI/dOOnaueruenhH+7OtsYghBGMEdM1rxMroQcZrMtACgyc+1XLUBXHU461mjWWpdt5FIKknGKkZvkxnuBTZVyysgAxx9KDKrMhK81TdiLE0MXIUNnnmrXlsVPIzjFJDGM7lPz9/erKAZOcY71VtCGxsSsqbScVOjcEkgAmmBSTngjipNvJORntRYTZKDhC5PA7GpVRVjUYG7ryKr5Ycvk+9SbdxJJIH1qibD0jCuZMkk9hUsStksRjP6UyJOgAyeme1WcqPqOOadkS2L0cgnOB+FT2+0g/wgdT61XiIcN+tSgqqjLDH9aLoRJI2WIT7w6U9cqmSck96hST5wAvzGrGR5bDHNTa4AmTwCMdc+tMSdHdkK/KOvNPVQseDy2fyoWPJycCnqAIASdw4FR3COYyIJFR8fIzDIz7jvUhIO4gnPoabPNHa2r3DjcEGcDvTsIrxxartB+223P8A07n/ABqzp9s9pbsk8gkZ5GkYquB8xz0quzamWQC3tEzz5ZlbP0JxU9pcfaIXleMpIHMbR5ztYdRnvSYkecI7bgvVRkg1LFJuwpGTnPPeosiMDcc0MF370NM0sXWXjKnmo24Ynp7GmCdwDuGQOh9ackok4zz16UrjsKwSQliWB6c9Kqyp8xypyPalupCoGzOPrUcdyCQGx83r6VL8y4p20GGbaCpxn3qpcSrtO4mp51R2JJOazb5tq7c8eo7VlI2gkZt3MzsQpIAFZ7IQ+5eSe56VYkB35P3f1qE5UZU++Aag6UQyJ3ftnOPSsi7cwSjeCU7e1akk+8Ag/MvY+tYl9KZJmznI7DtREpDLbdLM7gcHoK1bG1EjgyOoTqF9KpaQbeZy7Ng9Aueta8dsvmrsYDPQmm2I0HHyqplUkgEU9FeMBllVscA+v1qHyXDcCNuKeAYiC0O/nsazY9idJ33g+Yvpg0l7FHJExZlDnnA71Qu3Bw8cMgOc9KvW8rTbRNEAq+gzSsO5kxwy2xLoQ6j25FMuHSY71O18c1r3oVYmVgdxHGOK5q4kmg/1kO4N/Gozx71SFcy9ZcGRZFTzFjOGXocVd09o5YyVQqGHKNzVe6SN5RJEysTwRUmjoWn2oec8Ej+VWJKzsWrhVaExGIYHII4xWYJI7OdXK7mAwD2FdRLbuI13APzz2Nc5q0GJwAuCT+lEXcmSJ/tWR5rSSySdjnCj8KpxwmdtxkYbTnB6ValCKqKq4wMEUQqCC2BgdqslRR5h4vg8nWZQDkHkVi11fjyIm7jm2YBGK5SuqGx4+Ijy1GFFFFUYlrS3Ed/Ax6BxXvOggfZEbnkZ+lfP8TbZFPoQa958KTpNpsJyMFefyrCqj0MI/daO10hmKfPjI9PStJR84GevSsnTZV27eMYrVO1lXjcOvWsUdDNG1BCHedwHTNRlgm4sOnI+lMSfYPLVgCRuwfSllYlQcAEcn6VdyLFuKXHzYbb6irkUgcfKeMcj0qlbybiORyMgDrVqFVySQRzzTEyxEHCAj5c9KnhR2bk1CXIxkfNiplOAWLfN24qkQ/IsPuVRlgQDzzSRHcSCG4602PLhT0BPWnjAclT7/U1RPkWM7Bg/KopCTtY9PSmM2drHJHekd93HPTgZoJJI2AAXkA9T3qaKNScnOKjt8ZJY5OcelSIuXOM+1FguWtwBGNvpThnPLBc8Cq6EZyvbv1pEMhcgHI657Ur9BWLSkFj6D0p6uzZXByetQDemNpGevFMRn2kg9D096aCxLjoqqQo68cc1JKIGtH+0lRARh95wMe9HyoQeSOlLIFER37fKwdwc8Y75oEzEZrMsyLrk6RAYwtwuQPTPWtSwFt9nT7IytCCcMrbsnuSe5rIgudNgQxo3mRKSUbyCQBnpnHQVtW3lSW6PCU8tzlSnANAjy93AUAnnpwKdEfn68dDioV+ZME8+tPj3L94Ywe1Tc32J3z68UkW4kjn8PSgKCM/Ng0+OPA/rQC2JCAeGHzEY5qnLGAvzDPoT2qSUMOnKnvVIPiUhwD7+lJtFRTGmb5SM49Cax9SZ4yf4l7YrVvHVl5xzXP3c7h2RxuANZM3h3K/muVwrYI6A/wAqgZ2DEZx2470skyk5jB3DqKgExf5XJB68ipZsLLgpxjBHHaseV0RmJO5ycE1pSTNGeuRnnI6VkXTR+cxUD5v1pJ6lomjjRVBwp9MCta3gUKHDsuT0zWfpKJHl4m3r3Ru1dCzK0eBECw6kc0pDQiRzDBjkU8dCadFJfJIW+U/jTo2iIC8euauRxEpkoOOflPX3qQHR3chjxNDwB1XsKfHcxnkDyxn0qSI+XGT8xXOApqrL5LZzKY884NJhYfOYpCG8xWx69Kz7qC3DB0k59jUskMf8KrJzxzimTW0Tqfk2jrTQmjE1i2h2maIASDup/pWbpF2I8CbaWB6r2qDW4pYJWwZAp4wCTis7QmaaRkI3sjYyOMitEroh7noKzeZbq+0MOxBwTWHqYVplc8KvOO9aawJ9kTkoc5AzisnVRyACcAdfelHRjauiqhDMWyRu6VZVdyBSOD3qraHewRAeBzx+lXokyvXJByB6VZOxyvjeyEum71HzR9PpXm9eva5AJrSeJuN64zXk93C1vO8b9VropPQ87GwaakQ0UUVqcIDrXsvw+uVn0OFTjcOK8ar0j4e3H/Ev8tSMg9KzqrQ7MG/eaPV9PyGOOVz2P863bc7lXb1Pr2rl9FmZABIcluK6O2cb9oO3vXMdzNAEkKvJYU7YVl39dyhT74pkT7T8xye9KJHZsoeKZG5cjVeHTgj0q9FI2NwwRjGaz4gXySAPerkbqvQDGKtGbLbSLs5IZvSnRybgoCkknFRwurAk4APANWUI/vYHXNWlcm9iSNCAck8jp6U8KEIwvXvTwy7Rk5+tK+GAA9aZDYobg4FQlcEMenWlz5eW/SlTIUB6AHAnPBPzVNCGIYbgPemnGeTgAZzTA/zhsnHoO9Ai2uUby84UDgDvUseQxHAyOKrQgj5mPIFSqxUAkZOKLCLO4ZIHPHX1pCArj+71qFSFKg881MTh8uctjgelAEigZPLceveor2AXVjNAXC7xjceQD/hTgTgAnk1W1NJpbKeG3xuZMLzjPtmgRXSe/LAR29u+z5cxz/L+WOKvaXH9msiu9HlaRnbZ9xWJ5A+lZQtlRIbnToTBKgw0LDb5gHUEevoasaIZBA3mI0aNNIwR1wwJOcmmSecBymCOnSp1kU4Pf0NU0kVscZFNeRkcMAQPSsbnXa5eZjuwpqWF27nFVlcMo5wTyKQS8hvfmncOUusd3B7flVWaNW4I59KVnzypyR71HI3BYdetJsEjL1IkIwbuOBXOvcSB8OD1PU1uX8gkGOVbNY80qMSjAZ9ahnRFdyq8+xsleDUUkiuBnJ9KfcFRGSevtWVIxDEAn1xSNEWZmO7qcfWs13DMyEDJPFT+aW6uDz0xVRAjzs0h2jPPtQima+noUUbossPfrWtG8ij7m1fUHNVdMjUH74ZR0Brajtw4OGwfT1rKUi0iG3jiZg28Dn0rSXbHGGUhh2AqKO1dtrJIDGfUdDTzG0cmDFnaMgrSvcdhxlUoAoOepwajkCy8YjYdtwwaUhGXLq4I65WopYlVvuqcds/rSuJCTWibSTAAfVT+tZ8ipCp2NKB6HmrzRiOJmWR1Ge7ZqhdO6EkXAKnsaaY7HP6mykblklBB/iGQRWLpTi01n92QfOGSB/Ouh1AzGJyjR468jFcXZ3Pn+J4fnCsnylh0rWBE1senRqgiy5XJ6GsTWWLsBg7efxrTj2hQpII6gnkGqFxHmUg4Kj2xR1HbQhso8IeOtWoYTv2KcCmWpw4O3Kjt6Vcif9715PFFyGjI1KMLIUOMdq858XWRimWZB8p4NelasFzkcc4xXJeIoDJbSJjqpP41rTlZmOIhzwaPP6KCMEg9qK6jxArrvAE6rdyQscMwytcjVzSLlrS/ilU4weamSujahLlmme72MjJ5Zz3z+FdZDMhRWyCegNcDpt4JIomHQiuq0uRCuCTzx1zXGz1mjo/NKQr796ktWG09ee+aoLJkbCQQKfFK2cYGc8U0yLGxay/wH86vIQqBuAT2rFhViCdxJPPHWtC2YHjdgnsatMya1L8e08kAk9KtxqAowOR3qjC2xcAYI461ajYcfN17VadiJFmFgASwqZWAfvzVdcFeB+ZpysVyc9uKa0IHp88nzD5R096eWOd/UHiqwZ9hJ4QHoO9WI2DRge3ShO4EkYLEknANKiKmeDx0FNLbfmJ6/pRvXYMZ9hTEywrDOcHinDawznAPtyTVVSzng8eoq2gJI9BQIapYSbm646VaUjbkDBPSoVJJwSOORS7wCTjJFMQK3lk784J6mi4mCRM7uAFyT6AVIZNy/MAcetUr9WltZRGMucFR2JBzj8elJKwxVu53i81bZShIXa0oDknpx0z7E5qSJ1mMbxElDzzwQemD7isgzobJ4ibcLIzFmd8SKScnKdSw6DHtVy2aWOEuylS8hk29wD6+9MhanmEbtkjPHNLuLMxPXOKKKwO8sRqCg+lBYq6jruODmiikCA5SUBSQCM0krEOV7DFFFIDIvVBBNY0p+aT2IFFFDNVsVLvgg+tZz8SnHoKKKTLjsPmULGMDrVbT0U3DAjPJ60UU0UtzpYYUR48L1rZiQYwMgKOMGiiueXU0RdihX5uW6A9amRd/DEnHQ0UVIx24hGGfaq0iIzLuReeTRRTkKJRvLePaQFAGCeKovaxGANtxg9qKKOpXQ5vWUVldSOF4FcHpzlfEoCgAFsH3oorenszGpuj0ksywhQxC+lMn+9jnGKKKXU1Ww+1P3B2Py/hUtu7FgScnJGT9aKKbMijqZ3PyM4GaxL9R5LDHUZooqokz2PNL9Ql1IqjA3VBRRXajwZ/EwoU4YYoooEtz07wpI8tpDvOccV3un/cxk9aKK4nue70RvW3zRK5+83BNX1UbfpjFFFR0M3sXYRSBiJQQSM0UVZHUvwMWYEk9DV61bfDGxAyQDRRWiMnuWGc7QO1Rl2OBngHiiimJbkx/1gB5Ge/0qVSQ20dDRRTRBL/Cw7ZxSpGu0Dnv3ooqhMmiAXAHTFW+iDHcUUUE9SOP7/puyTUjHkfWiigOoqfMOexqKTgjHFFFPoHUp6l9yN8DeGxuxz0qy7nyl6Giil1F0P/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_60_31681=[""].join("\n");
var outline_f30_60_31681=null;
var title_f30_60_31682="Noncholinergic neurotransmitter";
var content_f30_60_31682=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Noncholinergic neurotransmitters",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 359px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Noncholinergic neurotransmitters are localized to nerve fibers and neurons of human airway parasympathetic ganglia. In addition to acetylcholine, many noncholinergic neurotransmitters have been localized to nerves and ganglia neurons of the human airways. In this ganglion, nerve fibers stain for substance P while a subset of the ganglia neurons stain for nitric oxide synthase (NOS). Photomicrographs in panels B and D (1000x) are higher magnification of ganglia depicted in panels A and C (400x), respectively. Calibration bars: 50 &micro;m in panels A and C, 20 &micro;m in panels B and D.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_60_31682=[""].join("\n");
var outline_f30_60_31682=null;
var title_f30_60_31683="Contents: Primary care cardiology";
var content_f30_60_31683=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Primary care cardiology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Primary care cardiology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Advanced cardiovascular life support",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/33/13850\">",
"           Advanced cardiac life support (ACLS) in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cardiac arrhythmias",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/32/36361\">",
"           Ambulatory monitoring in the assessment of cardiac arrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/28/20938\">",
"           Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/27/35257\">",
"           Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/32/42506\">",
"           Antithrombotic therapy to prevent embolization in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/19/31034\">",
"           Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/41/23192\">",
"           Arrhythmia in athletes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/28/33223\">",
"           Arrhythmia management for the primary care clinician",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/24/36228\">",
"           Atrial flutter: Epidemiology, classification, and risk factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/35/39481\">",
"           Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/36/36424\">",
"           Clinical significance and treatment of ventricular premature beats",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/50/12074\">",
"           Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/57/18328\">",
"           Control of ventricular rate in atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/5/4184\">",
"           Electrocardiographic abnormalities and conduction disturbances in athletes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/40/37511\">",
"           Embolic risk and the role of anticoagulation in atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/54/28522\">",
"           Epidemiology of and risk factors for atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/16/32007\">",
"           Etiology of atrioventricular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/24/4490\">",
"           Evaluation of the survivor of sudden cardiac arrest",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/38/41574\">",
"           First degree atrioventricular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/24/20874\">",
"           Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/52/27463\">",
"           Indications for permanent cardiac pacing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/19/24888\">",
"           Maintenance of sinus rhythm after cardioversion in atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/6/39016\">",
"           Management of new onset atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/26/22952\">",
"           Management of nonsustained ventricular tachycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/31/22008\">",
"           Manifestations and causes of the sick sinus syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/14/26858\">",
"           Monomorphic ventricular tachycardia in the absence of apparent structural heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/41/13974\">",
"           Nonsustained VT in the absence of apparent structural heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/2/2086\">",
"           Normal sinus rhythm and sinus arrhythmia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/22/361\">",
"           Overview of atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/11/20665\">",
"           Overview of palpitations in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/55/890\">",
"           Overview of sudden cardiac arrest and sudden cardiac death",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/60/13256\">",
"           Overview of the evaluation and management of atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/41/31384\">",
"           Paroxysmal atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/6/9320\">",
"           Prevalence and evaluation of ventricular premature beats",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/57/22426\">",
"           Restoration of sinus rhythm in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/43/5817\">",
"           Rhythm control versus rate control in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/36/13898\">",
"           Risk of sudden cardiac death in athletes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/62/15338\">",
"           Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/42/18087\">",
"           Second degree atrioventricular block: Mobitz type I (Wenckebach block)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/62/998\">",
"           Second degree atrioventricular block: Mobitz type II",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/50/3878\">",
"           Sinus bradycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/25/14742\">",
"           Sinus tachycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/27/441\">",
"           Supraventricular premature beats",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/59/15285\">",
"           Third degree (complete) atrioventricular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/44/37576\">",
"           Treatment of the sick sinus syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Coronary heart disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/30/26088\">",
"           Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/55/13175\">",
"           Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/12/37066\">",
"           Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/28/28101\">",
"           Biomarkers of cardiac injury other than troponins and creatine kinase",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/53/31576\">",
"           Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/38/27240\">",
"           Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/0/27658\">",
"           C-reactive protein in cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/33/31258\">",
"           Cardiovascular benefits and risks of moderate alcohol consumption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/28/1482\">",
"           Cardiovascular risk of smoking and benefits of smoking cessation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/51/37685\">",
"           Cardiovascular risks of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/56/15240\">",
"           Chest pain of esophageal origin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/53/28505\">",
"           Classification of unstable angina and non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/9/41113\">",
"           Clinical features and diagnosis of coronary heart disease in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/35/28217\">",
"           Coronary heart disease and myocardial infarction in young men and women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/59/16314\">",
"           Coronary reperfusion for acute myocardial infarction in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/39/25209\">",
"           Criteria for the diagnosis of acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/57/28570\">",
"           Determinants and management of cardiovascular risk in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/15/34042\">",
"           Diagnostic approach to chest pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/0/26634\">",
"           Differential diagnosis of chest pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/12/6344\">",
"           Elective noncardiac surgery after percutaneous coronary intervention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/20/44361\">",
"           Epidemiology of coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/60/36810\">",
"           Estimation of cardiac risk prior to noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/8/39048\">",
"           Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/28/14793\">",
"           Exercise and fitness in the prevention of cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/43/1721\">",
"           Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/24/20874\">",
"           Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/43/15034\">",
"           Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/9/2201\">",
"           Major causes of musculoskeletal chest pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/45/29402\">",
"           Management of cardiac risk for noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/63/11258\">",
"           Management of coronary heart disease in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/51/9018\">",
"           Medical therapy versus revascularization in the management of stable angina pectoris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/35/3641\">",
"           Obesity, weight reduction, and cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/41/44697\">",
"           Overview of the acute management of ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/20/37193\">",
"           Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/28/3529\">",
"           Overview of the care of patients with stable ischemic heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/59/7098\">",
"           Overview of the non-acute management of ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/33/44569\">",
"           Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/37/34394\">",
"           Overview of the possible risk factors for cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/59/39866\">",
"           Overview of the risk equivalents and established risk factors for cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/6/35945\">",
"           Performance of exercise ECG testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/36/29258\">",
"           Postmenopausal hormone therapy and cardiovascular risk",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/43/2746\">",
"           Risk stratification after unstable angina or non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/52/35658\">",
"           Risk stratification for cardiac events after acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/62/15338\">",
"           Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/54/34665\">",
"           Screening for cardiovascular risk with C-reactive protein",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/50/26409\">",
"           Screening for coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/31/37369\">",
"           Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/30/44520\">",
"           Selecting the optimal cardiac stress test",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/33/28180\">",
"           Silent myocardial ischemia: Diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/35/4665\">",
"           Silent myocardial ischemia: Prognosis and therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/57/26521\">",
"           Stress testing for the diagnosis of coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/58/2986\">",
"           Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/20/41289\">",
"           Treatment of acute myocardial infarction in diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/38/39530\">",
"           Troponins and creatine kinase as biomarkers of cardiac injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/39/3706\">",
"           Variant angina",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Electrocardiography",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/40/5763\">",
"           Advanced ECG test",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/44/9923\">",
"           Basic ECG test",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/16/262\">",
"           Basic principles of electrocardiographic interpretation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/10/22689\">",
"           Differential diagnosis of basic electrocardiographic abnormalities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/40/34438\">",
"           ECG tutorial: Atrial and atrioventricular nodal (supraventricular) arrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/21/17749\">",
"           ECG tutorial: Atrioventricular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/51/37687\">",
"           ECG tutorial: Basic principles of ECG analysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/36/27204\">",
"           ECG tutorial: Chamber enlargement and hypertrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/22/37220\">",
"           ECG tutorial: Electrical components of the ECG",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/33/22038\">",
"           ECG tutorial: Intraventricular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/46/35558\">",
"           ECG tutorial: Miscellaneous diagnoses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/6/9317\">",
"           ECG tutorial: Myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/62/996\">",
"           ECG tutorial: Pacemakers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/4/9283\">",
"           ECG tutorial: Physiology of the conduction system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/43/21171\">",
"           ECG tutorial: Preexcitation syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/25/29077\">",
"           ECG tutorial: Rhythms and arrhythmias of the sinus node",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/52/16198\">",
"           ECG tutorial: ST and T wave changes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/57/1942\">",
"           ECG tutorial: Ventricular arrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/24/11658\">",
"           Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/26/4521\">",
"           Electrocardiogram in the prognosis of myocardial infarction or unstable angina",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/48/6916\">",
"           Intermediate ECG test",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/54/39784\">",
"           Left bundle branch block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/6/10344\">",
"           Right bundle branch block",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Heart failure",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/45/16090\">",
"           ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/53/35672\">",
"           Alcoholic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/39/2680\">",
"           Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/0/19465\">",
"           Causes of dilated cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/22/43368\">",
"           Clinical manifestations and diagnosis of diastolic heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/8/15497\">",
"           Epidemiology and causes of heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/59/28601\">",
"           Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/28/39369\">",
"           Evaluation of the patient with heart failure or cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/30/19945\">",
"           Evaluation of the patient with suspected heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/56/7048\">",
"           Indications for antithrombotic therapy in heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/37/7769\">",
"           Inotropic agents in heart failure due to systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/63/38906\">",
"           Overview of the therapy of heart failure due to systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/61/4058\">",
"           Prognosis of heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/54/7018\">",
"           Treatment and prognosis of diastolic heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/56/34698\">",
"           Treatment of acute decompensated heart failure: Components of therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/7/41079\">",
"           Treatment of acute decompensated heart failure: General considerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/22/29031\">",
"           Treatment of hypertension in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/54/28521\">",
"           Use of aldosterone antagonists in heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/38/12905\">",
"           Use of beta blockers in heart failure due to systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/4/18504\">",
"           Use of digoxin in heart failure due to systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/55/3962\">",
"           Use of diuretics in patients with heart failure",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infective endocarditis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/36/585\">",
"           Antimicrobial prophylaxis for bacterial endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/37/20058\">",
"           Antimicrobial therapy of native valve endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/57/34712\">",
"           Antimicrobial therapy of prosthetic valve endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/52/18249\">",
"           Complications and outcome of infective endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/24/41352\">",
"           Diagnostic approach to infective endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/40/2697\">",
"           Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/31/14840\">",
"           Epidemiology, risk factors and microbiology of infective endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/17/40215\">",
"           Infective endocarditis in injection drug users",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/23/31094\">",
"           Infective endocarditis: Historical and Duke criteria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/49/22297\">",
"           Surgery for native valve endocarditis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lipid disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/47/35578\">",
"           Approach to the patient with hypertriglyceridemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/50/19240\">",
"           Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/38/43626\">",
"           Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/42/19111\">",
"           Compliance with lipid altering medications and recommended lifestyle changes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/2/39978\">",
"           HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/25/37274\">",
"           Inherited disorders of LDL-cholesterol metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/56/28550\">",
"           Lipid abnormalities in thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/51/28474\">",
"           Lipid lowering with diet or dietary supplements",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/14/42217\">",
"           Lipid lowering with drugs other than statins and fibrates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/39/7800\">",
"           Lipid lowering with fibric acid derivatives",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/45/18138\">",
"           Lipoprotein classification; metabolism; and role in atherosclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/19/40248\">",
"           Lipoprotein(a) and cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/2/32\">",
"           Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/36/29258\">",
"           Postmenopausal hormone therapy and cardiovascular risk",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/29/33241\">",
"           Screening guidelines for dyslipidemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/38/43621\">",
"           Secondary causes of dyslipidemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/0/33802\">",
"           Statin myopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/35/32314\">",
"           Statins: Actions, side effects, and administration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/5/10329\">",
"           Treatment of drug-resistant hypercholesterolemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/32/10760\">",
"           Treatment of dyslipidemia in the older adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/32/14856\">",
"           Treatment of lipids (including hypercholesterolemia) in primary prevention",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/30/38375\">",
"           Cardiovascular effects of caffeine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/59/4025\">",
"           Diagnosis and treatment of pericardial effusion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/12/32966\">",
"           Major side effects and safety of calcium channel blockers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/50/35626\">",
"           Management of anticoagulation before and after elective surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/15/8442\">",
"           Sexual activity in patients with heart disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Myocarditis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/12/37066\">",
"           Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/16/26889\">",
"           Clinical manifestations and diagnosis of myocarditis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/28/22986\">",
"           Etiology and pathogenesis of myocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/39/10874\">",
"           Natural history and therapy of myocarditis in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Prevention",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/12/37066\">",
"           Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/33/31258\">",
"           Cardiovascular benefits and risks of moderate alcohol consumption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/53/26456\">",
"           Nutritional antioxidants in coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/37/19034\">",
"           Overview of homocysteine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/28/5576\">",
"           Overview of primary prevention of coronary heart disease and stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/60/40906\">",
"           Secondary prevention of cardiovascular disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Syncope",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/22/10598\">",
"           Carotid sinus hypersensitivity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/15/18682\">",
"           Evaluation of syncope in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/11/28855\">",
"           Management of the patient with syncope",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/9/5272\">",
"           Pathogenesis and etiology of syncope",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/0/18442\">",
"           Reflex syncope",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Valvular and aortic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/11/18618\">",
"           Antithrombotic therapy in patients with prosthetic heart valves",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/12/21706\">",
"           Clinical features and evaluation of aortic stenosis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/20/23879\">",
"           Clinical manifestations and diagnosis of acute rheumatic fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/19/25914\">",
"           Clinical manifestations and diagnosis of aortic dissection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/62/39910\">",
"           Clinical manifestations and diagnosis of pulmonic stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/57/25497\">",
"           Complications of prosthetic heart valves",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/29/25050\">",
"           Course and management of chronic aortic regurgitation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/24/13705\">",
"           Definition and diagnosis of mitral valve prolapse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/8/8327\">",
"           Epidemiology and pathogenesis of acute rheumatic fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/30/9705\">",
"           Etiology, clinical features, and evaluation of chronic mitral regurgitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/9/149\">",
"           Etiology, clinical features, and evaluation of tricuspid regurgitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/8/31881\">",
"           Indications for valve replacement in aortic stenosis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/48/30471\">",
"           Management and prognosis of tricuspid regurgitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/37/4697\">",
"           Medical management and indications for intervention in mitral stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/43/41654\">",
"           Medical management of symptomatic aortic stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/25/3476\">",
"           Mitral valve prolapse syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/53/30551\">",
"           Natural history of aortic stenosis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/31/6649\">",
"           Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/29/18901\">",
"           Natural history of mitral stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/51/33593\">",
"           Overview of the management of chronic mitral regurgitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/2/36901\">",
"           Pathophysiology and stages of chronic mitral regurgitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/9/38039\">",
"           Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/18/13610\">",
"           Pathophysiology, clinical features, and evaluation of mitral stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/4/17480\">",
"           Surgical management of mitral stenosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vascular medicine",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/43/33462\">",
"           Diagnostic evaluation of chronic venous insufficiency",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-6BCDE15F28-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f30_60_31683=[""].join("\n");
var outline_f30_60_31683=null;
var title_f30_60_31684="Anatomy of the thoracic esophagus anterior";
var content_f30_60_31684=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomy of the thoracic esophagus - anterior view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 691px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A thorough understanding of the anterior and posterior anatomy of the mediastinum is critical to the surgical approach to control and manage the perforated thoracic esophagus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_60_31684=[""].join("\n");
var outline_f30_60_31684=null;
var title_f30_60_31685="Viral exanthem";
var content_f30_60_31685=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F58169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F58169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Viral exanthem",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFDAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0e2JYZ3ksP5dwavtGpjwoDbh9xh0Pt7+9VbNMTYkHVevX860yipGfLGcdV7EV5J9NLezKsZL8ElewJ45FTKI3D+bGzLjB2cH8v6iql67xjzbYByuSyHuP8arRX26NHkDoc7Vbrn2OP50FxpOSuWfNEc0ayPhCcq+3j6VbQKXDrsLHkEdGHvVOV47mE+VgY6xrz+IqS2gQIq+XHKOv3cZ9x/hQEqelyV5raBjumRGOCBuyVPquP1FRXy/a4ZFhhJDjBaUFNp7FR1JzzVkQwmEgLGQRj5QFYe+exqEyPHGY7hySPuynjI9D2zTM+XUybZXliE8jF5gSJV2/KrDg/L/ntUqszMjAhig6cHHoferJh2Xfm7j+9GHI6hhwGx7jg/hUM1luRHJAdDkug6juDSOmMl1LlgY5LZ0kQlAflDdVPt7VakiDxtli4x24zn+tQWkJVEVCD3BX+IY7eo9qtwDDYGwIDtYHlaZz1ErtooxGSPMcv7yNR8vbGez+9aHzY2nCkjgg/u29iaaYzuDISrnhXYfoRVVnaG5XcuIs4dT1Gf5ijYi19i9LI0I3NFmL+ID7yfj3FPdy6q7MRkcOO34DrRExkiDR8hQQD3H+I9qgZlgZnX7oOSCPu/h3FDZCVxpj8sgp8uB1AyCM9/WnRoI23sxK4yCuNuPwqbzDHEsqglTzkfw//WpYTFOm+IfKfm+U9/UH19jTQ7jXdkUFDh2y3yf09fpTI5MwqyqCCCGBHH4+lI6N5RZXLckFdoIbnt6GoIjHsZpC8g6q3QY9170AlpoXGJkxHDK0R7N3x3Hv9e1Qtth+4GRUGCq/19aFuFceWVBVVBIH3hVe+bALpIGH9/P86dyoQ1sxUlMcgOWG5ch14H0x0ovGaW1kkSRRLH8+M7WGOpx379arglXfCjJ6qOh+lPez+0W5aBik6qdjHgk/3T7Gp3NZwS1NKMnaM5wRhXYcfQ08h4mVVGCRnbn/ANBqnpjy3FnAzyfKVHz7B6dDnuMYqYwmQrvdn55VW2qfpjoaZzPctGRUYKSQ3UBRlh7YrL1JnL28r7URZRuRP4g3ynJ9ORxVpoogyBI1AzkZXHzDv9R61S1mdGsHjYu5EsakEYZcuMZ9vencUV3HzSq0ZMKCMKeI8Y/L0HtWeX+zutxE3KkFh/AQeDkHoa1ZIE2ME2lt2QG659PpVKa3cibhgwUqUIyalnVBxtY1bQllcj5Vz8p6D/d9v5VZdQCXfIPVSTyB/UVnafcNHBG7KTHsBI6gjHar8csU6K0TRlG5G09PTFUcs4tSI5CEkBIO4D+A9aikjEr5iZRlecj7+Omff361NLLHtw7K56EPgN9PfNZEUXktI2n30iRMcGJlEgU/Q9qHoJK6NXeMYnBU9AJBkfQEUlyscSZkbgfd4yT9B/F+FVUs7uWEh9Vbkcqlsike4yTVT7NDZsJmee44yxmkLFf649qL2Fr0IZ7aJpSw3QFuscDZkk/3wMgfQ/iatx/2gY/3fksp7lfLcj3AyAau2YiMavCke0/N8ny5+mO9Jcq7hmjOJVP3SM8fWi1hp30ZSZpfmU2swcg/vEkWRs+ucjmoftkrIyajbySqFysyxk4x3x1U/TNTW139okNrNmG4J+43f/aQ9/p1qa5ZUA85kidehdwozn196RdrFVGgkTdGZjHn7rAtt/rimTyzjElsvngcNGVwzY6YJ7/Wj7SrYFuHmcfe2Jnj1DVKWurhdyJAN3I3tlvqMY59iaBvQZb3tuMSDdEzD5QyHk+h96cb+wT959ts4ZOhWRwVb2Az1/Wqt5Zs584XNzMc7ZE/1Yb3ZRjP86rJCqSKltBBHKRukhIADr2IbGc+5ptj5bq49LuzXmG8jQnJYAkhj2P/ANfrUk1/CQGJZpgP4FZgw/LkVoWMlvdO0SErOvHlMoVx7/T3GRUd8kkTzJJ88ajdkDke/wBfpU2BPUwYmYsskaXH2gnOCAqt7VqqzTQMRGqu3TLfNn2x2p0cqTkqro+MOQvJAPANJfSNa28kpAwgwQeSe2Bjgkmmi5y5mULgSKUtlkjWd/uIAAw9Wye39cVct4oo0VAryYAGx2wT+HSqMEflzPPLGpup1AcFcsqDogOOQOv1qm909rIheFntmODKgLbB6Ef4Uk7Gns77nQR3SGFlVVVCdp28c+6jpVSS+fT7pRLIDaynbDL0w39xvTPYng9Kppt84XMLCRD/ABDnH0PepJXt5LeX7WymJlKsHwUkB7Y/DtzTuTOglqazKj/vXby1RcsW7fX0qiEEgRUx8z/aXVs5A/hGfXp+VVILiRf3N55i2YBMHmL+8ucdI3HqO3dhjPQ1eiMkaPLMgeSUhpHAw0Y7L7gD+tBhY0oQN53EBT90kdKnBwqx/cbPykdCe+fSqVrMZHaJ1xngE9CPT61bTciqcCRSMOOh9jQjecbalKdQWLAbcHBB/hP+FQNFtbMSBQ/bGQx9/Srd7E+4MCC4GFxwD7H/ABqgX+zyssiFoDgsp/gPr9PekdMH7pII0kjXbk7DgH+JT6VJboUk8ssQhHyt6/j6ipEjbO12CsTlHPIb0z71bihzGEnyCTnOeh/oaLEznYikUoFVRtl6ZPCtz696WTaUIYAE8KDgrkdj6VI0LKJIyuWP3l65HqKjcGNlMZGGO0sR+jCmYX5iG0iEgIGSC2CHOCP91v6VZhKsHBYrL0YHo3oajERGTs4I4bORn0/wqheTzW0onaPzIh8suD8wHv8A49jQKSu7o20UQlsfdONyEZK/7QNBCoWcLvjbqR94fX1FRWsqXEEcscgkRh8rDg/h/hUkTEtjdhl/i6f99f40GVhsjGMo0T+bGx5YfMV4/UU5oA6sPlkRux5/An0phZVnC4Ecv3ih/iNWGyQzKF56np+dKwNlRBPZ/LHvkjxwrH51HoD3H61YiuIbgfKwDrjqoB9wQe9JPL5MWJtpjGAGx/P/ABpxjhnRTNGkp2jAbBz9D1xT8hPuWdgjyEBXjJRenPpVEWvkzSNbELCxywQ4we/FSQ20QJjSe5gXr8shYD2wc8ehprW00YyLskknBeNT+oxQ0SnYcEcKx3gtjkHgn3yODVK5Qq7Fcjd820c8+3oaueTclQWaJvRgjKD+vWqty6AhLuWBSOciTGf649qGawlZlO8lCWrbfkkI3bioznpkenXpXO2Wq3bIFvcLID+8cjAYdsEcEV0U/lSBVWRpcc5VCxz27YP+FUDZoJyyW8iMOQWA4PqP8KiVzpg4WL1vJv2bo+GGTt4OPUfpW0kirbSSfL8oOTjhvQEVi2yIrkSFIGZejZUH3TP8qu2qSrN5sglFtkHjhs9N2Oyj/wCvVxMazUloXraL7NMYxlA4AxjK78cj6Hr9RTLmeOCVUlXiU/I55XP+92P1qee2hmt2wWcNyH3ng9j1qksMM0EiTRRkggSDGRn1AHQd6ZzQV3ctLu4OAy5wCw4P196papGZbixhAKyNN5n/AAFAWxnuM4GKli3Wb7AzSRtwFf5mA9j/ABD2PPvSWzi7vp5lG5YEECcdWOGbr0P3RSHezLEcpSNVZFc9CmeR9Pb2qE+TIjSQqSuDuU5+Uj9RVlkzHnAJHdT19/aqd0kyRTSRqHbYcrnBbsCD6/zoY00LZwj7PbtkkCMcDjsPzqK5kVGJxESRkq2MOPY9jVizkjX5QfmUAHK4wcYww7fWqHiFGhje4hX50O50PIcZ5wfpReyLjrKzIkkjlceWAOoBz930H0q1azsXGV+UdQrcjtmqEWx5Q3l4YAbdvHy+3rVyNtrY6bcbePywf6VKbOqcFaxedcBQGbYoBVgeo9jU7fMfMPT+/jv6mkhyy4ZiCOcgcj8KmRcjGAH6kK2A3vWlkcEnYybqyQTOyBoSR1gfYefboagSKaUFPttz8g+UrtDD6/LVy8fylO3IGcYYcZ/mPqOKqAkRgxnnBXP+fepa1NoRurjbnT45kAvJLq5hBDENLjPocLj86dHpMEbl7OU46lZUE3XryefyNO84qRng9RhsZ+npn0NPFyGy2C3IyCO/9DTugdNkN0t7CvmOlvMg5DIxUqPyOadZzXLx744VZXPVZlIPp2z+FWiokXZLuUkZznBA9feqkkECTSGOUhm4zASCf6fnSFfSzGTmY/vDbY7/AOtBAotkkdgWto1K5AZpckZ7EAZxTTNqCFzBbCdOhadxDj2I5/kKzLqbWoyJkVURuHiih81gvfYxPJ9sUr2FrbQ0p7d5VMbwQSqnQKzbk9wwAIpkC3TCX7NqCy7CAY5Y/N2seRh85/DmktVsr6MGS9lusEBo559rKT0BQYx9CKWe2nhbzNPRY1QnMIXaknqPY+9FxWuyo8WoxyFg0IeXOXgcJvPurg5NPUXfnGSW3uXlj5UEREL7gBhz79atCWK8V3jJWYcMpXBU+jCrCOxiAkVMkYHy9cenoaSZT7mJJJc5XfayMuTtIUJtPtzioJmkMbIEJbaXDbsHj3HUe1aEiSKxcfv4Mfc+66H2/vfQ1VuZLedDBE+J5DtVGG10J74PPqaLHVCd0MNvmRbi2uY7YSDJMK5zx0ZW4J/X3pqoLZpJ3USPGM/aGO9VXudp+6P92kuStvte5Bjl+6i7M+dx0AHc9qLaIy7Z7yJ1iU5jtRyVOerdiR6dB79aZTSsSwz2+rSxx3ZeBgPMtouUZiP+WgJ/jHUDqAeeprUglky5m2+dDtR1UYzxww9iOR+I7VWmIeNA8e8ggjeMsD6g/pTS6KTOgZjGu2RFJDFOp49R1H40GEqbTubE1msnIBR1wd3bNT23Ay+A4HDj+vtS21wk0uMbJVHzIc9OxHtUxi2nEa8MMlQeh9jQS5t6Mhddxxgq+OeMhh61VmhyQ6YI6Akc/Q+1aCPiMdhnp0xVZH2TYilwQxyv8Iz2waBxk1sQxQ7FGNyoCRjGdh9/Ue9W7C4WZH8wCOdeGXsR2P0PrTftAJJ5XZ1A6j8O4qG4jDqro4V14ilQDIJ/mPUGi5M7vctBRkqyswHTufwqvdhpWDxyKs6jOAfvj39aktrgB0im2x3BGVU/dYjuh/pVW7usXBEiiOVT8wI4I/vA+9D1CKvKxatMuhUuEYDGwjhh6U2SBOOPl+6SByvsaS1lEyE8Ng5OB849/wDPWpTIQ37zK8fJIBw3saYneLZkrCbGdxZqPKOWkt9vDj++o7MO4HWtGCcSOhLYYjK55Dj2P+NVTua52TpiRMOFz29QaljjZp0KqJEYk7R8pB9R6H9DSRUlpcuTW7uFZR8rD5COeRVOK+WC9FtcBYpG5QnhJc+h6bvUVcikKghJnCZwQcED6g9++aZfRNJB5dwtvNCf4iOD9fSn6GSb2ZJJGpQqVzgH92xzn1GKzVtfJ3JbGZIzx5Ylxj1AznFSPFNbRgJcBIxxiZt6r9M/MB9DU0NxdsG32cTrjiTzNqP9AwzRuNS5dGI9g80X7u+u1kiO5W+UlT78dPaiLLMI5JrvzMcBZflb/dIA/Klee4D4cTpjo0cGcexOefyqGfy2J8wXiseSHDDPvwP160ErXctJY2jA5TzMno8hbH4E4zTZLeHauyCGM/7gUN7+xqjcThd3kz3Ucw52TIWGfT6Gksr6Z0Mc8DsBljtGc/Sk30LjD7SNKJS2RKzsMkKc5P0INRvbxyJsbdzyWiJ4HqPSoheB8sYbryz3MJP61I1ySuTaXLf7Wzb375PH1piuxEijCETBZShG2R+f/wBVaVozBSB80Z7P831Gf61lySyPIuy22ls5DyAE/l1p9rcSRXIiYpCHHygZYZ6UKVhSjzK5alGJHEfyORzxkH/eH9RUKlgDKSVaPgFTkMPQ/wBM0t1DJv3b5WwfuxYyc9gf1waozQ8q+4ux6Euc4HbnihtjhFS2Lt1OsNsZG2sQN3lbsFj2AHqSRUQtZLaNGtmzPt3Ojnb5jHkkN2Oc+orMtbmCTUBGFxDZncVIGfNI4A/3Rz9T7V0SsksWGVWB6heRRvsKUXHciguldQMlJs/NE4Csfw6N+FEjxsNm5g2d7I38JHt25xUU0A2MJkSSE55Y5/L0NVZLRyuRK6bsYV9xC+gVvvL7jJFImyJpw8jgkRgAZLnqw9velL+aHjbOMbWB+8B/WqqteWrMLi3SUD+JO49eOn5VWfUkeTalvcNjhSCNyZ9uCw+gqS01sTWUOYEJVWCkoxAwQRxn6nFXEHllfu7Acbs449DWXZ3kC3brcK5y+5JWjZOoyRjHBHPWtVbuGMkeYrRt3CkEf8BxyPpTRUptbjr8CWEKGlilB3IycFT/AFHtSQ3Vwqj7VbyMNuBJCNwP1XqKadSs4stJcxCEEcEHAPtxSy3sAb9zcg4yVIUjH6VaRm+xQvNSgUsXS524GVa2cn0x0/UVzYmuNO1CWWK21G5sZeSjJsMR/wBkk8j2rrbl0uMIS4JHHyHac9ePSs0birRuSir8pV/un2z+oqZHVSZUee8uYxc28VkkLH7+8yE++BgD6Goxa3d03nRahcRzjIXylCIwz0IHJH1NWBCAWwrwStg71IKt/vDo3161YD3K7TOiRLzieIGQN/wHqPxpWLcklytE1l9niAFzbiGZRzJkyIT67jyPoattKkzhQcKPvOBwT2FQ27RSqW85XTqVBCge+B/WnzweQC1ohJC/6sEBX9sdKZzNWZYJdi2/cCw4fIOR/ntURAdDCrgNjIwcBvoagtNSiuYSApwOqsuTGf8AaH9atIy4DREPF2GQw/CgVmjPmggupx+5kE44DphZF9skfMPY5FI0M9uhJUSxg53QP5TD/eQnb+R/CrV3LCyCNpU3YztXO4fh1NRRPchE8mItGB/rJcJ+Y68UCavqZ14kbzJIJ5raVeA0sOxlHoT0Ye3SoJ9bjsgReG2kGdolicAEe6noT7VtzZmtzEbnz/8ApjaxZYj/AHia5jWbOaW1eM52qxKkhRNx744+lTJNaocHfc0o9ZsJ4mG8sxG5UQFi59sdP5VTuXkukXzYEOPkV7hciMegxyfxxXNaQt7b3TeZ89sedzjBU+7f16Vt3F2xEEulpJM+CZICQNw7mOToT7GiMro05XFl+30uNRiKecT7MMztvUjr0bhQPbFVre4urG4AldbnTHJxcspXa47HGfl6fP09fWr1sRcwxzXE0VxByNkQKKrf3HHXP149q1I2+RtsZJ4+6cA+2KqxLkMAcqrNaFo8HBSRTx7eoqk5SOZZTDdK2cF/KOAO2SM09ZHsJH+wwSPD1NtwNue8fP8A4709MVbjvluYUkgQCNj98yY2noQR1HpzQHMzVWKOVlk2kSL0YDDD6+1XSu9cMSh7DPBqluNtIvmyoFJwML69vU1LcSytG+3KKB3HzfUelURK7ehQ1aZo32oNzgbh6r9faqUcv2jaC4kDAMG9T6mrCyKwcR7uuWIbdu9/ese5ElpM725Jzz5ecqfp3BqGztow6M2bdQfmEjOyEg5PzKf61dt282TIwhYcHsfwrFtbpJQgcmGU8Yc4De2e9bixeZCC2Y8+nOD/AHhQtTOsrDZowRsnAMI6nspHQj0NQTxeYsbSvuUfclHzEfX1FWkEiqUlQydty/xfh+tZt1OY9ybdpDdduAw/z3p6GEU29B9mpimAm+Ug7Q4ON/0Pf6VemhZ4ihXzA3LYXP8Ak1yzSXMEvlxMs0BBxFON2PUE1oWN3e70NobcIpAAlkfCj0zjI/HIoTTNJ05LU0mhljjRo189APlUth19gT1+hp9ldQuzCEDzVOHgcbWH4HvVOW8v/MYzR21o2cH5HlRh65HFMubO21KEPcXcs7Lwqq4XaPouCR7ZpmOr0YurXVvFMrRTFLgDG1B5jfQqOcU61nvJJTHPGtjuGV3YkZh/s9h+p9qrRQy2AVLQLs+X93tHP0YDn8eav+eksAWe2Mcbt1UkqD7EdDSNJKySAQQQOjqSJOP3sj7n59Ceg68VcMhXImG71TH3uO1NhIaIoxSWMgKM84HvTXkWIqkwwBwCWBHHvQmZb6FKa/NjdpuCy2svypnOVPXYf6H2q5G+9Sy7vlOR6gfT+lQalaRXkEhgmUyclBkbt45H61HZOJYIZdxUsmdueUPfHqM9j0o1uXo1puWCMnaykuOVK8qR1xikVFDx7NwA5AHb8eoP6U+W3aX543CHG4SIOM9PmHaljnYBjLxIowccjHuO496olPTQaXEZd2ydoGWTg4xycd6rfayy743Uns6jIYe9WrgCIh1yI8Z45wD+uKyiqx3LywECJ/vqBx/vbe3vipua04p6mmjBFyNgDDO0tkMfXPaldYpwEdd3IZgwwQfXP9aqOrAKvy4Odqk8Eeme3tSLI+SQAHT5cnqCexpFezvsW2llRDGsiyjPG9tr/if6mqGpTyw25Z7aQTOQsYADKX9Tg8Y6/QVbt4h5yTEjkFXB4xn27ipbaPzZWnlBKhNkIPVE4yf+BfyAFVuZP3Hoc6Ugjtkjj3FlziR4yGJPJJGOcntWnol1IgAYu2zjO05X2Prmp7hEeZkiOWAGYz95fceoojQxJ5i4Zs4DdD+Pt/KoS1ubuUZQsaO8zMCUZAp3AP0b/aP09Kqw3O66eFg0cw5ED8bvdM9c1LbOZUxIpYdTt6D6HtSXMKXCbbhQ0Q+6WGcf4H6YqmciVmRqFlXfn5gf4xwD6YPT+VR3UqXDtFNsMkeMpLyVz704xXFuqhJPPi6bJfvD/Z3d/wAQfrVO68t3DNvtrxM7DKNoYd1J6EfyoKVrgunW8k8rNH5b4GNjFVJ56gcA+9X4Y2VFQS3C8/dEpwfce/tVa0m8wOckc7WQjlSBzuH9RUvmAQr5hZVz/Dyp9j6GhDkriSxTK5ktby4jkfs7AhvYjH61WW7aP5Ll54JieVcqFJ/2TjFXXkbB84hkc53hRg8dx61Ew/dnBSSIjLI3NAJCxK8sZKSzMo5G2QHd+XSmfYi820Av8o4c8/4HqKhWxtpUM8VtEsTLlSFIJ+uO1Ri1hEqBmmjyOP3z4HTkc9KB3tsWZbRtrEgqVwVIHWqwmkjJi8srIhztIOG9x6H9KdNAFYDzLksOn+kNkj068iqT6fbysC6yOgOAWlYkHv34ofkaw1+IuoIpVd7hI12kDc+M59Cf6VJ9ps0ZlRWyoyGiZsZ9j0pltZW6SApDEkyjh2jzuHo4PUfqO1Pd9rlwu0IPnj3fdB/iXsV9aNjOTu9SnfWRvXSQLJHKOVl8zbJ+BX/64oOn352+VqKju6SxDLn3KkE1qxJgAFlA6DI+X6cVDJNht2W2D5SB1H+NBOr0RTit9QjhbBgyp+YQYjIH1KkkVHGJd5M9usjsc7ppmYfUjGK0GnyikEtj7rKOfb/JqoLp0DMcKWyNxBwD/tDtQXGm5IsRtdmMgPaLH1AjRufQjp+lR3dsl1bslzKZVcYDBMD8e+ajZ5CjSWuwS4+5kqJP8Casw3Au4BJGQyyDJXH58evanoQ4NPUwreBYrjE0A+0RHaSeR7MPqOfzpHYyhkALc/PGRwc9fpV+7HlSiXleoZT1I+nqD0/Gq8QWaQblIyCevc9D7VJ0011MWezZLkzWU09rckYz1Vx2VweHHvwavadrrxTLFqEC28z42yq+6GY/7LcYPscH61emtGl3bW3c/cdBnNUI4jFKVu8tbMdrqVDrj/aU8/zFBTUZK6N2Xy5YgZOJTydwKn6isa/ilgE80sZ3j5hPGwDYHGWHfjr1BFSQRPbKFs5JBbD7qEedC49gDuT8PyqKa6snuFtbi0ktxjzJGGZEIHRc9QD1OR0HvTaOZtw3Ot8pFG/b8/ZupNV728IBjYqZVXIPQN6Z9Kl8wNJtUCRXGc549x7H0rMvoWVgzOxUHIPc/wCPpSbNaUVKWpXuv3gSQAwzR/dxgDP904qeGQXYAmHlTDqvIz9DUSKNhGFb0jbuB7+tNeUzukdoA7KeJzwqHuM9WPtSR1NW0ROFG9llQMuec8q3v9fWtGEFceSTEeSD1X/vn+lRwxgQmORRJu+Ynpk+wHFYtzd3FtchPmktWOQxPKgdfxFDfKYSj7Q6BtyxEzGaYueVRvlJ9Qo5rPu1iIzJGCGGNwB49mq9bzRS2pKtk9d2M5Hr7VnTqZFkSTBbG05bhj6//Xqm+xFGGpUntzHIGjd1ibo2cgcdD3GKltZ5EDkg70BbAOeP6iljlYYEmdyj7pGeP6ipTtEgiYKJf+WZJ4cfX1pHVLTRluG43xxOAImXo6n5Qfb2oukS4ud7RRCVRhlYAE+hU/nUKsAdyxlFwMr6+ufelliWYmJeDu7dR9D3/lQ9TmcFe6LUMEJlAESB85wMj8QOx9quwr5aF8pg9CB0PuKq20gwIWk3TBQfm/j/APr1L9p3BmkUMV9ODn0I71SMJKT0Q+9EAtyz4C92XIIPqO/4GqSSwyRsYWDkDlJBu4/nio7uaQLt6wuuCrHlM9Me1V9PtnhDnaxYc7G6j6f4d+1Q276FKmlHVmhaSsxHmRhZB91gQCR6e9V4kWKe4RiyrG+4DBDKG5zj65qdo0u7RohJ5qq2AyN80bD/AD0qmr3aXiec0cpZNoZiYzweM9R3PWmTbsW7K5k+0vE4VW25wv3JV/vA9j6+lWp9qjLggAdc8r/n1rOkchCJLO6R4zuHlqGIPcgqf1709dTtxAolaaM4GGaFxn6cU0K13dE80TlCQAwPRQeDnn8D7VHbW0Tt5m9xxxgYZfY+o/WsubVIIpzJFcLJCxxsAKFD6e9SjWbDzA5uvLPBA5+nvR1NuWSjobBwo+8q7jyp+63oQazrncMlcxOB90rx9TUc2q2s0bm1urd5M/NG5KiQenoDT4r+zngD/aEVl+VlcHevsfem2TF8r1GgC4kWGE/cXMv91h1Cj1J746D61ofaDkI+9G9P7vuD6e1VYJ7YDbEy+WeQFXHPqPQ1alVXhCbJJIuh4wR+NSEmuoTQG5WN5VVypOxhwQf8acI2VAEllUjgA/OD+B5zUUT3MTCJYPNXonmMqnHv1Bp088sLHzbO6ByF3fK4/EZ600ZXvoVZ7S73/aNOuIbe8IHD7tkvsy5x+IwalS9vlfN3pvnbgATayBgfUbWwc1ALtyVJSVohztCE/Wp47sOxZN2zp/qiAR6e1K/Yt02QvrltFciM2upxDGPKngKY9w2cGrEOoQzx7UtLiaNv73ljP1BbmpmuG2mPDOp+6r+/v3pggt5ZFkaGJ5R1DoMtgcHNO5nysz5LW6jfztPtZkK5EkTOpDqD2Gcgjt+VSi+lCK8toXibjzImDg/h1BqxJa2oUqsWxuvysQw9+D+tU5LFIm3pJMqN98LIwIz/ABAZwfejbYuLb3K1rfGG4JLyPbsCQjIflP17j2q3DLFKrrbSiVGGNqn5k9eOuPaqtzp5PP2mfccEDzO/pTLSHe5V088H5l3ZV0/Ec5qNmatXV0bsaKIgFGxTwADgYx/Oq0qkFUkTcoyRuHIPoabL5yRA28z5ZeYrhi276Hv+GfpUVvKjOIpGlgZuDFIwxn0Vun4HBq2Yx7jjESm0nzYzzkHkfh1/KlwxBL5YqMBwCCB7/wCBq41uArbjL5npuwy/T1FNUFVVxJuIHRRkihlKVxYWeQEjbjPbo2PbsaLuMSJ+8z5i5KHoy8dR2I9u9Q3EE4UXFqU3H76DgOO/0PvU0Esd3AA4YKThgwxhvQjtR5E+ZjWF5JhrV2AmjyNoGFkUdCPfB5HUVsWhV1YNtORnnGfy71k3+nCS7uV2uH+R1KH5kIBAK+//AOql0ub7RBuZibhD+8CjByOjKO2eeKWxq1GS0EvLd7Wdp7OUNuID27nC/UN/Cfrwe9U47yC5uHxmOQDa0Uo2uD/I/UVtTzF49s6bwwxvC/jWPf2asUwAU5CyDBYe309jSbNKT6FiVQxwXUHg7cnB96nskEcjBWI3tvXnGG6H264/Osq3inUnzJGyOjKCwH1HUD3GRVsyxiREciN1IJPVXVuCQR9R/WmhVrbFnV4pBEZlJJUZY/3h34rLspBMyrFhZV5OUOR/+ut+WMsiO/3eckH7p6ZGKpvGzTGCVQdy/u5EPXH/ALMP5UutyadS2jKJuvssyNIHMb/8tAchD/tCp5Cn3pCFIyQynoT71Hch3OyVeVGGG3kjHXHoagjt3thGYThAcgP8yke46j6j8qLm+m5ZU+REZSdkY5bB59/wq1CDHAjTfu5puS3JXJHAP4YFZ8t3FcT29vOhhjJMkjINy7VPTIHGWx1HatsKklqDCySK3JI5Wmc1SV2WTAtxGVJAY/dfGPmHTPoao3Nyq2+ZwWdztWNBlnccEBepNLNdiSYR2samRRmWRnwsPoW9T/s9enSnR2XlXbsN8sky4e4fhpPYf3F7cf8A16BKTizJa3lu4x5o/wBGVseQjZz/ALx7++OPrVh1Mkqy27HcgCtEBhWUenvWx5YKDykHl4wVxgofSohCjk7CM5xjpn3B9aDoVZWI4ZPMhOwEhuhJxnHoR3qEw5kUyggtnDY4b2Pv71a8g7i0GFdx83Hyv9R2PuOabJcWqRM104gHT5jkN7A+v602Z+0sVbjdZWrSkeWz8JsGMHPX6Yz+FNRGkkLyKAX5HdSCOD7e9WYxNeKrTAiIgCONhhlGeh7c9/y6U6W2dIpBEAWTqQMMD7D09qSTCE7bmS7qSkj4MYPzL3U+ox2qygiwu7DqCQfT/wCtToYvORm2gvu+eMjGD65qpcYiITyuGHyn7vPoaVzqupaFtJnXlCMLyeeR9fUe9TKI87ozsXorA5wT6n0qmXmWZZYhyB3GSvHOfap4lMrLJEFUHJZOwz6e3tTuRKJJLGsyvHN1HOU4ZT9ahjvX87yJceaF4LHhx6+/9Kl8wtnsRwM8ED0NQyWaXazK/wAzZ3DjIPvj/CgSSW5K7M67FBYdduckjrx6/wBKlgJAQxOZNgwuTnv0/wDrGqNmbi3wnzTYGTyPMH+6ejfQ4P1rasViuYzJCQ3Y4X/0JfWhK5nUkluWIWjaSQpGqPnL8Y3nufrVHVIy08G0KCWZRu5BG3OD6f0rQlRT8zBldTs3A5x/vetULi5dru2TYjSqW4LhQ3y464wRzVM5Yu2qH2wkki3AjKnK8/Mnpz3FIzxSho1JjuAN4UHG7nHA+tOiuFgBWeC5h2nk7dwH4jP+FQTSJIfNKx/u23AhuqnryPukjn8KT0Kvd3RTknbcMlg4zkHqD7n/ADmpIGYZIKKOMHGF/H+6ammjyDIg5XndjO7/AGWHv61ViZUh82Ikgk5XPT1Uj/CkdUZcysi2zbiPMYEY+YN1HuKriOSK8EtvvFwVAaMtjzQO3pu9D+FQFSkqksDC5wAeqt6Z96u2rASFH5VQBtIwc9/rRe4TjoaVqwuovMAyjDaeOcjqCOoI9DQvB2r0x8nOOPT3qCRJIW+12245/wBaE5Dj1/3h+op8j7gpCja3Ksv3W4/nVPQ40r6Esccd2CqsVkj429CD64qG8YgeTLgEDbu6/l6/SorjcuFdFMiDIccEj2P9KrLdFpFUSAS45RlyT9O5+lK/QqMW3foU3kb7SYZ4liZssrqcJIO5Hv7VbgXZuzKYwfU5X8fWnXFuZYirQnZ2+bn8AefzqCxilgRY1JJUYKSL1Ht/k1NrM6VJOJYQKk+yUmHAzkcq1W2lES5YKQ3JZeRz6+/vVVARK7IjYOSEbsfYirCWqXEZLIM9CuMc/wCP6U/Q55WW4SxiUqXQrz8jpyfw/wAKz7B5YLo2epujOxJgmxhZ164x2cdx36ir8UJRW/eOiKcFA5GPzptzB9rjIcs6jB9eh69OtFib6jmhj8wRyFgjH922ckH+6T+op7RRxcyYRiciVeAfbI71SgMuGt2KsWHKE4EgHIZG7Eeh6Vat7szO1rNGI7raWUOuPOHqDnBYdwPrT0Jba0Hy7dpRijfxHBA3f0zVC6txFIjQAOs/ySJIflLfwn2Pb8quoTG3L89xsGB7Y7/Wku1aW1eOUMY3GMHqPQ+ooY9bEK3Ij2hSxToYmPzKfVG7/T8qt8PmQMGUj5XHXHv61VjYTWUUj7WiI54zg9CCPrSxjyJSbeT9y7DejZOw/wB4HrRuGxcR424OxVbqw6H8O1VJo5LeQyxoT0DIDnzF9M+o7E/SrDJvIdFAckgkNz9feopJ5oYi00e9DyHj6k9gR6/ShiG25WUyPEweCRlVGOccD/HNQXtqkjtcWjmO5j4cp1bn7pHcd+e/fmks2it5PJYsokBkUsrcPn5h06Hr+dXz5JhY5dwRkfIx2n2OOlIG7FB/PjgXyY4bjeu5DGxjJ98Hj9ao2jLBC6XEc1vIeeYyVz36ZFaaSPbO0c0UvkO2UbbjBxzj0GOaRXSMggs+MYZSM/j+dDXUuN7aFSG4tEkQrPGCD3faPpg4NGo2ttd20kn3ZV+YPC+GGOhz0P8AWtAOsz9FyOX3D7w9x3qlfrDHDIqwwhpEYDauMn/GgG2yKSS6sJXJUNBnKyxL+75H/LRD90+4OKjm1FJkRJmS3lwWixwrsOgDfT19e9W2RUBaMyIR/EjkEDHQioLiw3wOYrmMAqWIkiDKx6gkDjP4CjUI6bkz/vFDF/mADI3f1wRUOVj28lQxySvQ/wCFc/AmoWMcUM9pJNbqgJa1k3svfOxuSPYZon1m3nK2UThXuPlimzhdv8YOcYYDtQbaGxpgLSy38WP3zYVCeCicD6E8mrs0EN5H5qoIbgc70yrH8utVoZlW3EcRgEajbsz0x2/KpfmxvR1fnBiAP5g+vvSRjIWDT4oIIkgOxEOUTaWjRj3wORn1JNXpboqmy7jdFB/1q/MoP81P1FTwtCSShVSPlK5/nUF3cwxIS0kRVjyN4yMfQ1VynvYgS+LSWssLJJ5rMsy9ei9fY9KvF4jGhQYOfun/ADwfeuXvJ7dNX3PIilI8HYCHYueCAOTwOasSfb7hgvm/Z4MA7toMv5jO0H160rmnszVur4QsyxxNdTOM/Zox85927KP9o1TS1YsLjVClwoPES5KQ57c/e/3jU9lHbWCN5DNFj5mycvv/ANo9Wz6/yqyLgT7gMxuoBYZyCD/nrQQk7lZ4xCubSZlTdgLnenPbB5AoF1IYh56MydjG2WT6d8VKqMHO4cEcjHT6HuKikVonMvUDHKcZ9sU9jVRixpYSS7wxSU/xdOP9of1qOThtkigsRzu5UjPXjr9RRv8ANjSSHd5ZONw+8ntkdP5VMg3MRKQpHRgen0pF6xKqkxXIgmAjcnKNu4YezevtVsAxg7QWiDZYL/CfYdqSaCSRCgVW/iAIzk+oz0+lLbxsyMvz+XnBG4hge49D9P1poUpdR7QhHLw5bjOzqPzqWKFNoaFck8lSefw9KrBws4A5UgjbyMnvj/CtCPbuG0FVP6f40Gc20hjRLgLtG1uSGHI9qaI0WQuxZx0E0fyyx+zf3h9ac1zvVgYQSDgljlZP/r/rVWa4jI8rIEwX7pPzY9vUUX7GfI56MsvPMgBYfaM/8tEGCO2GX/CqiyQSXjygZhSIRluThicnP4Y/Oq8l2kUZd2K7ccdT14HvmmwrJExMj+VcSEyO398t1B/vAdPwovc1VJomvZWYhdwkTsQfmHpg9x7daI4GeBTHKHb7rNt2nB7MOlV5IvN3wzx5jcEMBnbj19vqOKlsbWVAEgvZkk4KCVVmDD+7k4P0yanluwn7i0LVmXMSxuSGjyh7HIOBg9CDxVe9KWd0GuoZRC/DyRx5UHsWA7++Oakiiv8AzbhDfwIu4FcWYwcgZ/i46d6sT6fcGHE2pzsmP+WapGPpkA1VtDnVTUpyT6ftxJcgwtnLBHGPTPFRjV9JEkaNdxSTJwgRXYg9ugNWI9Nt4v8AW+bKP+niVnKn88EVcjg2oEgVYxjPyLtVvoR3pXLcpdWJBfBgWs7W8lx1CweWQffcRVdZp4Wx9kdIZXxh2X5HPY9cA/ofrV+JypzI2x8cMep/HvUdwgm3JIT+8yMjrj1H9O9O9zJblGUSyE+aFKjlT5hJA9eOuKiWJ0G19rxA7yAOMHpg9qvWyNMGSVtlzG2Hx0Y4+8PqOarSusaPLIwhUDaSeQxz0x1/Kg6KclsRvNPCoEsrSRcBHIG4egb1+tT+cpAZpCz8fwjcPp61XypAEqmLd0JGPp/nrSIyqQP3a44Kn7p989qRo4Jo1UGQ2wxkrznoc+v41YE8UkgSUeTNjuOo9z3+tZccpWSNUJBC5Ugc+/sabdSLcRqlx+7IbMcqgjYw9uv1HpTuc86TbNPjzyhHKjHXGPcHpVa4EiN5sQPyH7qjG8emex96jgeQwZX5yMK8Z6/UHuPSrcZDq3lyEhjnBHI+o9PpSRGxXaS3u7cPExCk5RuhBHb2YehqqwFzA0N4u5FOQV4KtnhgOzD1qW7QmQy267psYeMcLKo/kw7H8DVIXG/95GJCinBI4dCO2P6UPQ0hDmVi7DI4f7Lcyp55+45GVlA9B/CfVfxHFaNzhFDDcEztGD/XtVBFinhWG6VWVhlHXocdD6gipjJJDGFYtNEcfvEG4j2ZR/MflQZvRlayGftcTkFlkJGHwSCAePzNVLqSa1aNv9Zas2yRuhQkcH254/KpJbm3a5umZl6RlGB+6dp7/wCNTTbvIYXJM8bqVLpzuU9iP6ihla7k1tPvhV5Co3qGJx045JFKY5blNwO2P+APyHx39sdvzqtpp+0qY2YPLEAFUH5XH8LD3Pp0yDV5iq/Kp2j+JQOQfcelNEvcoTTvG0bDchR1JV+QRnBIPQjn61pwzlTgkgryQSQOfft+PFU74JLbujZ+Zfm4JXOf0rOurttKdHuN0truCtMnWPPTI9KNh25tDSubpizqjsQnJB6j6fpVCa6XJ8ondnnA3Y9fqPanTEzxKyupz8ytnr69OlVEkzIzR4UAYznoff1pN3Z106asXPPCqTypPTacj8M/yqS6ZZ7eOJ9uJnVd2M4wc5/SqKyDefkw+eeeDUkUmLxcBAkYO7H3eeBkfSgmpSVtDQLqY0Dglz14xwPT2+tZd3K6q0WW8yUHG3khe5I9McfjVy4kR1G1WNw3CoDkn3P+z71VFmYG82TcZmwGlHTjoF9AKDGKS0Jo7uEAvuHlKMkn+CqE2nCZ5L1ImDsQ3kgfMB/eH+139+lONm09ysxfbAhBVV53tn+P29q0vMfnLBCCct/D+dMJNdCtZvE6KsQAL/d2Dhvp6fSrAPzbye+Aw/lWbqTi1dp1Gbd2/fL/AHSejj8f880+wvZZWkBT94hwx7Z/pSFZtGlFZwySMI7SwSUDlChdh/Lj3pJdKU72huJUkYBSEVYlbHbAH9asSQF5hLE4SaMfLkcOPQ+3arsciSw+ZgDJ+63Gfb6inuJ+67nNiwhihZIIjGWJ3A5L7vUk8mmO8xtCYMeamCpzwe2PatW+V9pXKn0LHBx2Den1rCMU0Vy5UhoiPnjfnBPOR/KoZ20pcy1LkMqX9qruu8AZAGVdD3wamtl+zxEEvJLBnY5HLJ1xx14/lWVbu0U7JbrtKjcqnoyn+HPsf510UKi5gJ3bZV7YwBj09KFqTWio6jRIMowwYmwUbJxj1H+FRSZKmSL5ggw3OSlR3LfZwcp+4c4lj7Rv/eHpmmFgxLoQo6EsDnPo3+NWxU1cI4S7b4mCE/e2jqc8kgdRVu3VSdxxHL2I5Vj6H2NUHBkTMThGC/cHBPuKsWcnnna7lfUk4P09CaS3NaibRpQA+QyOVYD8GX6Z7VVmIsIPOlL/AGdRlmYZ+T37EfqKkaRYHZ5CxiQnPbt1z2PtUs7rLD5kP3SAWUqDx7j+eKo4ne9kRLBHI3mK5kgC5wOduec+4p8myNcpsJYZHOVb29vrWRpb/wBmXY052ZYWGbKRfmyvUxfUDO3uV46ir1w+0lScZHC9AwPcEUiknJ2Y92iCkqSjngqTnJ6Y96y7y3SdAzKUKHKSLjdG3qPUH0qWcho/mIdf4y3GcevviiNoY1yoDJ6kHK+3/wBeldHVGNloR2gklZnmVBLFyIyDiQ/3/Y46DnFSswfzImXAUZaNvT2ps7FIyQQuBlZM52/U/wBabBKtyyiQKso4RwvGO/1pJ9B26kiu7hUfdtQ/LyTgVcgiAGQdpHVh/GP9od/0qJY8FsEGQ9QT/I/WrGfLi8tovNz8x9Qf55p2sZzaashoeU3dyjoSoCFlGeQQeQas2MuElADGHlRIARnHXIP8xWZZ3jJq1zC2WQiIRt3B2klPY/zrZjHyoybo1ByD1X8fSheRySVlZiyW+5fMUnbwePmH4j0pqOsLKHGxHbAIJ27v5j2qQEsT1UqcNt56/wAxTZFWSJg3AYfeXkDHQ+vFOxN+46ZlkjdW2sp5yRyPw/rWdMzQyIoDPnkdmb6epFXEk82MyfdZRhlBzj1K+1Z7NgAF9wUg7wMMSehx/e9x+tJ6lwV9ixHdRy3ETqxeKU+S/G0g87T+ByPxovbYiWK4XYCoOyTHT/DuM1nSSgwXTnG7iQlQQAw5zj3I7d62yBeQAoNhcBtpPDg+9O9w5fZyv0M15VkDKF2r95k9D7e9V/423YK9ME5P4+orRSH5toLFo+MEdPrVe8tiWBjLAqMll7j0IqVrqdUJx2RArmNTkfuD36ge1MbLqAX3DOQzDn/gJ/pVRtQa2vktZl2iUfuZwfllPdfqPQ81ZHmcquVGcjHGPcUGij1L8PAB+4f7wbKsO/ParVu4YnywGOfmQdfy/qKyozMoDKu5T94Lx+nr71WvpLiGMTWnKRj5jFwVHckf0pXsc8qd3uaN9GJxvgmaGXOA4HK+nB9aw5HnW8LXKIs2AC8eTHJj17qfzrZ09muYj56r5gG4SIfyzRc2zkg4zngkHOPqDRvqEHyOzI9NZZod0eRtYkqfvof8en1rSt3K5diEkxyyD5W9Dj+dVIrNZCHi/wBeg24Y4OP7pPUfXtSXEnlW5kZpNsWTIHP3cD+earoZyfMxFiFxe3coIicy4DqcfdUDr35J4pbeV9zjgCN9hVhxn1BHTI5FV9K8xLVEYkv951yMgnk8d+T+lKCYtTQbzsuB5TKflO9eV/MZH4UrBa2g64jktXF1Gm9eRLDnkqeT/wACGMircu94o5EYCUfck5/P1x7VLOnlxKeWXr7j8f6VDZNGkTRcNEOhPXaeh+o6H6CqM33KCXlxPKtjfKYbw8hU+5MnUsueT2yOo+lWLhEKbGGFxxkgqcio9Qtlu4sENIF5UKMMh9QeoPTBFZDXUscogun3FxiG4+55hA6N2V+OvQ9qRrTSEibysqWCrnAkzj8PY/zq2s5EyKT7E7Rn6H1qvc4UkONwOS67clvqPx7VFDL9nxHO+ID8qySDIPoDnp9ak7HZK5duFUQus4JTkEA/Lj2NMs0kUFYi7O2d3mDKgnsOATjj2qzbWq3UyNlWRfm2H7jnpkewq7tDLh12rz8pPSqOadQhht5Yrf5HQMTl38ss5/3gT2qe2XLtHcSH7XjKszZVv9w9vp1qdJgmFfkY75+X8KbcFJAWBUDqN3rjqKbObdlDUbeeG3aewCiRD+8jY5EgH8j71HHMWiR4QUfA4YdParbTmKPE5Z4/4iozsHqaz4UDoXiDYjYoHHf/AOtg0mNXZHctbzu1vMYxI8ZZok5+TuSKytNimn2XBukmCkostvkcJx83qcHnNLLc3VlqlxMkNuwu1QESTLC2VGPlLdvbrVrwvLvvtQcPD50j+dLDEcrE20LjPrwDnvRZMFNxdjrDLF/teXH12g7kB7/T2pUli89isish2iYgZUE/dY+h9aR8BSyKFUfN9M/09qit2ERkg+6ecZ6MO4+o/lT2KkuxLfEqG/d+Y4G1425yPb1rGMQdkkjc7cYQkZ289DWhcu5tvlOJY/4O+R6H0xzWdC5fzGP3GO0sP6/jUN6m1HQjnsgr+fbnyZFYMSnMbE8HIPQ1qwi62Hc9riMY5RgV9jg8io4YneNd4LBvlBHRx/SnxHzIY9rESgYVh37YPqKpaBUfNpchvor6bhxZrKB0y7bl9qy0F9av5ctxAyNwh8o8jpg5PX371vl324kVuR93uMd1qFokmiZ8AhiA4IyDj19D9KTWo4S5VqZkdtMJMG5eSFhkqAo2HuKsLCocsxMvGxg3Vh6f/Xp19E9tskK7gp+SU9weqn3xUbt5YLRltpXkA4Zfb3FBunzF23LeVhzticbWMh3KRjo1VWgls8LaNKbVSP3Ywzxj1Un7y+1MF2qLlGA3Dk4+X8RVi1V4wP40UZP+zn29Kd7mcqaWpE8a3VsQCJVc7gUO3GDwyehB5x1qxHJ9oiBeTcxHzdsH+8uO3rUV5aSIWmsmMTyDJwN2QPUdGx+BqlvYR70GyYk7Ruyjn/Zb+h5+tF+hFrq6JLqAibaw4JwwXow9RRFEykNHjevTPf296uWzpc2yzIhKMfmjIwAR1Ht3qncrNZRpNCjTWjf6wAZZD/e29x2NJq2psqt9CdQr4MWQ2cNF+PY0nkFyyxFUlVt+D39/88Uy3dJghRtyn5SMj5ce9XZFciMsdwB4bPT8ae4N20CJo51RQu1lUZIHT3qwQ4wk0YZwMKezA+h7U6IExgvFlhn58ds9QKkkXyl3OGaI5wcZHuD6UzlctTGEETX14joGEgiLc7GQ4PI9wRmrltqiW7GG4BWdWG7f91vQ8dMjn0oVSur7mf5ZoMBx8yna3cfRqh1WycGKZHRGBCk43I4P/wBfH60npsDcZaM0J5JUAlsf9YDuMbHG4d19j+hqe3mint/NR2jLH5cL0Pp7EVmW0EwR45DJHLjgBs/k3pVWS7mtLwuieW8hCyox+WUdAwPY+/ei/VkulfRGl5ot7t4rhTHvGVk2/KWHQg/zqG+tCTlABjng9P8AaH+FTyyC+VIYPlVT+9JGfLP93H97+Qp0bAwqZFxj5Tg/LnuB6GgmMmmYru0zS7l23ELbW9GGOvvkHNbGjSk2MG1T9xSU7dOo/rVa6tQs7HOVnidCG5GVG4fj1q7pEaG0RCM7VGecMpA5P6GhJl1KicS9NCjpuRvm4Ab0PsfT2qhKWZmU/JJyMgY3CrG5Y3AaXOegdcE+31qpfyomGzICBkHpj1FPpczhe+hlX9nFLFskj3xs2Dhu/Y+oP6iqXnTWUiw3hXyjylyR8o9nx90/7XQ98Vs2l3HcMokCOX4Eijh+OhHY1LLEI3yoIjbAZG6e/WotfVHSqrWjI7WACVdu4NjlWJOQe49qmuIhv5UhiOWHr7+tVWtZbLDWJ3W4Ofszfwn/AGD1H0/KnWl/DfeYkWFkVsurD5wfcd6p6aGcpOQ+2iDkxnidCCpj/iHb+XNWhLyfN+VgQQQeDioIFJlAIWOUnBTfgMPUVMzFZljz5U33lyMqfXB/pTsS97BPbgyCVflcj5mB69xg9zVLUVEkuxVJYKJJtv8AEoPyg/7WefoMVelnjgyoUmR/lWLs59B6fX0qKELb7/MPmSFt0rgcg/4DoPaixF2VRbriOaCQNG4+8OQw9aluYXuLUl13OuGRh2dTkf8A6vepnCQ5uYFD2xy0qqvA/wCmigfqPxqdmHmK8JUMQBjqCOxBoG5tlWTdJDHJGAEcFwwyAfUf59Kyv39mfta7mQA+ZCMfMuRlgenvWqQweaKL5T/rEx2BPII785rJjvnWU2+pRJbSyMQjqf3U4PbPZj0Kn8M1LCO2peDx3SuYnYSKfmjJKlfqKq6gkVxDJDdqrrIMOj8q/wBPSo4Cmw28qbpLc7PMJPH90gjnpjj2q5HayXMXzTrIFGNsg3Dr26GqNFaOpz8c8+nlVWGS5tEPyhjm4QY6ZP3x7H5qlQ22pxyiMxvC/wAjpyMj0I6rV6WEQbjJEmOf3inI/EHofeoJ7FLmWOUDyZtuRKmRuHbkdRUWN1JdB2gyraObF9xCYWGTnDLjIBz0ccj3x61vbN24jkEdPTiuelSeJo/taieH7jOh2MATwfQYbHPFbOnXcQVoZ28udDgiT5eOzDsQe/vVROeo+o9QIyrglsjng5X/ABqCGZvMaIrsdl3If4HGOdvuPSr87IqlpxtQ8eYG4FZF/avIn3uFIdXAGQeuR6//AF6HoRHXUmkWYFjG6+YR06dR0IrNiuF02W4Eq/6MzKfL6mNm7r6gkdO3XpWlbOHQgDJT+8ck59Pas2aFJdSljlYtGbfAAOCMkg/pxUlNXRS1KyxrF5PfaPPfRyImx1jDKuB93n88jvTNKtlFxcS2tndWYQKgBUB14yeP4h7VJBoltl7YS3zMF3J/pDnYg7Hnt29qnsNPfSpH/s8S3Me8PIkzkucjnaT39qptGai0zfd5YoQqIHTaVeMt+YU/0NOOy8gXy2DRfw7vvRt9eoqa4i2YeWNSgG0sf4fZu4+tMuRj+PDEYDgdfY+po8jW6exWiuBO8iIPnTAkjz8ykd1oSEbg7bdsmDuH8Q9/5VBeiWHULeXacFNkgXvjkMp/PitPzPNRXBj+YbuuVcetA1KysIpjjBSXC5PBBx9CPbtRbZzLGRyshOcZVgeecdOD1pwRVBR8bWPRucemD/WoIl8m6mXBIO1sbsMGwRx+VBI+7jJQYz8nBU9V9D9KcgMQ3uArMOSvcfTvVk7HUFz5iAY6fMKhnLwRkOnm2/GDtyU702Cm2rDLhVeB42UeW2RnPysccH61nGKRBHG6lg4AjkByT3Ck+o/Wr8c4DMvyMjDJUHAPboehqnbSqlogkDzRYC8cOvoP896l2Li5Reg14So82JuSCS4+775HY0+3lCo+AY2AwUb+npTnuo4o/MPmZwR5qjBYe49R3HfrTfPikhygVV5IdTx/+r2pbPQtSct0TxNGJCjMUR/utnofQ/40y6t1dG2ojlztOON3px2PvVXaYlYgFgoGfQcdcd/rV2zeO4QD52jZcZ/iX/EU/Ucly+8jKs2bTr4FfliuDscFj8svYHngEcYPfHPNaLXm12yDHkklWXoemMenuKTULTzQ6ybQZVC+YOc+nHscGqNq3mRAXAVnz80YHIxwefqM+lG2jCKjJ3LxtIi3mRhkJ/jibay/0Yexp7rcQICnk3MZ4wwMTfTIyv4ECoItzyAZ8yPGNw4z7t6/UVZhWaSRCjcqMuj/AMY7ZI4P1pkyRNbXPkbRPBdRqvcx7trf7y5p82o2mf8Aj5RcnPIOPqVx/KrMJ8lMKrEH/lmeq/SoTMdiukuxVOMDnHpxTvY57Nu5lG6gt54HjmiMCSY2bvuK3ytj2BwavXphe3lSNuWXaUAzk9j9ehzTroq0axvHhHOH9MMMH6U6wLPBtnUkxnY+Cchh3+hGD+NKLvoy33Znx37zRqY7d5sLuKuAm09yCeT+FJKst0Cs8iCMj7iA5+jZ/XApBGWtUYNmNQxWRRgr8x60wPIpG5S0Yxh1OM+2OxoUuhvTiug2zje1dWteRGvCK2QR7ev861bfUIZZy4Kx7iEmRhjBP3W/pmqMaAszpl19e4H+0P8ACq96AQkjBlbBCuOq56jnr9DSV0FSkps1tU2xvbIu8MZ13RkZBHOcfhxSGZAoaNih3EE91OeBz/I1iRajIz2sGoELPv8Akk/glQDgg9mz1B71pcmQMpKsPlJ68+h9qEzKNPoy5Ldo0bB1j3nn1Vvceh9qz7x1coI2aN1AIDcqM9wf6c0yVy4bCkK3Jx/PFViWdkKDzoyThVOGz9PT3obujeFGKEitpBfxsMRFyXlB5P8AvZHvxXQxRlrZRtywOAM8/hnqKp20JjX98CxbB3gZC+g+gq/b7vN2IpIHOQOM+n1/SiCsYVe41IoTyByBgHJ4/qKzdQsBLPvdtk6jaJo+rjtnsa2Jljcb0YKwGM4II+vtVV8nCOcMcAHGQfbHem0ZxkZIup7XjUYWlQcCePJwff0+h/M1oR3MFzZFYQtwM/KB/n5frU7xOXXKtHwAMdcehFUW0+0SdpiphnH/AC3iYq/sTjr9MYpjbTQksTRTLI7GSQjaOSdi99p7/wBaal0B84BPbf1I9/p7VE1vchkP2qS6iHfClwfy5P0pI7LzMst1Nn+JSgVlPqRU6m0XG1mX4VeJvMt13A8tGjYz7r6H2PBqqbiG0VmUiXT3PQDmFj6jqBnqOx9qVYJoQpYyXKDkoZPXuO34VKiJOS9mqh1G1kB2kj+6ynv70O/QyaSZFq87W8SXQVgsDZLN1KH73sfX8KyNZd7grcRoJwi4ntyuRPF13AdyOo79R6VtweXHGA2TZt0LLwh6bWHYfy6VTtF+wXp09+fLXzbQ9d0fdc/3kP5qRRqK6K8dtJCInsJke2kUL5VwxKYIyu1/vL6c5HNTR6glsyw3yPaSNwpk+6T/ALMg+U++cGr94qzIyAbc8MDxtPX/AOvVQztNEInRXDZV04OWHXA/UUXVxrUujkKZFDxsMZAB3j+X4VU/s/7HJvsJniQ8mPrH9Qp/piqUdqIBus5J7Uhvm8kjGfUqeKnS7vghAlt7n5vlYqYSfrjI/lQ2gs0WpC/2aRXhVyBndH94fgefyJpk8cV2rSQgeeh3Lu43eoOeoPoaqzXku0m5tZLbAIyWDL+YzU1leiQbiAy8AEMGHT26UkxWIQsc8isCcMcdCjKe4OOOOnSnRW1xaoq2M0pjXkQuQ3Gf4T257dPpTJiYb7dE0kPndyMru7fmP1FW0uXVyJYgHBAVlb5WB559PpTuNoVZlMibpliuACSJUKsfqOhH0zVJJfM1lSxG5oWQ4ORlSDn8QatzJJPGRJDG8Y52mT8yO9Y+oW11AUuIWRxb87Xc7gOh5xzgdjzikybaF/UJoLZXIdInth9oxuGVXoSfYjIpmmTNeySXVtdF7d2xGGIG0Y4HAzke/rWDdS79ZFtfXNpbR30sEpVyfMk2dEQ9CrcYJwPxrd8OohtryWeaN55rly3kcoNp24H0AGaroSpa6m5LKCxieUMr/OCejDuD6GmTIIwWjzsxkqPmx7Y9P5Vl6jORa/aHLh1IQkrymcDBHqDitAXPlw4c8Af60Z5zxk0GyjbYjlmV7Yj5m2FXVRjIweq5/Gn+YsZZo4/Mhc5eIev95fQ+3eqly6IhkCebFkho1/h+g61ZtljmiikikChgBuOMe4I7H3pLzHKCRPE4LlPNMsCgOhPJ29xTQXSZgkQlSSPBR+OjdVPfANOmzATIqsrbvmjI4z3Zf8KWWVZGimiGV+bI7ZwO3+FDMyxHgurrK3ygfvQMMuD3FTyzI+zGFkzg7eh/z/WqkWFucA5ZuCrn72e4NMkcRxNOQx4wylclQD39qpMTSuQXtsFlkYLggbthyAQOp9QaNOVltEDozIFAKkZZRj9fwo1A7Ym8gFlYgFCxO3Pp7VWin+yzLHKzSW0pxE4Jyv8AsH+lTomaK7RoGIMjBn3QyY2u3qO31qAWy2yl4wNp4K9QPp7GpkniErLGDNHkbxjH/wBamSznzFKHKscYyCCD2J9QR+OaeglzXIdp+9FyCT1wcnuAf6Gn6ejwynywEbPK44z647UZ/esoZXf029T6H396W3nTz1SSZ1VuA0mCPpmg2d7Gnjz4miKHDHO3pj/PrXPzwNaahOm1mBZZlY8MgIwf1HSt6M+btjfc5HTjj3x6mqN3tkvQkh5MPyODwfmzwaHqYU5csjOySM7wuejqMjr1PpU9tK8Dh1UrGTllH/oSn+lRzLLHIXUEDoSAMH3Iq0gCKiqmAdoKAZ/L2+tJI6pSTRp7fMVeWeI87uAVpiDLbfk3NxvPGfYiq0Ei20fk8sqtgZ7dx9PpViMBo9hySTkbuPw9qrdnI42GXEbRoxxsYnbg55P9On0qHzfLl82M7Nw5yccjkfpkVY3g4SR2xnHK/MPYjv8AhVDVIGlhWFCC8xxjtjuwPakVHXRklgN9pE2FSYKCw9c84x369adc26hT5SLtfqB0P07ioLVjPAsgXauSH2gBo3HB47/SrlnMipkFCM/MOqt7juKa7MpNxd0LbwgKAWVsfKSeCM/5/GoZ4BG6sVypJGff3Herly8TxhzJsforj19D/hWe80gyZBuh5/eLwMjsfSh6aAm2+YyryEySkJGrrHz5Zxg7j0H5VZ0qeC4eS2keQMpIVzwy46q46ZGevcU6RULCWV0WdzuHGeg6Z6cCo3gjju471SQf+WuOccYD+hxzn2PtUbGkldXL5QgssKxsG5L4+U+4HrVFbb+z7lrm3VnSQgzx4+c/7YH8x37c1tKshA+VGBHIHf6UssYMfG5to6EfMv09apIz9pYjWXfAtxCBKGAPyN8xHt6/SrNrLFLGJ7aTcjLk8dT+P8qyJI3tTJLakMzDcYy+A59QT91v0NYNr4ij/taSELLa3DNuZZFGc99w7+oI96JTS3IUXPY7uNhKu7zCuQSrAZFV59zofMiYsMEnrn8PSq32yeOLzZIkbIBzGeD9Qen8qU3YxlI5FXHyg5P5GndMhRdxJPPib9zIskLnlJH+4fr2/EYpstxEWCXCPGRwVkXIB9mGRTBdxOpOFY5JBOQxx/eB60+2eFoSVO0jgoxGQfbPSiyL5WtWUyjwyvcWMu+IkGWFiGBPtnof0NTm4jusyEb8fKSo5Q+h7ipZo4mXIjVdvVgMMKz7xvLmMjlopR92VF7Y6EfxL6g/hU2sWk5Gkin5ZY9kgAIy3PHcBuv51TvVUS7mR0YAhXU/MOexHb60xdRWDH2mDy1k/wCWyN+6P17qfrxV63HnMQwQxjlSjZI/TpzT3ISad2V0nmiYlwLiGTh2UAPk8AkdD6HHtVHUo47iFYvO8po23wyFSGgb3B6r2I9K03X7MhHLQY25AyVz39xmq8khlSN3K8jBcAFTzggj1pNCS5noQQXj39kPMUQX0J8uVCSQr4yOe6N1B7g1RWQNO3mIom6uV42sMD9Rg1FqNn5N9Dd2sot5ovkZufLkQ/wsPTPpyO1NkLy3kWfPs5eI5Yi+4FScKyn+JQcc+/apki4rl0LLXCu4Cjcm3hwfmHt70sbSicSbgysACzDK49xVCYmDUoRNK0QY54IXcR1PSt/7Ih+dUlwwO9JG4JPfj2weKmL5ty5NRIhMyKSwBXO3Gcg9+KrQtaOwjdUEqnOCMOOeD2JFX2EUQHyYU915U4rP1KwZylxbeW93EMxMx+Vh3RvY/oea0Mrln7OXiaOGZvm58uX5gffPUVBbMSsyz4BJK46jjjH0PWmaffx3yEQkx7hks5GUxwVB/vdvap5o9jrsbCONgHow6H37igXoQu0xuAsb44yO+QOx96mmD7lYgLx065/GqkUssJUyFSQchxwVPofatJ8yxsWYbWAZR2IpJIcrnEa9EtreyxPZSXFvPLDJG8YGYgpO6Pnseo/WtDw9De2J1CSPMUEs/mhG+fyVKjG7HXPqvTvWX4i0+3TWruXU4ZJbVwhjRixXGPm2sP4s9j+FZfhoy2erxR2ayoz3DbFuNys8AX+JT6cYNVd9SLJu6O/1JZbt0lRlFoQQsj8faGH3SfRQc4J6nkcVfsZ/MgYsGQ8BkfpggdPUZp10Rd2s0U2z51A3KeGHT8CKo6C+6yizmVoW8puueP58YOKT3N1dLUkl3Rhg+4hQcOCOR6ZHUU/Sp/3MYHzKVwWA+U+xqxdRxC0c8JuzjHQnuPY5qr5bWSNK/IVQGUdcDuR3+tFtTZSUommuGR2LSFMjtnZjsR3HvVdkdJme1BBUZaIHKsD+oqxbtD9nBRhuK8HHzL/iKidjFciWPaQ4wQDkHtkf4U7I5uo2OFZhvC/uyCSpGChz2H9K0YiXRWcA8HDjHzjuD6n2NVLa7Vblo5N0YLEru4ZT3Iq87kMwiYMTyVA/U0kRJvZmU0n2JwJgfsSkkMOsJ9D/ALPv2/WmXtsjq8MihlbglujA+uOM+4q3KXOdilHb5igxiQev/wBaqUXnW7N9njMluMeZbjrGP9jPb/Z/L0pmkXbUyLcXVrfpD5rNtBwrtxKvrkfxDvnr1rUdkZSyrhmP3T2P8wf0qS8hguIFlQlgvzLKowRz0I/pRAnmQ54Dg7cx8YPpn/PapUbGinrdkE0j7FMjKI2bKkn7319D9KtKwnVFlIZDx93j6f8A16gSPJdW+eNuCNvf6UiyeTtjCNIOm0j7tNG9k1oaenyOu6Mt8gOeWyRjofp79asj9/PMZd+VwAynGe+QfXms9Z42tAwY7s4RRwc+w7H1qxZErEqSjgZLSFeGz3I7VRxzhZkd5HIjbl8tph26Bx3B9D/kUyymW8iIddhDHzIpOGT2yOo/+tS3nnK2dy7d2wOGyfUA56/WqlxKkEwk3KnRLiIjK47OPpwDjsfapY0nymg0YiuAJCZImXKv1PXGCfxq4kqCMoMsvdSMkj1HrVFC5T+J41BUjPI/xFRCTyIgodsZJ2jllPqB3+lNMTV9y4XCJvwDEPm3dCo9QarSKGIlmU/vB8jHjaPQ+/c1CZ2d0lfCkkbTGSVP+9nvWnb/ALyJjIud3B7hvb2NFuwNOOvQx1jePUnVyxS5G5JB1Dr6+vGOfapLWPyJrsLnLSZwPu8gHOD71pXtskVm0kYXMB85N3T5eSPyyM1GinbHIRtWf94B9eQM/THWny9R+1T2KdyrR5A8sA84UnDe49T7VBJIu3HJi4BUjqa0Lm3KhkkPyYzgnkfUf1rFe4a2uRFKGltm+4QvI/2SO/qCKl6aHRSnzIsPsLMrEcH+Ljn+h96uwmRUBUeYO64HSqG4XPzQHcnTqCc+mfX2q1ZMGJcsDIP4cbc/X/Gg0nblLkEv2UlAoWyIyrM3CHuMddufyz6VYVhJ9wgnuh6/gadDCEVsfMCMshGT/wDXqktu1o7GLm0Of3ec7P8A638qbujg0ux9yHRW5AQD51fjA9fpXNal4fgvJoxIAqg71cn51Pbaw7e1dLPvnKeXIvyjBVhzj+tRyt9nAjaMfLjgnBGTmplFS3LhJpaDbeK5t7JYN4lcAplhhgf97oe3X86ikkWHAOYS3BSQ8E+oPSrERaBQ24Fj129Mf570TETqUBUY4wy5H41VhRumVZFbAZgw3EYC9D7/AF/nUMqI7ynYANuN/U59/wAKFKQHyiGjf0U/Kfz4NV7iVlKtgFQSODj2I96TZ1pNlu3uSHCs4+Y4DDjIx2/z3pblcYdP9VnJK4OPfHpVODy1cxg5Y8lW/pV+CJGTaWZh1BJ5H+Io3FNKGqKsS7SwDMUx2IyD6VZ0+BBJ+7LwyDrt6H6jof0qeKyVDyqyAnhsnNSonzbl3EsMZXkimk0ZTqKWgskjOhiuIgJMZDQnII9QP6ViMhV5xbvkLICQeQcjPI7fhW1C8Zz5rAHkB1yB/wDrqjcxn+0HKkPmMHphlIJHX8aDGm7Mo3M3mRt5igBjgoeQR3wTVPyme0+zSKZ7bJ2ox+eMn+63+Pp1rSljPmYBzIefn/iHvTmhWMKVjKAnBZDnDEcUrG85RtchtITfW0U6NDO2MFLhfmRxweR7+1XXd4SsYj/dDgbJBhT14zzVC2t1DzBGHmRuT83DEMAePXnPWrk5LAbzlQMgqPmU+47/AIUzB66ErSSzB1VEjlYYDFsq31AqnLBIqjq/dogCFPsPWoftEgkG1XuVyMhPvDHfGaspqdvMHSO4jbuUkcKxP0OOaBWsZhaLc13A3+j5xMgXGxugfHYjuO457VeilaaEpHIpZwPLK/dZh0+h4/Go57Zseejr5wHMu5SG9nA6+metUxe2+nERXDxwwPghDID5fqODyue/UdOlJF3Vi1dL9otAyD5z93bwQ3TH4GrdjJ5dgYJ12zQLy/OWXs4/l7GqMN1FJLstjJLCcyKcbVD+hY/nVu5tzM0M8siRzxHdDt6J7H+8D3oSsS9TC1SS5Mt64v57VYjC6wRsAHjY4Zzx2/SotIiiu7TUbW6mN9tu22zO24twMEHtj2rSN/e3VxeRWkdjB5QEZ+0oWdmfqo/2ffvVi00x0shFK1qNn3BbJsVR9DVvYmGktSy0zAOMBZVGBgAg+hx3HvUKxzWd+bmNP3W3EyJySvXcPcdcemadLIolhaZk3DKhwen1IrQyeSu0OpDRuOA3t9azR2T2H3xWSJDHtcTYw3VHz39jimOjCJMKzqG2shGGUe3rVOUw2cqxSH/iWykbTjm3kPAU/wCwe3oeO4rTVWW2YSKSBwW6YOeM1Rz3sirph3WZaVgHhYxNtGChB4OO3GM1KrR4ZDIEmZcLk4WQD09x1qK2Ii1C+RZDG7FJA+ODuXkEf8BqS6hhvbQRXSKpXkHPMbdsH+E9wfwoFZsmmiFxZFmAMmA8bMclSOmT6H86mtZTJErfdA+UbgDt9j7Z4zWbbXk1uY7e+KrPu2pL2k9h2B9VP4ZqWW6UTthsKTlnX+A+4/SlewlBl65t4pkKy4Dryu3IdD14Pf8ArVSWRoQguSJyvAlTgge47/SrNvIspWKRSHXOB1GPVT6VHd4Z8xyfd7MOR9fX60xRTTsyCNgwPlMA+CQ3QPjtg9DVVA0Ey9oZmELg9AcHaD6HPGehBGKlVNxLRKMnjyyePqpPcehqvexvdW0kdu4Wdk2hc/KT1AbuOcc9jQW12JZnRJdrsWjGPmJzt9m7/Q0GMGbKMzIBj3Ue/r7GpbG5jvLOO9GVldcM4H8XRlYeoNSzuIEZyo25C7AOmSOntzSNI1LbEEMZEwfuMADoSP8AGpL66Nv87jEJIBZeNvv6E9qY8uwPtAOc/Keh+ncVU88TDZngnLRt3z1/z3ov0NVDndydGG0FXOzGSM9c+n+FVJovM3qFyjdVY459vTvTkSNfljx5RAGyQcKe49vWp9iGN1XMZH8DjIH/ANakXpErWdxi1Ec80m+AmLHAIx7+uMH3pTC3nedayOyggAjAb9fyxUJVU1KeMNsM8QZkI+/t4JU+uCPyp8DARyFGYFCQDnHHqD6+1D1JUeqLsanazuSiseZBwR7MPStC03BRsbhuqNkBh6g/5xWPayMZtqSLnJO91OQe4IrZtRtj/ebEYcjJ+V89we1EWZVfd0Ls7wzMkAY4fmZW5+Udvx6fnUFjceXAIJG+47RBlOQQDx+GMU2KPYvmScb2yPVB2H0/xpIkLSXSsARIysM9G45wfw6Vd2c3KkJcOu1/MY4I/wBYOQR/n1rOuFVk3FSYwRjn5vwPpV4q2Pk2sx42Mcfl6fyrJnVom/djac4aMr0z6UpO51U2tkIIhw7FlnJ4lT5G+p9e3WraPOMOyx3AUYLJ8rgEd+xH0psUSCPDBsnlRnOfofWrlrE2H3/xdM4Bz7ikmxVHcnt7+ORljZiknZHG1vwzV6dFXjgA4+bn9aoRxR7XCRblPVHwcfQHtT3VkRHh3xJ0PcDt9007vqcskr6DoYGhlJlc5JygPQ+4Pb6UyVfMfD/NIpKqP41P9alLyCHkLLGACWX5T9cHj+VU57qEriRtuOPnGGH+P0zTsOLbZC0n7zy5Mu3QqeCR7e1VpHaNtwO9VOUP8Q+nciprpo5F2zBcHkTIMYPsaosXUIqkOV4wR29jUtnZTjfclmdJEkZ1EqPzwfu/4U2GOPySspHqWz90nsR/UU7ZHtJUHJHQ4INWLSBXO5gyFemSDuFFi5NRRALcxRsWjEqoNwxy31960IohJFG8ZMiY+Xnacexq1GpibAwGxkDPX6VXYNBPL9mVs53SR5wDnuPRv0NO3c5JTch6T/ZY8su+Nj/rB2P+0B0HvUqkTsRlgcZAPLY/rUaTLOgeEkgkgkDkH0K1UiQwMWLgIozhD93PfH+FLYjlv6li4+QYYbQx27hnA+orNuJPJuYWkjBJyhwSRyM8flV2Vh5ZAICkYKsSAfoay7tFkQszESRMJFYd8df0zTZrTjpqWxLlSZEJQZCsvVfr7VKqieJoxhJCvykck+hH44qvCAJMRkEdM9iO9MlZYnVHzGcZXHCt7Z7GkmE4pbDQ6maSRUaXMSuVAOVPIOKQTpcQKw3MD8q5+XHt7VJHIBqUsbyKSsIZdxx1OefxzRcRRu/nI6Av96MHgn1FMhOwxArSZ2kMQR8p+Ye4NNnCvtEixToONsqDcD9en5imPHDCXdDG+/lmY4bOMZB+gFULy9mt2JkhjaLK4uM5C/76jn8qC4x5iS8itA26axhUNjLNEo5+o4IqYx20Ns+IIfKIOf3a8jHcioY5I5Yg8XlupOTtbKk+vFRxlJ7nys/cwXXoWPYY9qVy5QSRGjyWS7iGltRg7VO6WAgdf9pcde4961PtMN5As0EqSoxASRPp2qMsIMngMfm6cKK53UrRoJHuNMujbrcf66LP7t898fwn3FFyIpJ3K2qLu1+a5udMuL0oqqNqHaAByg5HPcH8K6Lw/c2n2Mm0snsYy27y5RtZj3KnJ/L2rAj06zdkhnk1CGftuuT8w7FT0NWdMjfSnltk82ZWJkPmMSWHsD0Ip8xcad3ex0txZLeQC7hkMTnDiZOhb0cevvUsEzW4JkT5WwAwHy/8CHb61W0l0D3kIZQN7SKCMBlJ5x9D2961NPQEb0GCoKgeoz2z/Kl5kOTSsyO4UqnllUkScHKSAFXz1x/nmqMVy9gPJZ2ktGykbsTujz/yzfPb0b8DVyTNqzosZNu/ziMcDIPJHofakuijxySlA6uh3NnJC/Q9R60NiVnuVoZAmpSK0Z2m2TGDwBuPI9Qas+buXG5XkX5cZ6j/AA+tZCvJHfRqxJItwsUvtv8AumrC3YExVgEG4jKkFc+hFFzWnHmHTRfvJcRtPZS8NG5zt46H27/hUEcJDpsczwAbE3thgP7qv/RvzqwXwnyHA6AoTx7E+n1p8wVYNzYyeCeASPf6dqW5typaM2LcrJEgjVmdOQpAVh9R2z/OkdjITI7lQrbVfuPr61h6fczRt5cz+a0Z+9jDY7fmOnbIrajvNg3uS6Mc+YRyPZh396e5yzg6b7jRHu+d8Mrfe3AEHv8Al/Kq8lojFZo8peqBluTvUdiOje3cVfumSMCS2ZcNyVP3T+NM/wBYgXG0E/dY9/Y/yoI1epi6VK1u7uExGJHjmC9AoY4cfTP5fStm5iaeGNWzsWRXZevCnOQe4JrLsg21y4BR55WOT7kfkcVp6dJJ9naN8rLDlDkcEDBB/EYpoJK2xHM8U6yA5Mi5GGGCPx74qjJA2wvgjIyHPT8D/SrdzukuXQqUduVX34ztPr3HvTN5VuX/AHL8BuwP+0Ox96VjenJpaGb5ZDbiQewOD8p+n1qVGBYGZ2jU52sozg1JP8km4BUfv2Rx6expkI8xT5WSm75lxyBnvS2OjmurlXUxiSyMmGUyMFKjg5U5PqDxVmBSrDzgGDjchz0J/rWZOZLa9tbSRy+ySR42J+8hU9foTj8q6C0QTEoFUFgVyOn5Ut2TJ8sdCsFdsDDJKM7ZMA/T61pIjTRxo52HHzsgwGx1GD0qroRMdmsE5MjIeQ3Xbk7WHqKvpufzHKk7wNhUdu2adjlqT5tCclDGzKwUf3h90/Wo1IdSJRtGedpyPr7fWnxfLGVZSkh+93DVXYvEBLbxlkzlk6Ef7v8AgaZkuxII3ZmEiM645/vL6Ypk0byRgFTIgOQ64yD6+tSRyQSbVEjRt/CSMfge1LIXMjFyyPgAuvQfX2pjTdxtuFByQG3cHnAb3+tWNse4MMqegOMg+3Paq3lOsYBiVTnG7+Fj6+1W45AE8tvu9djHOMdcHvSQpPqNkDSOA6ccY46EenbNKG2BnAzj7wRvmz9DTGTy3LW65jz88T9ue1DxxPyG2H16YPpTIK0y5aR4shW4YZIz+FchrF3PaSsuSpQZiJOUbn/9fWusvcmMqzbZCvy84/HPT865xvs+oI63EgicgqWxjHsR+VRNHRS01M3TdS+0MY5Y9lweT5TZDgn7w9R9a2SzPHuhmG7/AKagc/iOlc/FpE2nXoFsAyk7sK2ef9g9s+hrpreFpkBlIYdNr/KR/SlC+zOpSRGbxFcfbUaAjgSn5kb2LD+uK3oWEp2qMqRkEEFTx2NZMNocuqbu+VHUD0x3FNghjg3eagQg4IUn9MVafciaUtjSle5tSR5Yki6kkcj2+vvSGVpsMRiP1YZx+NVdqNxAZpI2XjMrZHt1/SqjQxx4+SSRMfeZs7c9ic9PrTuZqn3L8e1ZTLDLGzkYZS33x+H86tzFbiPIVhKFzhlwfx/+tWfHlORlGHQquCMeuODT/toLb5ECsBgDoGHt/OlfuRKm27oRI2COrlnV/Q4K+2e9VmZosxvEfKYfLIvzNt75H+HrWgk/mqzq2Wzhk/iHpUVzEs0RZWJ2nJXnKnHHFC0BNp6lCyZCyR4FwCODkhivrjvitGaG0mtypiV2fjgZyO5x2xWdLDBc2/8Aq9ssZBDjjafXPUGq1rdyfahBcF4bvG0EkN549Qe59uv1p3FK8mXoI1i1ImMqwWIJtk7fMSMH8K02eFkAUlDk/eHT6GqVt8zTEgN+9RQQem0Y/qadL5cMzzIzsmPniUZBHYrnv/Ogye5DdnymIYhckYbPB+nvVeeJnctHgqRgNyPzrReO2uYAEbMTjIxyp/wqhdzT2DBBEZoCOQh+ZfU47j6c0MuMrbbmcIZBLmOANctnDKNpJHdsdQPcUtzYCW0VMBZozuErZyWPXkevf8K1baUSRiSCOOZHHDIckKPT29qkIjeDarDBPHOVJP8AnpQo6WCVTXYx7W5mBKXAdmj+VwVyQ3YkDnnsRwfapHiivbOZ4ZUfI6Jhgv8AwH1p01nItxHJbt5d1GMRsV4I/ukDqp/TqKbHBBf3LR3kIS+UbmR+H/3lYY3L7/nUpWC5yN5IdNuPsdxq1xcxcMY1tVcxg9CP8OtaWnZvLMvY3st4m7928sewow9COcdjmoNX0xl1C7ghu5EeWOOdU3tuR0PBPsateHoRcRXF3LdTFriYuyxSFVDYAwTgHdxVPaxpGdmbs8Ygaa4j+ZIJyzKq4yrAb8Dtgc+nFbMJeRpfLkDxvghiPvDHc/yNRWPlyXF28G2XEpJGcn7oH41Sth9hmVYnIELlCh7xtyjfUEFTRbsQ5GlcITCBt3MOqnquOM+9V1k+WWPcN56KR8rn/wCvxmrs74ZmbPGNzqOR6VlX63MUqywkGVSGYD+Mev1xnkUCV+pGrCLUXieLAaNUKk/dGWb6H2qvdL9j1ONtwMV1+7BwABJ2DDoCR3709LlJr2fzVZo32ruQ5IAGf5ml1G3a9tmgmJlhkUqkgHX6/Tj6VNzaK1uPIZifNGGAwGyeR2z709OhBcbgeVBOCP8APeszS5rgP9k1DmePILjjzAP4gfXpmtKWIb2zLsKnCnHAPoR/Wg6roWQRreKQGUSqYyvbcOQR+o9qms7iWCY2lyjPG4JjYDJ4PIHuP5Gq88mIF8zO5XV8jGAQcH8eaddAsh2Z8+Jt0Zzghv656cetBm43LySpE/mIQUzho1GQx7kD19u/1qz9si+zM0ISQIpO3qH9B+eOlZUUouYUfc48zLbh1JH8iD29qSF994ihTsMmSw4DSdsenqe2aZjKjdF/mws0ZfMktVG2YZyyN1Le+D1qaGRBLJsxsYI3yn24x6U+KfbkysPNX5juGDz/AD+lVreNbVW27vs7nnIyYs/wsvde3qPpQYbaMfemRUy2NyncpDY+o9jzWZdyeTiSSXG4gblA69gR3B9auXe5EZ4sFlXdtHzDb6+4rGuA0ltKkqMJChwOoOBnFDZ1Uoq1zTSVGjTftIPJTPyH3HcUtnDIrmQZLE4K5ww/z6VSsUBMbxHGR8qnkFsZ4rZhR3UMRuY+2G/HsaFqVK0UZWsWrXep2UdqQkkMUk+1jhc8KAfZuRirsM/+gmaEAN/q/Kk++knTY3uDjn0570lkfOuZ7zO7ewRGYZ+RMgZHudx/KqmoQvJMt/YLlohho15W7x1Kn+8o4HryKH3OXmdrGjODBFBJE52RjypGA5Cngn8Dg1owHzwu1VXttOQAR/L61StQlzajzZD5My7QwHGCPT29KLI72ty7YkKNExP3dynv+R/OhX3Ib6Itl2WQIybSOdpOSP8A61TMiTDKuc9CvcD+ooLbkCZCyDpt56VA02yRUnADZJjf+FvUe30pivcrXEJjYtvId8KCPl3DHp609iwjHyh2HtjP4GkeVZRtfEkYyNm7IYeoPrTvORUG9maIkA7+Sp7c96Vi9bEqMY1yoyAPmTJ4Ht3/AAp6TJJl4tjr0bHQ/UetR+blN0hJHVZD94fWqF2N7u+4I3UsBkf8C/xpt2BQ5maX2hAzJuxzwG+8PpntUFxNLHmRQXAHJQZI9iPSsua5MqADaXUEEA7tp+vUZpxwyM7yspA4YfeU+nuKVzRULbk8xS6DK42t1wOQR7VmHT2jYvy0Z+XIP485qQXGJEEjBwOhzhvwrQjdHQI5VlYfeBwR9ff3pWT3LlFw2K9hFtVA584kdCu1l9/er1uqvG+e5wT1B+vr9etMIKxqzx/KpA8wdRj/ABq9HGflYjqMh1bLH+hqrMwkyo8EkZWSEZA4AY8jPf3qCdFYDzWAkPR+/wBDWoY2jBZGWRj2C9fqOxqjKYrlmCNsuI/lZHGCP8R70NFU566mfIAJgQAZOdrqcEt6EdPzqMvJJKAq7CRg8YyfQ1MATKQiAbuSueH+lT2yneVZdwIyCDyPw9qm1zq5uXUgaN48BG2Z6bug/wA+tOuEwmJOH9V5U+57/lVm4hRYSXdlZh95eRn1rMYToVUo23semB7+1FrExfNqLHFIjo0DhXHOxxkOPTPWtmJ4rlBuzG5GACO/p71jOrImFO4qMqE6ge5qaz1FzulTDRnIdRz+OPUfyo5kjOrFvVFua2VyMAbhgAHOevUVlXy24QrqcW6FweScYPrnsa3JJEVI51KgN03dPwNUr8pcDyZABG/3twC5HccetNmCbMjT5ru0iSGUm8t8bw6ndMvfn+/j1HPHQ1dkvYmtxKJYprdyQGVsnPt6Gnx20MZaOSISRHkMV+Zfx9vWpPskQuFe3xb3OMCaEACQejr0Y/r6GhBzWehXh84gS2ICq33llyI5D646hvfp60yKWOXzogXE6kbxMAD+I9PccUX0TQSefIws5z8plBLW8o/uuOqfU9PU0z7ak5SG+jZSOVJYH8VYdRTuVB82qGhDaTeZGXgYcsM/KT9P8mrDTi5Bc7Y5D1kQZVvZv8f1qrulVQJB5yqOMgbsZ7jofwqKxlYO/wBmACxtzlSNpPY96S0NZQUteosd09hOEvWLQynbFOTwh/usf5E/Q+tXNQSKaMtOzRmL5wxbY0fuG7GpGj89doRFZhg7fuvn1B4/Csq4mbS4vJuo5LmyJwJNu5os8BSD1X0P4UGJm393Npeoys9xY3Ed0qMzSS+WwwOC2OxB9KtaLGIxcXa3cMr3MnmP9lbdEDgAL+XemQzz6pqVx9ifTzbxJH880G9iSOmfQYx+lOsPtK3oVjbW5a5a1kNrHgbwu4MVPDA/gRVWuhc3K/I6OFYXd5WY+aZXbeo27hnAB9DgfjRqVqht0uo5DsTKs47KSM7h6gjP4VEE2WcPm/vFjURSZPJI7n+f41E1wYZEKxEiQlH57gd/XjPNRc1UFJaGhDdAxxyuwhQttD4ztYdRj+6T0+tOk2TsY2f5s7gQflHuPb6VlWc5t5WimG62bEco65z/AKt/b+6T7CrN1LJb6dPA6AykBIywxksdqnI78/pTuS4WIdGh3W6zSRn/AEh3nUr0ILHIH6ce9XXiEjbAx2Nlcr1THQ/SqJkXT1ZYmZrWNgMP1hdR0PscdauyTpI2+P7jgMrKcKSecZHb3oRUU2Zz20jwxmRv3sZ2+aP+WbjoxHoQcHHZvarKTieBJm+Vm+VjjcY8cEEd8Ypl4wEyOyyiBhtmQdUHZvw9aplZ/tbElBKT84Y7d7AZDDt8y88dcUrmsE09SzK2yBgGLRup+Ycjp2B/lU8Mnlw/uxkuowgbP/fJPH4VnQ6jahFkEsa5JLKuC2PUe/tT1ZJbSOSKYhSoKMEOzPuOxPtSNnuSwBlmkjI/cSky7FI4P8XP5H86vPbt9k3Kjsqj5Xzgqe3Ss9nlePzH2LJG24lT8rEDp+I4rZtGlCjyl3KMZAwrgemO9NGVSTSJEt5p4UuVlFx0ZRjaR749fepJHdMtKzMSQDIB09yB+VV7KcG3KxRTI8Zw0RGQpzx/9Y9Kc9xFJDvjlCuDyr8YPuD09KZyq73G3SNt+Q+Xc9Ub+Bxn09D+lVAUvFV8FpOFXb1z6fTqKjm1dRdRW7w7lmVtpHO1hyUOO/cfjVp3SJzPGyohwzh22jPsezfzpc1y480Svo1vjTIGD749mNyjDKMkYPrj1rQmH7s2/mqjbdzzDgKnqe2T2/Gs/Rr15dOijsEVWO4i4nG0KCxIwvVj+Q+tXIbVFZUYNJNnewkA2se5x3Puf0ppEOUp6MhVjcMqNE9vCi4DRrzIvYLnovv19KmjQgxoNoTPAHCEdsehFWXdHbhSTj7gPIHqPUj2qLCcIZXDA4B6A+zD1pjI4opbO9MVuA8MpZgjDo3VlH16j8abbzRNcy+SckSlij9RlOVPryKkvVDwiGRwgGCsqnIU/wB4/SqVneC+1GSUYLLCFkeM7gXBIJHfGPXg0hWaNksEUDaSBg4H3k+h9qju1xGXPzKOrnv7nHf3qYYSNd7BoiMqw5B9fcVWLSWzMFTfAeSCfmT8KHsEXZlHc5baGwnZh90t68cg0rMkBRlOFUghhyAfcelTiOEo72oEoUFnjAOQPX1H0qvHKLoI0c+UILKc5zxjrS2OmLUtDQtWLoWR44yx4I5B9jUNzCGO5PknXqE7j6f1qK0jZGd1yrFsuSMhhn0q3cuFjy2SAM5HJXmmjN3jLQyIyizPhGSVCVKkHB+tIgDQAgAqudqZ549KLqU/aAuAQyA5GNrAdPoaihYqo2euACR8o+nY1NzqWquzE1lbyFTLbEmLJDBhnj0PpiotMu5Ypo/tDlc8A9CR6Y710kkMwIbqpGM+vsR/WmHSIJXjnY/ulPVeqH8e1Ty3ehMqiW5oWNy7DyxsIyCFPb1FaUW63kBiPGeYGP8AI1nxW6RKkZ+4QSCDx+HpWhBLE8YBUsueD0IrRHLVtuiaSeMqd4aFicYYYwe/PcVnXifaVLbkeRPulW5/A9voatyOYCwZvk7P1x/smqt4I5XPKRsxG1tuR/8AWpszgrMjViYy0j74wvJK8ge47fhxRHzGq7/kboy/MOe3rVeeUEj5pIShxx6/5/CoIZ2E67C22Qk5zxnHT/61K51KDaLbCRMbmIU8Kex9jTHhJkLHdjPRSSPXGDUyOXt8YO3rkcge2KFZVzgnYQAecEfT1+lNEOTRVaNJTnYNygjB+Ug/WqqRtHMGLbW77ecVNcOuc7AMHlycHPuO1REuwwyhypDBg3IzUtJm0U2tS2ZdokMWM+jHJIPGR9KhnJV1SVGjZjkAHKfQZ6fWoJZlmjDx7TMo6gHdnpzzS2Gp/vjFIN5IHHp/9andbGTptLQvxYOYixC4HJGPofcdqSeFoSCikhuNg74/untUrNHMiDO3bwMHBB6flVN3lUtHuV2B4G0jPt709jDlbZahnWbPUtt2nPyn3BB/Wsy705VEn2Py0X+JCm6M/Vex91xTJbj7TIGhd45cZbjr6da0Yb3BEdzHt44I7+/0oVmNxcNTILyWe0XMDIj5wd3yfRX/AKNj60PGLoLLbHfNEcrngkEcofT/ABxWjexzxnfaOkiMC3lsBtkHsfX9Kow2sJdJ7Nvszbv9WeUY91YdvwxSZoqmmpaRTJBHLFIjRkBgsvUnoVz2I96bIC0UqXEEmD95Bggf/WxTo5VhuilwvkJcnDA8os3bDejj1xyM96dfO9u58xFe3KknC5ZCP4vcY6+nWqMlK7OF1FFt9Vc2MIkhUKk0zzNF1+6jEdSP7351s6NJa5Rktktp7RmTyzJuVWYAk++QevWpb/To7qVpra5mhMyKsgQKyyrjg88Hg9aoaABAk9rI0jyRztGZ5GyzvgcH8MUX0NFTs9Udq+2S6ddg3Mo3xk4ORwcfgRURt3eKRIXxPE3AI6MOg/GnSSsRBcZKurAMW6lenJ9eR+VSTBwxlkJUnhyeVYD1HqKQR00IZyhigu1Ijgl/cT4XoG6bh2w3B+tREH7db28qhhbKZG5yHJyqfj1PpxUF0ywvNb3BCrcqWLHgZxyPfIwR7ip9JYXenCadC10zkzgDDRlRjA/ADj3oE1bUkuLpXTD7QVGVPXj0PtmsazgWa3lWOADy5DuTkNjqMYPIwfrSz3Ya7kjkUrcFN8Lj/VzJ3P1HQjtRp7FZLoK3O5XQDJ6rzg/h0qXudMIq10TPa27gSOrGPABPmsRg/jVFILO2urXfAjJ5gjbeCdy87W59CcfQ1swbcnBRA/3ioJAJ65X0NZusW58xREMeXGzFAcqQRgY/I8UmXZPQs2y28VmiKiLvw4Krznucjv60Wkogt7Z2J2uuNw5XPY+oqjYTyraqp2F4sKy9C3AwSO2RVjS1/wBCt90QZSv8RyB7GgvlSVzTli+ckkKxA3YyQw/oP1qfSpt1tslADRbo89+Oh9+CKoaOiW4mtN3ETbldvn+U9Ce/HTPbirduSuoTqVTyZFV8YyCeVJ9ug5pnNOV9GX3CPbbpgRIFwHU8kH0I6fQ1RvImkfyzdu2VBDmNScejZ6irDTxwpGsiGS3J8onrsJ6Z9j60PCrRoibmQ5KkDO3/AOt7im0Y6LUw7rTTcpIJZZABgnaPLYY5BDD/APXTtLZ7Z2+2kPdqpdWkGROo/iTPAIHVe3XpW7JArPFNG2GHyZUfLIp6E/TioNYt47q0WNxzJIMsPvKf73tgZwaXKDqJ6MqW+JBblWySmzg4bPXB/pVi1umikFtdKJuSYZI+M57eze35VXt4XhlEVyB5n/LKYDhx/Q+o/Lir8gSaICVAXIw/cHHofX/IpA7dCeNxLuZVzHgkeoP94+n1pZVMblGZG3ZwTwCfx6VBbOyTGKSVpJSp8qQjl1HUH/aA/Mc1LOTjynCtEeQ4zheOhHbirQk9TNvIVlhKM3mQbtxg6fh7/TpWdbSfZNR8+E+XZTMkEmzhQwHyn25O306VoXts8Y/ck72YqrA5w3XP0A71QitneBoZ96xzck9AwPTP6GoaZ1e7Y6e1uFeRyFKsTho24/z9OlSTMWThWdBx93kVh6QX2eRcI8rJ97d1wTwwP+eQa0ZnnhAIcvEeh/i9waroYOC5tB6HKq0o4/hkU8p+I71WltpLdmlR90UzZK9D7k46n1qfdHIN8ZEeeHA6E/TvmnRljuWNiNp4U/MPqO/4UCs4u45QvlfMhXj5SpJU/UjtUN45t49yKR6EAELnsR6VLbmRS2wKhzuKN938KmliWSIlFO4H5kz0z3/+vRfQSnZ3ZjeS0mxo1GCDuHUdP0q7Z2yuEZJNnY5HDY9azr222XfmW5SGcDBfOVb2wOPWr9s1zDFvntJJM9Xh+bP1HUGhI0nU925YdV27ChHJ5PRqlhC8BiFkP3Rjr71WW/s3fYLmPbkfI58tgfdTj8xQrzYUDmNjx3AJ96exjfmWgXcVwhV4xlcklR2+g7iremMCCyPgsME+vsfQ03zCs6qQcAck5BH40qgh1JJDDk8YzS8xXdrMnlwjk8DdxtYDGaozebt2wKJI1HPOdv4VLPFI5VkG+Ijhccj3NVNoKDyn84KfXn3pNhGxV+zKdzlXAHSQMDyexFVZYmjKpIu+NhuEiHIVgPTrXQWY3KACSw7kYI+o70ksO1l2YWTf1/hb6+hp27GirtGLDIDH5qyABvvKQQQe9aCqSpZRtDcEjOcjviia33XXmFdsvQhB37exqUFYwMgITjbIGJB9aaCVXmRj6hItq5eRk80cjnG/2rOvNSt1iDLmIPzs+8rfiOlXNdtXu4W8tWcngEYz9CD1rz2W42XIt5ZnMQO0ZQhlI6H/AD2qJSszWDujsLDUreY7o+p4PTg9Mir7KjXCyKFDj5lZSPzrzIXphm3AShkOCfTn24//AF13uiXRvIRt2thcK6DBHpkUoyvoa7K5txXIkk+cKcnJkHb/AD6VbuoVljaN2OMYEi9VHY/hVGCATLwQrL1A5BPrWlKDDCXSXdK52+WcEMx4GMfrVq9jmqtdDJ0qTzJvstwcXB3bW6eaMn5kP8xV54yF8u4O9OCHA2svv7VRu9OBiEDrmMAEDJyD/fUjkH3FJa6jKoS3vmZ2Y/JdNxux2kx0b36H2pLexnJuxZ3lZljk/wBW3RwAFI9WxUN0rWzm4iG5v7ueHHv/AENXUZPM8uN/33BKsuCR6/T3qO6tCid5EY5IPUH1XH8qdiU02Vt6ajayyRA4K7JFP3k7g49jznocUySO5msN0H7twCp7hXHUgfXn0qX7KVIdG8mZRhZRxkHsfUVH9qaw8yadG8raxYr2dRkcdsrx+FNIb8jCNlqaKfsmoxOc72tvsyrj1Kc4B/Q1Z0i1Ag1APcx3XnSh5SR5bxkqBgr2IxUd/b6pdNHqFsbGwn2hgh3NkEcBscflVSz1Bbue7a5jay1G3YRSGNwyjCjueChz36e1GxpTu2jp7eVbi3kWGXzIp1IR24JI45B6MDww9frWjZXqzRxRyDY7L8xxxn0+vWsy8WC1ka5tm+aQBp4k5zx/rVB744I7j3FVNJeWdXgglEkkM5BTGREDypJ7gg9O/Sk/IzWu5p6naCbNqpXYoEm7G4RHOQv4/oKo2EzRX9wpKhpVE6hT8yOvytnPUfdPvW9bQlVLwEck7txzuY9WPpn9OlYGsxyWt9ZzJi3VrgIxOMLvG3n/AGW4/EU/MqMuhS1i2a4jTdIFfd5sUqnBR++PT6fnUWkXPk3M63zIgYqnmYIjkbHQE/db2PHpmtORvOEkcqbW/jBPKehz6ehqlbx5sJt+AXR2cMMrIDyAQfYAipOxPQ05UZWV0fy2HBB/u+4PUVBAySWhil+Sadwu3054H4AHmpbJY44Y1Uu1k+GRX5KnHQMecfX6U8wQXt9FG+UaAFiwGGQnhefpk0WYOSa1K19GtveguQVljYBs4wcZ/GrNhAUtol2K2EXGG46D/Oai1u3kFjcwXDfOq+ZDKvRmHH4HtWlDay+QrwrhAByozxj0o6mXtOhFcnyXW7gj4QfvcfeC92x3x3q6UjN1HNCVKSxEEIQQRwcAenNLbSIkvltmOTAdTt4P0NVipt7uGOXH2YhyjAcRDjI/3c847Z9OKo5pN3A+WYZIZXk2nguMFl9CPapLCdZ4QJHRbhCUk4+UsO5x0zwQfeo3MgmI2xsV79cjrxUG0fbNyBCJ1OQT1K8jnsdp/SkdHKacZOX/ALxOWWTjn1Df5FQxFZdSZWKp5AI5GDvbqCPYY9uaQyrbWgYo0hztjQ9dx6D6ZpwtDDBGG+YffZlH8R6sO/XtTMZWTFlUTQlMbdh5Ur0x3Vvam2LhJPId/LkU8MR8j+nPY+3Q1OF2qodm2dwTlT7j0NLJHGcMke9tpDxyc7x7D19KCH5DrqAOjI+YpMhlkXHykdCD6g1Sa6LR+a37qeN8SnBKn3+h9KsvIEWNmLyWuMHeTuT0z3x/tDp3qhdxm1kaZ8PCgy7H+4eS3vjrQxxILlpfMEBXH2j5FGchE6tg+p9D6gVplBNbPE8avERzH0JX2PrVGCJwZLl0MsEi4VM/NGg6DHv1q3Bc20i7YpFlbAPlk4Yj29aRcrdCrasYZ8geZLGpZc8GVP4k9m6HPqPepJXRwW+cwL8wJG04Prjr9afdp5hjkBKyK2FIHzL7EVQsbmOSS5tpMxNGcx7uVweqjPPByR9aT7Djo7lhdzMAjDDL9/IIJ9Gq5bkRqqvv3bsgtj9D60sA2k4AUsNwAGEcevsaS9kwg8kl1OMxuOR/9bNFtLlSlzOxZjdGOV2tkYznIPqCKfBKH+XDhQflPG4e3vVBkljKSxkFW+8hI49qsiUbHdG3TZ2gA8Me2R/npTRk0ixLCsnmuQuSdmSMq23+XNUpEnhLNbEugwTG0nJz6HvU8c0mPJj5ZVwY+/v9e/NJInnRlIyFYAYD/r+H1osRFW3EE0V1GfMKlxjMMqjp7g1SFnaq+YUdXxyIWKED6Dg1L5KHLOm0rzznAH9BTWXdK3luSmMbiclf8aLstJLQeYpNmIr13jI6Sqr4/Hg02wuL9BKC1pcRo+wA7kYAgH3qRlhSEySlMHqxyQT6Ef5NQaW8W+4dC22ST5VI+bAAGR/hSE7bFsTTLtdbKdMnkxusi/iOCKrXhkinluYbeWNX/wBZEyEB/cH+9/OtESsGOGYkjJbbgEe4qSWT5ApTZKeNuflb8fWna+5GqKFvf2whYtMTtOGJADJ6Ag9KuJdpIQTIHQgYJweP896ryW0JU/OwdM4O4B19s9x9ahjV7ckQ+XMRySCEcjPdfun6jFNMGN1VVli8yznWGZDuRt3yk+jL/dPTjnuKjtdUW52QSKFuv4o3PzY6HB/iX3H44qW4lhCHz18phxiVNufoen61nzRWlzl3EEpzx8wVvqCOn1FJspQuP1k/Y4jKI5Hgz86p99PdR3HsKwtS0BdSt/NiKTKRgMCQ3TqB6iukjhlFsFZ5bmEDAJP7xeOnPDfofrVSzlURoySoJWALH7p7ffQ9/f8AWhxvuOFRx0RwbeFbgXJhliLOoyCG25x6/TNdP4d0e5s7lDIrlOVALAH25Fblxc2qxhZvK3cZePJI9iOooBKOvlo5B6NIMDHcY7+2aSglqa+3clYjneONSzMW2/LtThjj09fxqtp90ZH3zjbtGEwMjHckdifWlntg7ZZ5HyOfM64zwAPTrwKjixECYXBGMYI2nA7c+1DepqoJo1ZLdbpE3rt7hgeQfb3qIwI6bHZsr3A6f4Utrcb8tjIfjBGBnHH0pksxsjvlkMcb9G6gA9j7U9NzmlFxdmVxaybhLbsIbiA7tpH7sg8ZHcZ7gce1W7LUElf7M0nkXBXd5LHHH+yeh57ipJ4X/d+UDlRuUk+vv6Gqj28VwjK7sHDF13ICVb2P+c07mdrl1o1PmRMAw6BG9OvB/TFY9+v2aCfCtLaMp3xv8xVR6HuB1APPp6VZklurNNjuBERgeYMxk/73VDz0OV96huERnVbt5IWbkJKcKRjPBHDD3FA422ZzEsuiPAHttZnwF5hguD+6x256D2NM0rTLeewR47iKSNWZv3bEjexzhyfvHpkHirN1NpFqS9nHeGJ3zNJbW7FY4u7IccgHsQeCa0p5vPsxcWojuYW+5NaJjOOu+M98en5U5LQdKTvYvNZiMbrWRUAOfLkTcgP06gfT8qozz3FhJJPFbG2cd4gZYWBxlTgbgp9cfKa27e4KK0MpicAEnPGAfb9akQRFH/dnyWY45zkdMj1pAVrLXbC63qk0cM6ABoZG2yISO+cbl9CM0/WbX7VpN3GCyExFlOM4xyD79OKiMEMk0STiGTcCtvJKm5WAyTC/oe4NUL3TtNhtXna1ZF2kbIpHUrkdRg4I/CgFLsJK+QpJWO4xslZuFI4znPYg5H1qpfaraRW1w4mJZoypSE7vlx3AyAQcc1Ne6dZQOlykcTrtCyMy7iF7MPUgnn2p1/byJbgQCIrJIsKMo2ZyRkED1ANTqdcZXWo9J5jbRiC2k2KgLGUiMYC9weccZzTdN+0TZnfdDLI25o1U704ACHPUAY7UyPdPdLahGWA/PhWDHb/c7d+celabSKJCd25h94chgP72OoI/lQaaNExmbaq3CodzKglC/K3PQ56H2NWdOhV7RA6FmQlSyMRjnjjOOh6VFa+YY98+2RCp+ZU+/wBc5U0+1WSxeR0VpLcbGcDkocdfUjj60zkqRSLNzp1u8W1RIjDLKySHIP4n0qjOZIsNczyFYlGJ1G8KSf4lIyOO4rakkhuLcSxsh35wqnO4HkD1qFreJ4n88KGznemQcnrg/wCNFn0Mr9zFc7ArfuzGOvlHIx6gdx04Bo4NuZIUI2P5xA5Bx3x9M0r2Zt55IQxhdTlXCgowP95en4jH1pEjaLdDKqwGRQokjbdGw5yAeoHpnpSOlS901bNWlu45UO+3HEQOSrE9W9x2H4mrMaNDdNFEzxZ+dFI49wfb3qpp9yv9nW2CEV0CnOCOOOO3Y8VJeOZMujNlTuAPBH09eKpmDTb1LLyCZQqHDtzsb7j/AE96ZFEwt2cDKZxuPOw+tVvtCmVkblePlBBAPBB6cVZR3JYRnfIOx4YUbicWtCAjyWBUu69N/Xn2/wADxVKJ1kkxA6PYN80oQHbn+6e+0nr6dKvxst3JLGuEkX/WAHjI7Y9azZwNMd5CdtmR8x6+Ux69Ox6+xzQwtfQsQKRut5I18xG8vOeHXGRz644/CqbmOR5IypYKc7MYI9x3HvipIfMS+MEu0K6BsfeHynjJ+h/KqWrWI0+9hmJ3W7yBc53BGPTJ6gHpUyvbQ0p2W5bhJmVUkBLrghgpwee470l75UUiSSIpKttJ2/KVb0PUYODVwvAjRhiqnkYIx+Z71FdyRT2r206hA42kg5wPY9j7dKq1jT4tg+aPcUZSwGflXapx2x249OKSK/Dz7G2K+QvPVfy6isxZykaLOyHA2M6j7wH8jVmSNZkDbwv+yCTz/Opu+hqqatqa8uQQUCjg5QnG76EdKacMUcJsYYGG6j1475qHTSSTHIWAGCFB6j1q0YI/PJlzvAPIHIPuKa11MJJRdhGILL5qGMdAynJB7Ed6s2V1tcrPiR8ZJzww7HFQIqDcHIV1XOT3+h9KjvOqtGSSQOw4/HoR7U1oZuPNoWrnYMNExViRjAOQPTFVIJVDyLfeUAnzeYo4ZR0b29DUMmoqSYETzZ8hvIXlvqp7D69Kie1W8mRrnClDvFs5Oxj/ALR7n26fWkxctkOiRtSmRkUR2x5DHnzvYEdvU+nAplvKI4FWfAaWRmUY4GWOOe3GMVoyyDyWkgGxowWKjkYA7j+oqC1EElvFEwBXywNjnIPGTg96LAn3LO0xoQVMkY6NnJI/n+VSROPKKEiWMjcMHOP8+tU45pYlx5hMYx+8Iy6fUdwPX+dTz42GQHG8ZyjfKw/lmmLfcYPkYCMAx4/iAyv41MSCqghQ+cgjhunbtj6VFFIzKWjIYD7zYwPxHb61HcTBYmMuzLcg7eh7ewo2K5W9ETJL5gK8ZHDLkjP4D+dZmpaeGXdAoikTouA3b9RikF0yFGndCeRHIuQR22t6fyq5bXCuMxZPXhiM+9JpMfJKLuUDAYLZjtjDY3DamQwx09iTiqsxjS3EbWyNJsAJZPvAe/UfhWsQk8iW2AAg8xkf9B9e9QX9r5pVkf5unJ5Pt70Wdgjy82pkWV5PAAtpM5jPy+VIA20/UckfU1rB5pAZPJUjqVVxhvoO1VWs4/tQKnH+2OCCOucdKktpWjdS7ZVjtGcAt+PTNJXW5pKHVBLdwyIZEPGCfmOMcdPYiqqxqRlpFBb7qlsHp+vFSXVssrFg5KHk7vvA+tRpp4dEin/eqAGVlG0j3FG5cXZFq0VY5CAj7yeuPlIHP5e9aBKyxBvlUgY2N1we3/1qyLrdap+8ZXIOBMeR07/5xVzTr0sgScNj+6R8w9SKd1sZT95XQ14Ps8g+xu3k4O6ORjt/4CRyvP1+lTRToxKyJsEnBSTrkd1bvVmSMOpXdGqY3YPr/jWdcyrGg3ZQKQxDNwfc+1GxnuW3ZrUNhmliIwRtyR/iKyZ4LabTblBM9rCylHAXfEwbvsPRvpitNgNgwQikdjlcfSsu9imvoJdvETIywTRn7zYwGI/u+n500Q0tmcqkut6aM20dlcRYVHWG5LAKOFBT7y+4GaTw/qcVrdXNtJOiyTOZDGAVVD3QA9hxz1q8bJPsELWkMdlqNv8AKAxAyRwQw/iU+vvUWm2T38N8upWyxCSfzVilwdrbRh1PfkfiKGuxtDRJnSyr9qjWdHCzLjY68kfTsR6g1PFI8MO6dVWIDBdFOwEf3h/Affke9QvDbTyxyW22F9+CVO3DdMEdDz1q1ALmJ9olgO7u3ykn044NBLfYrXrRXltiXMfm/eK9GxyGB9QcEVBbXLXLR2t5gXOA/nZwJkH8Y9MkYK9j7Ul/GgiZrVXtX3fPlcxZ9wOh91xWUysgV5yIH3b4bjdujY9CC3YHoQcetTsy48r9TRvElscPaos6tk/Z3ODk9QP8D1qjp98Li4itWyTEjOiHh+eFHPXbzz9K0IpGa2LksWV9skDjDxEc4z0IHYnqOc1nXcUctr9rMIEch8wk9YV6A+uMfzoNn8Ni7FOTcvFI7C4DCRZlUfOezbfboR2FbcVmt2gmGElzgsDgg9CPwz+NYiWUtxADHO0hRtyhsMyH1B+8P1FaFhdz24V5oUdWGHeNhtfsG2nkHsR9KF5mc5WWhbtvMfdbl0ikRtrMpwCfb0OKvy70kBzjMePMU85z3/xqrE0K3LSBZFDD5lkQjmrcUsTysiuM7VBXpnnPT19qqxg5dxtsgtZhJkBXxlweFPr9PUfjTr774JCqx5ZQcBj7dh9aW9kjSFtrkrypVl4HsazHkEaiKcMV4dMcsMenr9KW2hVOPM7sgu7rbKp3FM/KBjB55z6HHtTInEg2nasnRlzlTz29Khu7dXjWSVm5YYBOMDPP9eRUMgAlheNmZhmLPAZlzxn6Hv71NztUFbQsadJttpEjkI2yyK6MOB8x7e/860BMpWKGWTbtJ7jDjBAznp/iKqaSubSGT+J9zAjqAWyRWpHHGriOcr5vQ8YyvoPUD0NUjCVloU7lHaOMrIomQDHYn2z3qGzvZmkAcS7CCuFwGT1B9voe/ai5tJreUm32jPIjlOFI/wDZf1HtVVkKzPIA6PuBlhJAznoR2z6Hoe9LqWoxa1N1TDPCHQCOWIbS6cDHYj19KbM7SqRIVHrnjd7fj71lx3XnKwUbTnjjGD0xj+E/pUN1G6xmBFeSPbsC5JYHHBJPv3p8wOiiztNlLata+Y0C+ZtUcyQ8cr/tL146j3q5MkV3aMCTLE6nocDb2ZT7HFZlrI889pISQoiLYz8wPAI/Ag+9a0KK6t9mbZJyzKRlWH07EeowaEYSi4mVpTyndbPLl4h88cg4dSeHH1x+B4q6+1wW2/KBjDchT0+tU75t9z/pAaO6Vt0cyfMQT1we4PoaLe985zDcRqlwAdxjOVYf3vcfqO9LY6KaK99HKgDWqfMhwYt3BHHQ+vXr1qxp7Qv/AKp9k442Nw2fTHrUspjwpDZQ9cDj05zUDwQFkS5QSjPO5ckenzdval1NdlZGsCpjVPM2SIc5LYxx1z3p0GoQK3lX08XyY2kMGP6c1QXT7MHymtoXXOY5Aoz06H3rVs4VtPmhgjUcZMaBT9eKrqclRpohnmeVle3iuWbP33Xy0I9QTyR+FULYTTPIl9NFFMrEeSmVVhnj5j149K6Ih3UsmWVhkrjKn6e9Z95EzxPHJGJV3fcbqPcZ6UyYSsZuI1J8pPJCkkYIyp6bs96S/uRcQeXcSKswAbcp5Ujo49R9KWaG2GEe3XJPy9mA9MVA8Udu7AQjcc7ccY/CkdCtMptqsrWrlVYjOMk4I9f8981padOu9oJmUyHlYwPlP4d65/VYXBhe2U+ZI33eoJHqPSrOjGaMbbkEshyNxHI7D8PWou1oNwjY62Vi8inAjdCANvI+lSMHALQKAmTvhbhSfUf3T+hqGyJkQJIg4HJxnA9c0sbIkjJ5rPGeinqK0OWUbaFS6EkUbTWMbOI/9ZA2d+3v+Pp2qOeRLhRJbklJFB3J0Pqcd/p+daEiCRsPv3p/Epww/wAaybmB7S5eRfl8wgydlY+oPZ/boaGVTdtxivHLOflYN90k8fl/Ks68dLV12h97DA8s7fozD07E1pzs0pElvnY42+YQdvvgHnP1qu0aRRyBVLbh+8ZhnJ+lTY61aWxYsZHjijBeOYDLNJyrg+p/xFXbySeOFi9uZUUjzNsgOPcdzWdYeaEUybVKZVj/AHjnH6+lWmdfJKKGX5SjRkAgE5H/ANemtjCdO70BpleIHDo/UORy31PesLUHLSgNgdMhflz6EY7VtW2J44sllJUbwRkE9if8aS4t4iQtxGSykBZFOdo9iKHsbUpchTsATtPmxkryJF+8PqO/0rShmA38qSRnA6nn0qF0AjR1RJAo+Zsc5Pt3qAWdu8nmoAvHGw4KH3o2Jn7+rLl15TxsD8rDhsKDnj/OarW0x3h9wfcP3Yz8wA7D2/Wh4WZeJ5CCdqtv6HHeqFsrm2Xy5iCq/dZFJ3DtnikZ+yutDbtpRKreZg7hnB6n60XLRtAUkIIZcrnGMfWsO4uZRGA3lGfOSF3Bmx145z9as2ModVgngeNGwVUsGBHbp1p3uZSg1oyv80BYEl9KDZMYBDH1Kj+5nqvftxW3vWWHes0axFd/mr0UAfyxUM5U+Xsx127uhUdj9P5VSe0kWzu44WZUlVt8QGcE/wAa/XuO/amkJq6uUb2aSW3eWW1tGtVwCZZcMoP3SePkz2z680sMMTxkxNNDIhKNG758th1GDwfaiS6Bt7qMyWkQusmVJgwdSwww2gEOP7uD6CmafAxsJnnDL84Ta4+bCqFXPuQAT9apq2oqTcnZl6a3iF/cIEG0tGxHuWIP6CrkMaG1c7FyHIHHTFFFZoctkNs+Ssp5dwoYnnPNZwJSXUYl/wBWkzKo64A5xRRVdRdTJupHtvEi2sDFLe6tl85AeG+ZePYcngetdNOxlgO8A4bHQDvj+VFFLoaxKlgPIa3EWVy0idf4QeB+FaExzdCM4KSqQ644PT/GiilEzluGkTyvpiF5GJjLopzyAGwBS63NIsxkVzv85U3d8YHFFFU9jNbm3tBMBIyW6k9+KwtSY28ieT8nCtwO5JB/SiikzWhuZ9+7RTyojEKFJAznH0qGdimnTSrxIIid35UUVLO37LNjSZGUJGD8nldDzWhfqBFOQOY1V1PoaKKo45bkKMZWVZPmUqxIP0zWTff6iWU/6xCoVvQEnI+lFFDNqexFNGqW0k6jEycBvb0PqK1rNRJNIHGQpVBn0xnFFFCK+2zP00bryYNkhVO3np8zVe1SR4YRLExSQSquR6UUUIyn0KF6xeJix53E5HHNQa7Ei6WtwqhZ1hMquvBDAA5H+eaKKnqax+FF+yG/TY2bkvCGb6lQT9KRRtkiYcEopP40UUMqL3NSEBl+YA5BBqbSnaW3TzTv4789yKKK0OSoSBmidljO1c9PxpdSiT7RMMHAVSOTnOaKKXQxjuYeoorJKWHzLCXB7hgeDmq4ZprSJ5CSxiVyenJooqTqgUo5Hka2ldiZEV8MevUCtm9jQGzkCgO6HcR34ooprYJbmjaKA2Bxhc8cc0+cn7SD3ZeT60UU+hjLckulAgusceX9z24FY8aLdRRyXCiVi+wh+RjHp0oopsVIhtnbfMNxIR2UZOeAQBTp1UwSOR8y5waKKl7HbT2KVpIyR3JU4JlIP6ValRVLEDBQrt9s9aKKRr1IgSllEUJU7B0PuaLORmt4ixyWAY8dTRRS6g/hCdQU9MNxg4p8bHIbuRzRRVMzew6EDzUjx8hwCvbpnpVRoIy+MMAW52sR6elFFIOjGwgQ3CiMbd+7ce7YPGT1p0Kq7JvAO5sH86KKaCew8sQHT+FZdozzxWjaKFJx396KKo55bDJnZbi4VThViWQAcYYtgms+6UGSdsYJkAOOBjaO3SiigKOx/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous macules are present on the skin of this patient with a viral exanthem.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_60_31685=[""].join("\n");
var outline_f30_60_31685=null;
var title_f30_60_31686="Avascular necrosis of femoral heads in sickle cell disease";
var content_f30_60_31686=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 650px\">",
"   <div class=\"ttl\">",
"    X-ray and MRI avascular necrosis of femoral heads in sickle cell disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 630px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The images in the top series (A-D) show a patient with sickle cell disease and bilateral avascular necrosis of the hips. Images E-H show a normal patient. In image A an arrow points to two arcs of alternating densities. This finding is magnified in image B, revealing a superior subchondral lucent arc (arrowhead) adjacent to a more inferior sclerotic and denser arc of sclerotic bone (arrow). The subarticular lucent arc reflects resorbed bone and is known as the crescent sign. The sclerotic arc represents the reparative process. Image C is an MRI&nbsp;STIR sequence and reflects edema (arrowhead) in the superior subchondral arc. It is seen bilaterally but is more prominent on the right. Image D is a T1 weighted MRI image showing abnormal heterogeneous signal in both femoral heads. The dark signal in the femoral bones reflects increased hematopoiesis relative to normal. Images E and F reveal normal femoral heads&nbsp;that are less dense than the abnormal hips. On the MRI STIR image (G) there is no edema and no crescents are present. Image H is a normal T1 weighted MRI sequence and shows normal signal in the femoral&nbsp;heads bilaterally compared to the heterogeneous appearance in image D. The bright signal in the femoral epiphyses in H&nbsp;reflects a greater amount of fat compared to the femoral neck which contains hematopoietic bone marrow.",
"    <div class=\"footnotes\">",
"     MRI: magnetic resonance image",
"     <br>",
"      STIR: short tau inversion recovery.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_60_31686=[""].join("\n");
var outline_f30_60_31686=null;
var title_f30_60_31687="Soft tissue infections following water exposure";
var content_f30_60_31687=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Soft tissue infections following water exposure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/60/31687/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/60/31687/contributors\">",
"     Larry M Baddour, MD, FIDSA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/60/31687/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/60/31687/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/60/31687/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/60/31687/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/60/31687/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft tissue infections can occur after both fresh water and salt water exposure, particularly if there is associated trauma. Trauma can be caused by living creatures or by inanimate objects found in the aquatic environment. In addition, some aquatic creatures can transmit soft tissue infections outside the water environment. This can occur, for example, with the use of leeches for medicinal purposes to relieve venous congestion at surgical sites, as Aeromonas spp, a normal inhabitant of the foregut of leeches, may contaminate the wound and cause a secondary wound infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the array of microorganisms that can produce soft tissue infections following water exposure is extremely large, this discussion will focus on five bacteria that most commonly produce soft tissue infections in association with exposure to water or water-related animals. These include Aeromonas species, Edwardsiella tarda, Erysipelothrix rhusiopathiae, Vibrio vulnificus, and Mycobacterium marinum. The acronym AEEVM will be used here when referring to these organisms.",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, diagnosis, and empiric treatment of AEEVM infections and specific treatment of Edwardsiella spp and M. marinum infections will be reviewed here. Treatment of Aeromonas spp, Erysipelothrix spp, and V. vulnificus infections is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23943?source=see_link\">",
"     \"Aeromonas infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44710?source=see_link\">",
"     \"Vibrio vulnificus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/28/1478?source=see_link\">",
"     \"Erysipelothrix infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local trauma or injury, which can be either minor or major, coupled with water exposure is a common theme that predisposes to many of the AEEVM-related infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma leading to infection with AEEVM includes puncture wounds due to fishhooks and fish spines and lacerations due to boat motor propeller blades and a variety of other inanimate objects present in areas of wading and swimming. In addition to trauma by accidental puncture, bites from fish, alligators, crocodiles, sharks, and turtles can transmit AEEVM infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A case series demonstrates the importance of trauma as a predisposing condition for extraintestinal infections caused by AEEVM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/5\">",
"     5",
"    </a>",
"    ]. Twenty-three (82 percent) of 28 patients seen over a four-year period had preceding acute injuries. Twelve (52 percent) were injured while in a lake or river and subsequently developed musculoskeletal and soft tissue infections due to Aeromonas species.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Water exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of types of water exposure can result in infection due to AEEVM. This includes fresh water, salt water, brackish water, water in swimming pools, and aquariums. In a series of 63 cases of M. marinum infection from France, 84 percent were linked to fish tank exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/6\">",
"     6",
"    </a>",
"    ]. Infections due to V. vulnificus are more often limited to salt or brackish water exposure.",
"   </p>",
"   <p>",
"    The first published outbreak of Aeromonas wound infection was reported in 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/7\">",
"     7",
"    </a>",
"    ]. The outbreak occurred among participants in mud football in Western Australia with an attack rate estimated to be over 40 percent. It was theorized that the players had skin abrasions and cuts that predisposed to secondary infection due to A. hydrophila. The organism was recovered from a water sample taken from a river that was used to irrigate the field before play.",
"   </p>",
"   <p>",
"    E. tarda is an uncommon human pathogen primarily associated with gastrointestinal disease. However, wound infections, including myonecrosis, have occurred when wounds are exposed to a marine environment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Gender predominance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gender predilection is an intriguing feature of both extraintestinal Aeromonas and Vibrio spp infections. A Mayo Clinic series found that 90 percent of cases were in males, a finding that has been noted by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/11\">",
"     11",
"    </a>",
"    ]. There is no explanation for the male predominance among patients with Aeromonas infections. Increased exposure of males to outdoor activities does not explain this association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gender predominance is also seen with Vibrio spp infections, approximately 75 percent of which occur in males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Studies in mice have shown that high serum iron is associated with increased mortality in animals infected with V. vulnificus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/14\">",
"     14",
"    </a>",
"    ]; it is therefore possible that lower iron stores in females may make them less likely to develop infection due to this organism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Underlying diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with underlying hepatic disease or cancer have an increased risk of infection caused by AEEVM and may present with life-threatening infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. These patients are at particularly high risk of infection due to Aeromonas spp, V. vulnificus, and E. tarda. Disseminated disease from a primary soft tissue focus of infection is common in these immunocompromised patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;AEEVM can produce a variety of skin and soft tissue infections including cellulitis, abscess formation, wound infection, ecthyma gangrenosum, and necrotizing soft tissue processes (eg, fasciitis and myositis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/15\">",
"     15",
"    </a>",
"    ]. It is difficult to determine the etiology of an infection based upon clinical features alone, since other organisms, such as beta-hemolytic streptococci and Staphylococcus aureus, can cause similar manifestations.",
"   </p>",
"   <p>",
"    The clinical presentation and severity of illness can be extremely variable (",
"    <a class=\"graphic graphic_table graphicRef75469 \" href=\"mobipreview.htm?21/48/22283\">",
"     table 1",
"    </a>",
"    ). This is related, in part, to underlying immunologic or hepatic disorders seen in some patients who are at increased risk of AEEVM infections. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Underlying diseases'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Rapidly progressive soft tissue infection with fever, and in high-risk patients, sepsis, may occur with Aeromonas spp and V. vulnificus infection. Consideration should be given to V. vulnificus as an etiologic agent in a patient with an aggressive soft tissue infection with bulla formation (eg, bullous cellulitis) and soft tissue necrosis (",
"    <a class=\"graphic graphic_picture graphicRef63423 \" href=\"mobipreview.htm?31/11/31921\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44710?source=see_link\">",
"     \"Vibrio vulnificus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, soft tissue infections due to M. marinum and E. rhusiopathiae are generally indolent and are not associated with systemic toxicity.",
"   </p>",
"   <p>",
"    M. marinum lesions usually appear as papules on an extremity, especially on the elbows, knees, and dorsum of feet and hands, progressing subsequently to shallow ulceration and scar formation. Most lesions are solitary, although occasional \"ascending\" lesions develop with \"sporotrichoid spread\" (ie, resembling sporotrichosis), which is also called nodular lymphangitis (",
"    <a class=\"graphic graphic_picture graphicRef81640 \" href=\"mobipreview.htm?5/19/5425\">",
"     picture 2",
"    </a>",
"    ). Clinical involvement of regional nodes is uncommon. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12469?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and diagnosis of sporotrichosis\", section on 'Lymphocutaneous sporotrichosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/42/11942?source=see_link&amp;anchor=H5#H5\">",
"     \"Lymphangitis\", section on 'Nodular lymphangitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a case series of 31 patients with M. marinum cutaneous disease, the upper extremity was affected in 27 patients (90 percent), and lymphatic or local spread was seen during the initial examination or during observation in 25 patients (81 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    E. rhusiopathiae most commonly causes a localized cutaneous eruption, erysipeloid, on the fingers or hands of fishermen or seafood packers who suffer minor trauma while handling contaminated shrimp, crab, or fish [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/28/1478?source=see_link\">",
"     \"Erysipelothrix infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    E. tarda soft tissue infections are unusual and have been associated with a spectrum of manifestations from a simple cellulitis similar to cellulitis due to S. aureus and beta-hemolytic streptococci, to fulminant wound infection complicated by bacteremia in patients with underlying liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic tests to identify the causative agent should always be performed. Gram's stain (and acid-fast staining when indicated) and culture should be performed on specimens taken from soft tissue drainage or biopsies. The culture should be incubated at two temperatures: 35&ordm;C and 28 to 32&ordm;C, since M. marinum is restricted to growth at the lower temperatures, especially on primary isolation.",
"   </p>",
"   <p>",
"    Blood cultures should be obtained when systemic toxicity is present or in patients with underlying hepatic disease or cancer.",
"   </p>",
"   <p>",
"    It is essential to obtain a thorough exposure history from patients who present with soft tissue infections, since microbiologic data may not be available. Questions must be directed at occupational and home exposures and hobbies of the patient. It is important to note even minor or seemingly trivial trauma in the history, which could account for the initiation of infection. Recent travel history must be obtained, since a salt water-related pathogen may not be considered if the patient lives in a noncoastal community.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin and soft tissue findings following water exposure can be due to noninfectious causes, in addition to AVEEM infection. Injuries sustained in a freshwater or marine environment may result from bites or venomous stings of aquatic organisms as well as from accidental trauma. As an example, catfish farming has become popular in the Midwest and Southeast regions of the United States, and catfish spine envenomation is a common noninfectious complication that can mimic certain aspects of water-borne infections. Severe pain promptly following the injury is typical and the skin and soft tissue develops local swelling and erythema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/21\">",
"     21",
"    </a>",
"    ]. Soft tissue necrosis at the envenomation site can occur, as can secondary infection with progression of local findings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/26/42408?source=see_link\">",
"     \"Marine envenomations from corals, sea urchins, fish, or stingrays\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of soft tissue infections following water exposure includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment to determine whether treatment requires hospitalization",
"     </li>",
"     <li>",
"      Empiric antibiotic administration",
"     </li>",
"     <li>",
"      Assessment of tetanus vaccination status (since tetanus has been reported in this setting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/21\">",
"       21",
"      </a>",
"      ])",
"     </li>",
"     <li>",
"      Surgical consultation for potential debridement in patients with necrotizing infections",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A thorough history will dictate whether empiric therapy to include coverage for AEEVM is indicated. Even with a history of trauma associated with water exposure, we recommend empiric coverage for beta-hemolytic streptococci and S. aureus. The latter two types of bacteria account for the large majority of community-acquired soft tissue infections and can colonize normal skin and produce infections at injury sites. We also administer broad-spectrum coverage to cover multiple organisms, since polymicrobial infection is typical of water-related infections. In the Mayo Clinic series, for example, 65 percent of cultures had more than one pathogen isolated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/5\">",
"     5",
"    </a>",
"    ]. Polymicrobial infection is not surprising since local trauma precedes infection in many cases and the injury occurs in the outdoor environment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     When to hospitalize",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need to hospitalize patients for treatment of AEEVM infections should be individualized. There are no established guidelines to assist in this decision. Nevertheless, one should more strongly consider hospitalization in patients with underlying hepatic disease, cancer, or immunocompromise. Because of their underlying disease, these patients do not always manifest signs of systemic toxicity related to infection, and they are more likely to develop complications such as sepsis, bacteremia, or death.",
"   </p>",
"   <p>",
"    Patients with systemic symptoms (eg, fever, chills, rigors) and leukocytosis are another group that should be considered for hospitalization and treatment. This is particularly applicable to elderly and diabetic patients. If ambulatory management is initially selected, then outpatient reevaluation should be performed at 24 to 48 hours. The ambulatory patient should have family members or friends who will be available to monitor the patient and to secure travel to a medical facility if clinical deterioration occurs and for follow-up appointments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Empiric antibiotic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized controlled studies have evaluated empiric antibiotic regimens for treatment of soft tissue infections following water exposure. Treatment regimens are based on the most likely organisms to cause infection in this setting, in vitro susceptibility studies, and treatment case series with some organisms. We recommend the following antibiotics for initial empiric therapy whether treatment is ambulatory (oral) or inpatient (parenteral):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Either a first generation cephalosporin (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/37/37462?source=see_link\">",
"       cephalexin",
"      </a>",
"      500 mg orally four times daily or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      1 g IV every eight hours)",
"      <strong>",
"       OR",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (300 mg orally four times daily or 600 mg IV every eight hours, in those patients with immediate hypersensitivity reactions to penicillin)",
"      <strong>",
"       PLUS",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"       Levofloxacin",
"      </a>",
"      (750 mg once daily)",
"      <strong>",
"       PLUS",
"      </strong>",
"      either of the following if the epidemiologic risk is present:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      (500 mg four times daily) if exposure to sewage-contaminated water or if soil-contaminated wound; (not necessary to include if the regimen includes",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      )",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      (100 mg twice daily) for coverage of Vibrio species if seawater exposure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Empiric antibiotic coverage should not include coverage for M. marinum infection in most cases, since the presentation is subacute and without associated systemic toxicity. Instead, a specimen (eg, lesion aspirate, biopsy) should be obtained and the microbiology laboratory notified that M. marinum is suspected so that appropriate culture conditions will be included. If acid fast staining is positive, or if the exposure history and physical examination findings suggest M. marinum infection (eg, laceration from an aquarium), then we suggest that specific treatment for M. marinum infection should be initiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Directed antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend initial broad-spectrum empiric therapy be subsequently \"tailored\" to a more narrow spectrum coverage when specific pathogens are identified in clinical specimens by the microbiology laboratory based upon the isolates susceptibility results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Aeromonas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Directed antibiotic coverage for Aeromonas spp infection is based on the results of susceptibility testing of the specific isolate. Specific treatment regimens are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23943?source=see_link\">",
"     \"Aeromonas infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Edwardsiella tarda",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic therapy for E. tarda infection should be based upon in vitro susceptibility testing. Most isolates are susceptible to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"       Ampicillin",
"      </a>",
"      (but not",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cephalosporins (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/15,22\">",
"       15,22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Aminoglycosides",
"     </li>",
"     <li>",
"      Fluoroquinolones",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Erysipelothrix rhusiopathiae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although erysipeloid skin lesions may resolve spontaneously within three weeks, we recommend antibiotic therapy as it shortens the clinical illness and prevents relapse. Treatment of erysipelothrix is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/28/1478?source=see_link\">",
"     \"Erysipelothrix infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Vibrio vulnificus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a presumptive diagnosis of V. vulnificus septicemia from a serious wound infection should be started immediately on antibiotic therapy and aggressively managed in an intensive care unit. Specific antibiotic treatment is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44710?source=see_link\">",
"     \"Vibrio vulnificus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Mycobacterium marinum",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to treatment for M. tuberculosis, the most appropriate therapeutic regimen for M. marinum has not been defined in clinical trials but is based on in vitro susceptibility testing, clinical experience, and case reports.",
"   </p>",
"   <p>",
"    A number of different treatment modalities have been used for cutaneous disease caused by M. marinum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. These include simple observation for minor lesions, surgical excision, the use of antituberculous agents, and the use of single antibiotic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. By standard susceptibility testing, M. marinum isolates are usually susceptible to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    , intermediately susceptible to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    , and resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    . Isolates are also susceptible to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , sulfonamides or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    and susceptible or intermediately susceptible to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    A reasonable approach to the management of M. marinum consists of treatment with two active agents for one to two months after resolution of symptoms (total duration is typically three to four months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/27\">",
"     27",
"    </a>",
"    ]. Therapy could include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (500 mg orally twice daily) together with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    (15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally once daily) OR",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    (600 mg orally once daily). For minimal disease, some favor single drug therapy with one of the following regimens:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      (500 mg orally twice daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"       Minocycline",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg orally twice daily) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/18,28,29\">",
"       18,28,29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      at 160",
"      <span class=\"nowrap\">",
"       mg/800",
"      </span>",
"      mg orally twice daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the French series of 63 patients cited above, all patients were treated with antibiotics for a median of 14 weeks (range 1 to 25 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/6\">",
"     6",
"    </a>",
"    ]. Fifty-five of the 63 patients (87 percent) were cured; treatment failure was associated with involvement of deeper structures and not with the antibiotic regimen chosen. Sixty-three percent of patients received a combination regimen, the most common of which was",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    were the most frequent drugs employed as monotherapy usually administered for infection confined to the skin and soft tissues.",
"   </p>",
"   <p>",
"    The rate of clinical response is quite variable, and a minimum of four to six weeks of therapy should be given before considering that the patient may not be responding. Surgical debridement may also be important, especially for disease involving the closed spaces of the hand or disease that responds poorly to drug therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/24,31\">",
"     24,31",
"    </a>",
"    ]. If a lesion is excised surgically, many clinicians provide antibiotic coverage during the perioperative period. It is not clear if longer durations of antibiotic treatment after surgery offer any additional advantage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Duration of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clinical trials that have evaluated length of treatment for soft tissue infections due to AEEVM organisms. Except for M. marinum infections, we suggest a duration of antimicrobial therapy for most AEEVM soft tissue infections of 10 to 14 days. Occasional patients will continue to have local signs of infection at the end of two weeks of treatment. We suggest continued oral antibiotic therapy in these patients until resolution of all erythema has occurred. In patients with necrotizing soft tissue infections, treatment duration should be individualized and a longer course of parenteral treatment may be necessary.",
"   </p>",
"   <p>",
"    For treatment of M. marinum, we recommend continuing treatment for one to two months after resolution of symptoms (total duration is typically three to four months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31687/abstract/27,32\">",
"     27,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no strict guidelines to indicate when to switch therapy from parenteral to oral agents. We generally switch to oral therapy after the patient is afebrile and the skin findings have begun to resolve; this usually takes three to five days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Soft tissue infections can occur after both fresh water and salt water exposure, particularly if there is associated trauma. The most common bacteria to produce soft tissue infections in association with exposure to water or water-related animals include (AEEVM organisms) Aeromonas species, Edwardsiella tarda, Erysipelothrix rhusiopathiae, Vibrio vulnificus, and Mycobacterium marinum. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with underlying hepatic disease or cancer have an increased risk of infection caused by AEEVM and may present with life-threatening infections. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Underlying diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AEEVM can produce a variety of skin and soft tissue infections including cellulitis, abscess formation, wound infection, ecthyma gangrenosum, and necrotizing soft tissue processes (eg, fasciitis and myositis). Rapidly progressive soft tissue infection with fever, and in high-risk patients, sepsis, may occur with Aeromonas spp and V. vulnificus infection. In contrast, soft tissue infections due to M. marinum and E. rhusiopathiae are generally indolent and are not associated with systemic toxicity. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic tests including Gram's stain (and acid-fast staining when indicated) and culture should be performed on specimens taken from soft tissue drainage or biopsies. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Besides AVEEM infection, skin and soft tissue findings following water exposure can be due to noninfectious causes, including injuries resulting from bites or venomous stings of aquatic organisms. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of soft tissue infections following water exposure includes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Assessment to determine whether treatment requires hospitalization",
"     </li>",
"     <li>",
"      Empiric antibiotic administration",
"     </li>",
"     <li>",
"      Assessment of tetanus vaccination status",
"     </li>",
"     <li>",
"      Surgical consultation for potential debridement in patients with necrotizing infections",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend empiric antibiotic coverage for patients who develop a soft tissue infection following water exposure (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Water exposure'",
"      </a>",
"      above) to include coverage for both S. aureus and beta-hemolytic streptococci and the AVEEM organisms, except for M. marinum (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Appropriate antibiotics for initial empiric therapy include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Either a first generation cephalosporin (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/37/37462?source=see_link\">",
"       cephalexin",
"      </a>",
"      500 mg orally four times daily or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      1 g IV every eight hours)",
"      <strong>",
"       OR",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (300 mg orally four times daily or 600 mg IV every eight hours, in those patients with immediate hypersensitivity reactions to penicillin)",
"      <strong>",
"       PLUS",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"       Levofloxacin",
"      </a>",
"      (750 mg once daily)",
"      <strong>",
"       PLUS",
"      </strong>",
"      either of the following if the epidemiologic risk is present:",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      (500 mg four times daily) if exposure to sewage-contaminated water or if soil-contaminated wound; (not necessary to include if the regimen includes",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      )",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      (100 mg twice daily) for coverage of Vibrio species If seawater exposure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Empiric antibiotic treatment'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend not including coverage for M. marinum in the empiric antibiotic regimen, in most cases. (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Empiric antibiotic treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial broad-spectrum empiric therapy should be changed to a more narrow spectrum coverage when specific pathogens are identified in clinical specimens by the microbiology laboratory based upon the isolates susceptibility results. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Directed antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most cases, a duration of antimicrobial therapy for AEEVM soft tissue infections is 10 to 14 days. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Duration of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend a duration of treatment of at least three months for soft tissue infection due to M. marinum. (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Duration of treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/1\">",
"      Mercer NS, Beere DM, Bornemisza AJ, Thomas P. Medical leeches as sources of wound infection. Br Med J (Clin Res Ed) 1987; 294:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/2\">",
"      Mekisic AP, Wardill JR. Crocodile attacks in the Northern Territory of Australia. Med J Aust 1992; 157:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/3\">",
"      Flandry F, Lisecki EJ, Domingue GJ, et al. Initial antibiotic therapy for alligator bites: characterization of the oral flora of Alligator mississippiensis. South Med J 1989; 82:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/4\">",
"      Pavia AT, Bryan JA, Maher KL, et al. Vibrio carchariae infection after a shark bite. Ann Intern Med 1989; 111:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/5\">",
"      Voss LM, Rhodes KH, Johnson KA. Musculoskeletal and soft tissue Aeromonas infection: an environmental disease. Mayo Clin Proc 1992; 67:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/6\">",
"      Aubry A, Chosidow O, Caumes E, et al. Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates. Arch Intern Med 2002; 162:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/7\">",
"      Vally H, Whittle A, Cameron S, et al. Outbreak of Aeromonas hydrophila wound infections associated with mud football. Clin Infect Dis 2004; 38:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/8\">",
"      Slaven EM, Lopez FA, Hart SM, Sanders CV. Myonecrosis caused by Edwardsiella tarda: a case report and case series of extraintestinal E. tarda infections. Clin Infect Dis 2001; 32:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/9\">",
"      Hargreaves JE, Lucey DR. Life-threatening Edwardsiella tarda soft-tissue infection associated with catfish puncture wound. J Infect Dis 1990; 162:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/10\">",
"      Clarridge JE, Musher DM, Fainstein V, Wallace RJ Jr. Extraintestinal human infection caused by Edwardsiella tarda. J Clin Microbiol 1980; 11:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/11\">",
"      Baddour LM. Extraintestinal Aeromonas infections--looking for Mr. Sandbar. Mayo Clin Proc 1992; 67:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/12\">",
"      Tacket CO, Brenner F, Blake PA. Clinical features and an epidemiological study of Vibrio vulnificus infections. J Infect Dis 1984; 149:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/13\">",
"      Levine WC, Griffin PM. Vibrio infections on the Gulf Coast: results of first year of regional surveillance. Gulf Coast Vibrio Working Group. J Infect Dis 1993; 167:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/14\">",
"      Oliver JD. The pathogenicity and ecology of Vibrio vulnificus. Marine Tech Soc J 1981; 15:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/15\">",
"      Czachor JS. Unusual aspects of bacterial water-borne illnesses. Am Fam Physician 1992; 46:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/16\">",
"      Baddour LM, Baselski VS. Pneumonia due to Aeromonas hydrophila-complex: epidemiologic, clinical, and microbiologic features. South Med J 1988; 81:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/17\">",
"      Janda JM, Abbott SL. Infections associated with the genus Edwardsiella: the role of Edwardsiella tarda in human disease. Clin Infect Dis 1993; 17:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/18\">",
"      Edelstein H. Mycobacterium marinum skin infections. Report of 31 cases and review of the literature. Arch Intern Med 1994; 154:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/19\">",
"      Collier DN. Cutaneous infections from coastal and marine bacteria. Dermatol Ther 2002; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/20\">",
"      Burke WA, Jones BE. Cutaneous infections of the coast. N C Med J 1987; 48:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/21\">",
"      Murphey DK, Septimus EJ, Waagner DC. Catfish-related injury and infection: report of two cases and review of the literature. Clin Infect Dis 1992; 14:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/22\">",
"      Wilson JP, Waterer RR, Wofford JD Jr, Chapman SW. Serious infections with Edwardsiella tarda. A case report and review of the literature. Arch Intern Med 1989; 149:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/23\">",
"      Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 1979; 119:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/24\">",
"      Collins CH, Grange JM, Noble WC, Yates MD. Mycobacterium marinum infections in man. J Hyg (Lond) 1985; 94:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/25\">",
"      Donta ST, Smith PW, Levitz RE, Quintiliani R. Therapy of Mycobacterium marinum infections. Use of tetracyclines vs rifampin. Arch Intern Med 1986; 146:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/26\">",
"      King AJ, Fairley JA, Rasmussen JE. Disseminated cutaneous Mycobacterium marinum infection. Arch Dermatol 1983; 119:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/27\">",
"      Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/28\">",
"      Kim R. Letter: Tetracycline therapy for atypical mycobacterial granuloma. Arch Dermatol 1974; 110:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/29\">",
"      Loria PR. Minocycline hydrochloride treatment for atypical acid-fast infection. Arch Dermatol 1976; 112:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/30\">",
"      Black MM, Eykyn SJ. The successful treatment of tropical fish tank granuloma (Mycobacterium marinum) with co-trimoxazole. Br J Dermatol 1977; 97:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/31\">",
"      Chow SP, Ip FK, Lau JH, et al. Mycobacterium marinum infection of the hand and wrist. Results of conservative treatment in twenty-four cases. J Bone Joint Surg Am 1987; 69:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31687/abstract/32\">",
"      Lewis FM, Marsh BJ, von Reyn CF. Fish tank exposure and cutaneous infections due to Mycobacterium marinum: tuberculin skin testing, treatment, and prevention. Clin Infect Dis 2003; 37:390.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7646 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-213.134.24.46-B0B7A2AA67-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_60_31687=[""].join("\n");
var outline_f30_60_31687=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Water exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Gender predominance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Underlying diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      When to hospitalize",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Empiric antibiotic treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Directed antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Aeromonas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Edwardsiella tarda",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Erysipelothrix rhusiopathiae",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Vibrio vulnificus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Mycobacterium marinum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Duration of treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7646\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7646|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/11/31921\" title=\"picture 1\">",
"      Bullous Vibrio vulnificus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/19/5425\" title=\"picture 2\">",
"      Fish tank granuloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7646|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/48/22283\" title=\"table 1\">",
"      Organisms soft tissue infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23943?source=related_link\">",
"      Aeromonas infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12469?source=related_link\">",
"      Clinical features and diagnosis of sporotrichosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/28/1478?source=related_link\">",
"      Erysipelothrix infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/42/11942?source=related_link\">",
"      Lymphangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/26/42408?source=related_link\">",
"      Marine envenomations from corals, sea urchins, fish, or stingrays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44710?source=related_link\">",
"      Vibrio vulnificus infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_60_31688="Antithrombotic treatment of acute ischemic stroke and transient ischemic attack";
var content_f30_60_31688=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antithrombotic treatment of acute ischemic stroke and transient ischemic attack",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/60/31688/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/60/31688/contributors\">",
"     Jamary Oliveira-Filho, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/60/31688/contributors\">",
"     Walter J Koroshetz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/60/31688/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/60/31688/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/60/31688/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/60/31688/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/60/31688/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients who have had an ischemic stroke involves several phases. The goals in the initial phase when patients first present with symptoms that are consistent with an ischemic event include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Insuring medical stability",
"     </li>",
"     <li>",
"      Quickly reversing any conditions that are contributing to the patient's problem",
"     </li>",
"     <li>",
"      Moving toward uncovering the pathophysiologic basis of the patient's neurologic symptoms",
"     </li>",
"     <li>",
"      Screening for potential contraindications to thrombolysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Timely restoration of blood flow using thrombolytic therapy is the most effective maneuver for salvaging ischemic brain tissue that is not already infarcted. There is a narrow window during which this can be accomplished, that is, within 4.5 hours of symptom onset. Thus, an important aspect of the hyperacute phase of stroke assessment and management is the determination of patients who are eligible for thrombolysis (",
"    <a class=\"graphic graphic_table graphicRef71462 \" href=\"mobipreview.htm?31/40/32397\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic will review the use of alternative acute antithrombotic treatments (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , and low-molecular-weight heparin) for patients who are ineligible for thrombolytic therapy with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    . Recommendations for patients able to receive thrombolytic therapy are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/26/6570?source=see_link\">",
"     \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41098?source=see_link\">",
"     \"Reperfusion therapy for acute ischemic stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment beyond the acute phase for specific ischemic stroke subtypes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/33/32281?source=see_link\">",
"     \"Secondary prevention for specific causes of ischemic stroke and transient ischemic attack\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTIPLATELET AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In large randomized controlled trials, early (within 48 hours) initiation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    has shown benefit for the treatment of acute ischemic stroke. The utility of other antiplatelet agents, alone or in combination with aspirin, remains to be proven in this setting.",
"   </p>",
"   <p>",
"    The use of antiplatelet agents for the secondary prevention of ischemic stroke is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two major clinical trials studied the benefits and risks of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in the setting of acute ischemic stroke.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The International Stroke Trial (IST) enrolled 19,435 patients with suspected acute ischemic stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/1\">",
"       1",
"      </a>",
"      ]. Patients allocated to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (300 mg) within 48 hours of symptom onset experienced significant reductions in the 14-day recurrence of ischemic stroke (2.8 versus 3.9 percent) and in the combined outcome of nonfatal stroke or death (11.3 versus 12.4 percent).",
"     </li>",
"     <li>",
"      In the Chinese Acute Stroke Trial (CAST), 21,100 patients were randomized to 160 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      daily or placebo, also within 48 hours of the onset of acute ischemic stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/2\">",
"       2",
"      </a>",
"      ]. Aspirin-allocated patients experienced a 14 percent reduction in total mortality at four weeks (3.3 versus 3.9 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, the IST and CAST trials demonstrated that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy in acute ischemic stroke led to a reduction of 11 nonfatal strokes or deaths per 1000 patients in the first few weeks but caused approximately two hemorrhagic strokes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, approximately nine nonfatal strokes or deaths were avoided for every 1000 early-treated patients. These effects were similar in the presence or absence of atrial fibrillation. Using the end point of death or residual impairment leaving the patient dependent, the combined data demonstrated a reduction of 13 per 1000 patients after several weeks to six months of follow-up.",
"   </p>",
"   <p>",
"    A systematic review of antiplatelet therapy for acute stroke included 12 trials involving 43,041 patients, but the IST and CAST studies contributed 94 percent of the data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/4\">",
"     4",
"    </a>",
"    ]. The reviewers concluded that starting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (160 to 300 mg daily) within 48 hours of presumed ischemic stroke onset reduced the risk of early recurrent ischemic stroke without a major risk of early hemorrhagic complications and improved long-term outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Other antiplatelet agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only preliminary evidence is available concerning the use of antiplatelet agents other than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    immediately after acute ischemic stroke or TIA.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The open-label EARLY trial randomly assigned 539 patients within 24 hours of symptom onset to treatment with either the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/52/19271?source=see_link\">",
"       aspirin-extended-release dipyridamole",
"      </a>",
"      (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      25 mg and extended-release 200 mg twice daily) or aspirin (100 mg daily) alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/5\">",
"       5",
"      </a>",
"      ]. After seven days, all patients received open-label aspirin and extended-release",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      . At 90 days, there was no significant difference between the aspirin and extended-release dipyridamole group and the aspirin group in the primary endpoint of good neurologic outcome, defined as a modified Rankin scale score of 0 to 1 assessed by telephone (56 versus 52 percent). In addition, there was no significant difference in the combined endpoint of vascular adverse events or mortality (10 versus 15 percent).",
"      <br/>",
"      <br/>",
"      The strength of the EARLY study is limited by methodologic issues (the open-label design, telephone assessment) and small patient numbers compared with the IST and CAST trials discussed above.",
"     </li>",
"     <li>",
"      The FASTER trial randomly assigned 392 patients within 24 hours of symptom onset to either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (300 mg loading dose, then 75 mg daily) or aspirin alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/6\">",
"       6",
"      </a>",
"      ]. In addition, patients were separately allocated to receive either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      or placebo. The trial ended prematurely due to slow recruitment. At 90 days, there was no significant difference between treatment groups (aspirin plus clopidogrel versus aspirin alone) for the primary outcome measure of combined ischemic and hemorrhagic stroke (7.1 versus 10.8 percent).",
"      <br/>",
"      <br/>",
"      Since FASTER enrolled mostly patients with mild stroke or TIA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/6\">",
"       6",
"      </a>",
"      ], the safety results of FASTER with respect to hemorrhagic transformation may not apply to the general ischemic stroke population. The much larger MATCH trial, with over 7500 patients, found that the combined use of aspirin and clopidogrel did",
"      <strong>",
"       not",
"      </strong>",
"      offer greater benefit for stroke prevention than either agent alone but did substantially increase the risk of bleeding complications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=see_link&amp;anchor=H7#H7\">",
"       \"Antiplatelet therapy for secondary prevention of stroke\", section on 'Aspirin plus clopidogrel'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A 2012 meta-analysis of dual antiplatelet therapy versus monotherapy for patients with early acute ischemic stroke or TIA identified 12 trials with over 3700 adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/8\">",
"       8",
"      </a>",
"      ]. The meta-analysis included patients from the EARLY and FASTER trials, who were all enrolled within 24 hours of onset, and those patients from secondary prevention trials who were enrolled within 72 hours of symptom onset. Treatments involved two different combinations of dual antiplatelet therapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      and aspirin plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      ) and three different monotherapy regimens (aspirin, clopidogrel, and dipyridamole). Compared with monotherapy, dual antiplatelet therapy was associated with a statistically significant reduction in recurrent stroke (3.3 versus 5 percent) and composite vascular events (4.4 versus 6 percent) and a nonsignificant increase in major bleeding (0.9 versus 0.4 percent). The strength of these findings is limited by a number of issues, including the inclusion of patient subgroups that enrolled early in secondary prevention trials, the open label design of six of the included trials, and small event numbers for certain outcomes such as intracerebral hemorrhage and death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence from larger rigorous randomized controlled trials is needed to confirm whether other antiplatelet regimens (eg, the combination",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and extended-release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    monotherapy, or aspirin plus clopidogrel) are equivalent or superior to aspirin for the early treatment of acute ischemic stroke and TIA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Early aspirin use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , and the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/52/19271?source=see_link\">",
"     aspirin-extended-release dipyridamole",
"    </a>",
"    are all acceptable options for secondary stroke prevention, aspirin is the only antiplatelet agent that has been established as effective for the early treatment of acute ischemic stroke. Therefore, we recommend early aspirin therapy (160 to 325",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    rather than no aspirin therapy or early anticoagulation for most patients with acute ischemic stroke. This recommendation is in accord with current guidelines issued by the American College of Chest Physicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/9\">",
"     9",
"    </a>",
"    ], the American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Stroke Association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/10\">",
"     10",
"    </a>",
"    ], and the National Institute for Health and Clinical Excellence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/11\">",
"     11",
"    </a>",
"    ]. As discussed below (see",
"    <a class=\"local\" href=\"#H1180709\">",
"     'Role of early anticoagulation'",
"    </a>",
"    below), we suggest early parenteral anticoagulation rather than aspirin only for select patients with acute cardioembolic ischemic stroke or TIA who have intracardiac thrombus. The use of antiplatelet and anticoagulant therapy for patients with acute stroke or TIA caused by cervicocephalic artery dissection is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/28/21960?source=see_link&amp;anchor=H28007410#H28007410\">",
"     \"Spontaneous cerebral and cervical artery dissection: Treatment and prognosis\", section on 'Antithrombotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be used as an alternative to intravenous thrombolysis or other acute therapies aimed at improving outcomes after stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    should be started as early as possible after the diagnosis of ischemic stroke is confirmed and ideally within 48 hours of stroke onset. However, aspirin should not be given for the first 24 hours following treatment with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    . Aspirin may be used in combination with subcutaneous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and low molecular weight heparin for deep vein thrombosis prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17610?source=see_link&amp;anchor=H6#H6\">",
"     \"Medical complications of stroke\", section on 'VTE prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    is contraindicated in patients with aspirin allergy or active gastrointestinal bleeding.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     Clopidogrel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    are alternatives for patients intolerant to aspirin, although the effectiveness of these antiplatelets in acute stroke is not established.",
"   </p>",
"   <p>",
"    The development of secondary hemorrhagic transformation of an ischemic infarct does not preclude the early use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , particularly when the hemorrhage is petechial (ie, scattered and punctate). It is not clear that stopping aspirin will have much impact on hematoma progression given the long lasting effect of aspirin on platelet function, even in the rare situation of severe hemorrhagic transformation associated with clinical deterioration and development of parenchymal hematoma (ie, larger confluent bleeding within an infarct, often with mass effect). However, it may be wise to delay initiation if aspirin has not yet been started in patients who develop parenchymal hematoma. Aspirin can then be given once the patient's neurologic condition becomes stable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PARENTERAL ANTICOAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available evidence suggests that early anticoagulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or low molecular weight heparin is associated with a higher mortality and worse outcomes compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    treatment initiated within 48 hours of ischemic stroke onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/12\">",
"     12",
"    </a>",
"    ]. However, as described in the following sections, clinical trials have not adequately evaluated adjusted-dose intravenous anticoagulation in patients with selected stroke subtypes, and only one trial has evaluated the role of very early anticoagulation after stroke onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While parenteral anticoagulation is not recommended during the first 48 hours after acute ischemic stroke, oral anticoagulation is recommended for secondary stroke prevention in patients with atrial fibrillation and other high risk sources of cardiogenic embolism. The timing of its initiation for such patients is mainly dependent on the size of the infarct, which is presumed to correlate with the risk of hemorrhagic transformation. Thus,&nbsp;for medically stable patients with a small or moderate-sized infarct,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    can be initiated soon (after 24 hours) after admission with minimal risk of transformation to hemorrhagic stroke, while withholding anticoagulation for two weeks is generally recommended for those with large infarctions, symptomatic hemorrhagic transformation, or poorly controlled hypertension. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39383?source=see_link&amp;anchor=H789229204#H789229204\">",
"     \"Stroke in patients with atrial fibrillation\", section on 'Timing after acute stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest randomized controlled trial, which was performed in England and studied two doses of subcutaneous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in undefined stroke patients, showed no significant benefit with heparin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review published in 2008 examined the effect of anticoagulant therapy versus control in the early treatment of patients with acute ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/14\">",
"     14",
"    </a>",
"    ]. This review included 24 trials involving 23,748 subjects. The quality of the trials varied considerably. The anticoagulants tested were standard unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , low-molecular-weight heparins, heparinoids, oral anticoagulants, and thrombin inhibitors. The following were the major findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Based upon 11 trials (22,776 patients), anticoagulant therapy did",
"      <strong>",
"       not",
"      </strong>",
"      reduce the odds of death from all causes (odds ratio 1.05, 95% CI 0.98-1.12).",
"     </li>",
"     <li>",
"      Based upon eight trials (22,125 patients), anticoagulants did",
"      <strong>",
"       not",
"      </strong>",
"      reduce the odds of being dead or dependent at the end of follow-up (odds ratio 0.99, 95% CI 0.93-1.04).",
"     </li>",
"     <li>",
"      Although full anticoagulant therapy was associated with about nine fewer recurrent ischemic strokes per 1000 patients treated, it was also associated with a nine per 1000 increase in symptomatic intracranial hemorrhages. Similarly, anticoagulants avoided about four pulmonary emboli per 1000, but this benefit was offset by an extra nine major extracranial hemorrhages per 1000.",
"     </li>",
"     <li>",
"      Sensitivity analyses did not identify a particular type of anticoagulant regimen or patient characteristic associated with net benefit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 2002 systematic review assessed the effectiveness of anticoagulants compared with antiplatelet agents in acute ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/12\">",
"     12",
"    </a>",
"    ]. The reviewers concluded that anticoagulants offer no net advantages over antiplatelet agents and recommend that antiplatelet agents should be the antithrombotic agents of first choice. However, this conclusion was driven in part by the lack of randomized trials comparing anticoagulation with antiplatelet therapy in the high-risk settings where we believe anticoagulation should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Stroke subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials have not adequately evaluated adjusted intravenous anticoagulation in patients with selected stroke subtypes. With this caveat in mind, there are conflicting data regarding the benefit of intravenous unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or low molecular weight heparin in the subgroup of patients with large vessel atherosclerotic disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The TOAST trial evaluated the efficacy of the low molecular weight heparinoid",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/18/41254?source=see_link\">",
"       danaparoid",
"      </a>",
"      administered as an intravenous bolus within 24 hours of symptom onset and continued for seven days in 1281 patients with acute ischemic stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/15\">",
"       15",
"      </a>",
"      ]. Compared to placebo, danaparoid was associated with no improvement in overall outcome at three months (75 and 74 percent). However, subgroup analysis suggested a higher rate of favorable outcomes in patients treated with danaparoid who had a large artery atherosclerotic stroke (68 versus 55 percent with placebo). A subsequent analysis of this study suggested that acute performance of carotid duplex imaging to identify patients with carotid occlusion or severe stenosis may improve selection of patients who could benefit from use of this agent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The FISS-tris trial evaluated the low molecular weight",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/41/27286?source=see_link\">",
"       nadroparin",
"      </a>",
"      (3800 anti-factor Xa international units, 0.4 mL subcutaneously twice daily) versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (160 mg once daily) started within 48 hours of acute ischemic stroke onset and continued for 10 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/17\">",
"       17",
"      </a>",
"      ]. The main study population was 353 patients with confirmed large artery occlusive disease, consisting of 300 with intracranial, 11 with extracranial, and 42 with both intracranial and extracranial disease. The mean time to treatment was nearly 30 hours. There was no significant difference between treatment with nadroparin or aspirin for the proportion of patients with good outcome at six months (73 versus 69 percent).",
"     </li>",
"     <li>",
"      In the only trial of unfractionated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      in hyperacute stroke, a single center randomly assigned 418 patients with nonlacunar hemispheric infarction (of cardioembolic, atherothrombotic, or",
"      <span class=\"nowrap\">",
"       unknown/undetermined",
"      </span>",
"      origin) to receive either intravenous heparin or saline within three hours of stroke onset [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/13\">",
"       13",
"      </a>",
"      ]. Treatment continued for five days. A favorable outcome at 90 days, the primary endpoint, was significantly more frequent in patients assigned to heparin compared with those assigned to saline (38.9 versus 28.6 percent). Heparin use was associated with an increased risk of intracranial and extracranial bleeding, but no increase in mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy in acute stroke did not consider the etiology of stroke and yielded mixed results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/1,18-20\">",
"     1,18-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Atrial fibrillation and cardioembolic stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subject of intense debate is the role of immediate anticoagulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in stroke patients with atrial fibrillation (AF). It appears that early treatment with heparin in patients with AF who have an acute stroke causes more harm than good. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39383?source=see_link\">",
"     \"Stroke in patients with atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2007 meta-analysis examined seven trials involving 4624 patients and compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or low molecular weight heparins started within 48 hours for acute cardioembolic stroke with other treatments (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or placebo) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/21\">",
"     21",
"    </a>",
"    ]. The following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anticoagulants were associated with a statistically nonsignificant reduction in recurrent ischemic stroke within 7 to 14 days (3.0 versus 4.9 percent, odds ratio [OR] 0.68, 95% CI 0.44-1.06)",
"     </li>",
"     <li>",
"      Anticoagulants were associated with a statistically significant increase in symptomatic intracranial hemorrhage (2.5 versus 0.7 percent, OR 2.89, 95% CI 1.19-7.01)",
"     </li>",
"     <li>",
"      Anticoagulants and other treatments had a similar rate of death or disability at final follow-up (approximately 74 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the results do not support early anticoagulant treatment of acute cardioembolic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Progressing stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    was once widely used to treat patients who continued to have neurologic deterioration in the first hours or days after ischemic stroke (ie, progressing stroke, also referred to as stroke in evolution). The TOAST trial did not find an improvement in outcomes with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/18/41254?source=see_link\">",
"     danaparoid",
"    </a>",
"    treatment in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/15\">",
"     15",
"    </a>",
"    ], nor did a nonrandomized study of heparin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/22\">",
"     22",
"    </a>",
"    ]. These findings do not support a role for heparin in halting neurologic worsening after stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1180709\">",
"    <span class=\"h2\">",
"     Role of early anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines issued in 2013 by the American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Stroke Association state that urgent anticoagulation is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for the treatment of patients with acute ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/10\">",
"     10",
"    </a>",
"    ]. Similarly, 2012 guidelines from the American College of Chest Physicians (ACCP) recommend early",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy over therapeutic parenteral anticoagulation for patients with acute ischemic stroke or TIA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While many specialists believe it has no role at all in the early acute phase of ischemic stroke, some experts have used early anticoagulation for various ischemic stroke subtypes, including cardioembolic stroke due to atrial fibrillation and stroke due to large artery stenoses or arterial dissection. However, the 2012 ACCP guidelines note that a review of the literature does not support the use of anticoagulation in these subgroups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/9\">",
"     9",
"    </a>",
"    ]. Other subgroups at particularly high risk for recurrent embolism, such as patients with mechanical heart valves or intracardiac thrombus, were either not included or were underrepresented in trials of acute antithrombotic therapy for stroke. The ACCP notes that the optimal choice of acute antithrombotic therapy in these patients is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In agreement with the national guidelines, we recommend",
"    <strong>",
"     not",
"    </strong>",
"    using full-dose parenteral anticoagulation for treatment of unselected patients with acute ischemic stroke because of limited efficacy and an increased risk of bleeding complications. Instead, we recommend early",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy (160 to 325",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for most patients with acute ischemic stroke or TIA. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Aspirin'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'Early aspirin use'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although benefit is unproven, we suggest early parenteral anticoagulation rather than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for select patients with acute cardioembolic ischemic stroke or TIA who have intracardiac thrombus associated with mechanical or native heart valves. We recognize that this approach is controversial; some experts favor treatment with aspirin rather than anticoagulation in this setting for patients with an acute brain infarction. Our suggestion to use early parenteral anticoagulation for these selected patients applies only to those with a small brain infarct or TIA and no evidence of hemorrhage on brain imaging. Anticoagulation should not be given for the first 24 hours following treatment with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The use of antithrombotic therapy for ischemic stroke and TIA caused by cervical artery dissection is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/28/21960?source=see_link&amp;anchor=H28007410#H28007410\">",
"     \"Spontaneous cerebral and cervical artery dissection: Treatment and prognosis\", section on 'Antithrombotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Full-dose anticoagulation should not be used for patients with a large infarction (based upon clinical syndrome or brain imaging findings), uncontrolled hypertension, or other bleeding conditions. (See",
"    <a class=\"local\" href=\"#H1180605\">",
"     'Contraindications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1180598\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the selected patients who receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in the acute stroke setting, a bolus is not administered. One group has proposed a weight-based nomogram for heparin infusions that, compared with usual heparin therapy, is associated with fewer complications, fewer mistakes in dose adjustment, improved anticoagulation, and decreased nursing and house staff labor (",
"    <a class=\"graphic graphic_table graphicRef53377 \" href=\"mobipreview.htm?42/3/43068\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     Enoxaparin",
"    </a>",
"    1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    dose every 12 hours (or other low molecular weight heparins) may be used as an alternative to intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in patients with acute stroke when early anticoagulation is desired to prevent recurrent cerebral embolism; the limited available evidence suggests that low molecular weight heparins have similar efficacy, advantages in administration and monitoring, and reduced rates of thrombocytopenia compared with heparin.",
"   </p>",
"   <p>",
"    The use of intravenous anticoagulation for prophylaxis of deep vein thrombosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17610?source=see_link&amp;anchor=H6#H6\">",
"     \"Medical complications of stroke\", section on 'VTE prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1180605\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulation in the setting of acute stroke may only be considered after a brain imaging study has excluded hemorrhage and estimated the size of the infarct. Early anticoagulation should be avoided when potential contraindications to anticoagulation are present, such as a large infarction (based upon clinical syndrome or brain imaging findings), uncontrolled hypertension, or other bleeding conditions.",
"   </p>",
"   <p>",
"    Although there is no standard definition, many stroke experts consider \"large\" infarcts to be those that involve more than one-third of the middle cerebral artery territory or more than one-half of the posterior cerebral artery territory based upon neuroimaging with CT or MRI. Infarct size can also be clinically defined, but this process can result in underestimation of the true infarct volume when so-called \"silent\" areas of association cortex are involved.",
"   </p>",
"   <p>",
"    Clinical estimation of infarct size may be improved by using validated scales that have been correlated with infarct volume and clinical outcome, such as the National Institutes of Health Stroke Scale (NIHSS) (",
"    <a class=\"graphic graphic_table graphicRef61698 \" href=\"mobipreview.htm?39/33/40477\">",
"     table 3",
"    </a>",
"    ). As an example, one study found that an NIHSS score &gt;15 was associated with a median infarct volume of 55.8 cm",
"    <sup>",
"     3",
"    </sup>",
"    and worse outcome than NIHSS scores of 1 to 7 (median volume of 7.9 cm",
"    <sup>",
"     3",
"    </sup>",
"    ) or 8 to 15 (median volume of 31.4 cm",
"    <sup>",
"     3",
"    </sup>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31688/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, patients with an NIHSS score &gt;15 generally have a large infarct. However, it should be recognized that part of the clinical deficit in the early hours of an acute stroke may be attributed to the penumbra, where the brain is ischemic but not infarcted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/55/24435?source=see_link\">",
"       \"Patient information: Stroke (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/37/38484?source=see_link\">",
"       \"Patient information: Stroke symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/53/19286?source=see_link\">",
"       \"Patient information: Ischemic stroke treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346089098\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , and the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/52/19271?source=see_link\">",
"       aspirin-extended-release dipyridamole",
"      </a>",
"      are all acceptable options for secondary stroke prevention, aspirin is the only antiplatelet agent that has been established as effective for the early treatment of acute ischemic stroke. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Antiplatelet agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical trials have not adequately evaluated the role of very early (ie, within hours of stroke onset) anticoagulation for acute ischemic stroke or for selected stroke subtypes. However, the available evidence suggests that early anticoagulation is associated with a higher mortality and worse outcomes compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      treatment initiated within 48 hours of ischemic stroke onset. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Parenteral anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with acute ischemic stroke or TIA who are not receiving oral anticoagulants, we recommend early",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy (160 to 325",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      rather than no aspirin therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ) or parenteral anticoagulation therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Aspirin should be started as early as possible after the diagnosis of ischemic stroke is confirmed and ideally within 48 hours of stroke onset. However, aspirin should not be given for the first 24 hours following treatment with intravenous or intra-arterial thrombolytic therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Aspirin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Early aspirin use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of antithrombotic therapy for patients who have ischemic neurologic symptoms caused by cervical or intracranial artery dissection is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/28/21960?source=see_link&amp;anchor=H28007410#H28007410\">",
"       \"Spontaneous cerebral and cervical artery dissection: Treatment and prognosis\", section on 'Antithrombotic therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with acute cardioembolic ischemic stroke or TIA who have intracardiac thrombus associated with mechanical or native heart valves, we suggest early parenteral anticoagulation rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This approach is controversial. Other experts favor early treatment with aspirin rather than anticoagulation in this setting for patients with an infarct. Our suggestion to use early parenteral anticoagulation for these selected patients applies only to those with a small brain infarct or TIA and no evidence of hemorrhage on brain imaging. (See",
"      <a class=\"local\" href=\"#H1180709\">",
"       'Role of early anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31688/abstract/1\">",
"      The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997; 349:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31688/abstract/2\">",
"      CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet 1997; 349:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31688/abstract/3\">",
"      Chen ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 2000; 31:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31688/abstract/4\">",
"      Sandercock PA, Counsell C, Gubitz GJ, Tseng MC. Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev 2008; :CD000029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31688/abstract/5\">",
"      Dengler R, Diener HC, Schwartz A, et al. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 2010; 9:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31688/abstract/6\">",
"      Kennedy J, Hill MD, Ryckborst KJ, et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007; 6:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31688/abstract/7\">",
"      Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31688/abstract/8\">",
"      Geeganage CM, Diener HC, Algra A, et al. Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. Stroke 2012; 43:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31688/abstract/9\">",
"      Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e601S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31688/abstract/10\">",
"      Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2013; 44:870.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Stroke: The diagnosis and acute management of stroke and transient ischaemic attacks. Royal College of Physicians, London 2008. file://www.nice.org.uk/CG068 (Accessed on February 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31688/abstract/12\">",
"      Berge E, Sandercock P. Anticoagulants versus antiplatelet agents for acute ischaemic stroke. Cochrane Database Syst Rev 2002; :CD003242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31688/abstract/13\">",
"      Camerlingo M, Salvi P, Belloni G, et al. Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions. Stroke 2005; 36:2415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31688/abstract/14\">",
"      Sandercock PA, Counsell C, Kamal AK. Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev 2008; :CD000024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31688/abstract/15\">",
"      Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. JAMA 1998; 279:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31688/abstract/16\">",
"      Adams HP Jr, Bendixen BH, Leira E, et al. Antithrombotic treatment of ischemic stroke among patients with occlusion or severe stenosis of the internal carotid artery: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999; 53:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31688/abstract/17\">",
"      Wong KS, Chen C, Ng PW, et al. Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study. Lancet Neurol 2007; 6:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31688/abstract/18\">",
"      Kay R, Wong KS, Yu YL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995; 333:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31688/abstract/19\">",
"      Diener HC, Ringelstein EB, von Kummer R, et al. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Therapy of Patients With Acute Stroke (TOPAS) Investigators. Stroke 2001; 32:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31688/abstract/20\">",
"      Bath PM, Lindenstrom E, Boysen G, et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet 2001; 358:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31688/abstract/21\">",
"      Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke 2007; 38:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31688/abstract/22\">",
"      R&ouml;d&eacute;n-J&uuml;llig A, Britton M. Effectiveness of heparin treatment for progressing ischaemic stroke: before and after study. J Intern Med 2000; 248:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31688/abstract/23\">",
"      Toth C, Voll C. Validation of a weight-based nomogram for the use of intravenous heparin in transient ischemic attack or stroke. Stroke 2002; 33:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31688/abstract/24\">",
"      Thijs VN, Lansberg MG, Beaulieu C, et al. Is early ischemic lesion volume on diffusion-weighted imaging an independent predictor of stroke outcome? A multivariable analysis. Stroke 2000; 31:2597.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1082 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-C1CDB4E621-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_60_31688=[""].join("\n");
var outline_f30_60_31688=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H346089098\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTIPLATELET AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Other antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Early aspirin use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PARENTERAL ANTICOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Stroke subtypes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Atrial fibrillation and cardioembolic stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Progressing stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1180709\">",
"      Role of early anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1180598\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1180605\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H346089098\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1082\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1082|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/40/32397\" title=\"table 1\">",
"      Criteria for treating acute stroke with tPA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/3/43068\" title=\"table 2\">",
"      Heparin nomogram for stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/33/40477\" title=\"table 3\">",
"      NIH Stroke Scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/26/6570?source=related_link\">",
"      Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17610?source=related_link\">",
"      Medical complications of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/53/19286?source=related_link\">",
"      Patient information: Ischemic stroke treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41098?source=related_link\">",
"      Reperfusion therapy for acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/33/32281?source=related_link\">",
"      Secondary prevention for specific causes of ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/28/21960?source=related_link\">",
"      Spontaneous cerebral and cervical artery dissection: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39383?source=related_link\">",
"      Stroke in patients with atrial fibrillation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_60_31689="Exenteration for gynecologic cancer";
var content_f30_60_31689=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Exenteration for gynecologic cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/60/31689/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/60/31689/contributors\">",
"     Ken D Hatch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/60/31689/contributors\">",
"     William J Mann, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/60/31689/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/60/31689/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/60/31689/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/60/31689/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/60/31689/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exenteration refers to an ultraradical surgical procedure consisting of an en bloc resection of the female reproductive organs, lower urinary tract, and a portion of the rectosigmoid. Although rarely performed, it may be offered as a last hope of cure to women with recurrent or advanced gynecologic cancer with extensive central pelvic disease that cannot be resected with a lesser procedure, and in whom radiation is not an option. If the disease is truly confined to the pelvis, then this extended surgical resection offers a chance of cure: five year survival rates are approximately 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss the indications and operative technique for exenterative surgery of the female pelvis. The evolution of pelvic exenterative surgery can be found elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/3-13\">",
"     3-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total exenteration refers to removal of the uterus, tubes, ovaries, parametrium, bladder, rectum or rectal segment, vagina, urethra, and a portion of the levator muscles. In an anterior exenteration, the rectum is spared, while in a posterior exenteration, the bladder and urethra are preserved. A perineal phase, resecting the anus, urethra, and portions of the vulva, may also be required (",
"    <a class=\"graphic graphic_figure graphicRef74429 \" href=\"mobipreview.htm?34/62/35814\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There is no \"standard\" exenteration. The choice of procedure is based upon the location of the cancer, difficulties that may arise during surgery, type and location of previous radiotherapy, anatomy, and the patient's postoperative goals and expectations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential for cure by exenterative surgery requires that the patient's cancer be resected in its entirety with adequate margins. Thus, diseases that spread by lymphatic, blood, or peritoneal pathways early in their course will rarely lend themselves to ultraradical resection.",
"   </p>",
"   <p>",
"    The extreme radical nature of exenterative surgery dictates that it be used only when less radical treatment options have failed or cannot be used. Essentially all women will have received prior pelvic radiation. Occasionally, a woman will present with advanced vulvar or cervical cancer involving the bladder, urethra, anus, or rectum, which lends itself to primary exenterative surgery as definitive treatment. Before deciding, serious consideration must be given to brachytherapy (including interstitial placement of sources) and for combined chemotherapy and radiotherapy, alternatives that may spare the urinary and gastrointestinal tracts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cervical cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with cervical cancer who develop a central recurrence (vaginal apex or pelvis without side wall involvement) of cervical cancer after primary RT or after surgery followed by RT may be candidates for a potentially curative surgical procedure if a complete evaluation fails to reveal metastatic disease.",
"   </p>",
"   <p>",
"    Biopsy confirmation of central recurrences should be pursued if possible. If the recurrence is small and centrally limited, the patient may be an appropriate candidate for radical hysterectomy and partial vaginectomy. If there is a larger central recurrence or if the patient had a radical hysterectomy previously and has received prior therapeutic doses of RT, she may be a candidate for pelvic exenteration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33368?source=see_link&amp;anchor=H8642804#H8642804\">",
"     \"Management of recurrent or metastatic cervical cancer\", section on 'Candidates for surgical resection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a systematic review of 21 studies of pelvic exenteration for gynecologic malignancy, one-third to one-half of women were found to have unresectable or extrapelvic disease found at exploration, and the exenteration was aborted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/14\">",
"     14",
"    </a>",
"    ]. Resection with a clear margin was achieved in 75 to 97 percent of cases. The operative mortality in patients who underwent exenteration was 3 to 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Those who successfully undergo exenterative surgery (negative margins and no metastatic disease) have an approximately 50 percent chance of being cured; the remainder die of recurrent cancer (",
"    <a class=\"graphic graphic_algorithm graphicRef50168 \" href=\"mobipreview.htm?7/34/7726\">",
"     algorithm 1",
"    </a>",
"    ). Although the number of women who are cured by exenterative surgery is small, this surgery is still an opportunity for survival when faced with certain death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Vulvar cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar cancer, like cervical cancer, often stays confined to the pelvis until late in its natural history. Radiotherapy alone or with chemotherapy is able to effectively eliminate or markedly shrink large vulvar cancers, lessening the extent of surgery needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9303?source=see_link\">",
"     \"Vulvar cancer: Clinical manifestations, diagnosis, and pathology\"",
"    </a>",
"    .) Primary exenterative surgery is not appropriate for most women presenting with advanced vulvar cancer, but there is a limited role for exenteration in women whose cancer recurs, or in whom the cancer has destroyed the urethra, bladder, or anus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ovarian and endometrial cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with either ovarian or endometrial cancer, both of which have a propensity to spread beyond the pelvis, are poor candidates for exenterative surgery. Five year survival for women with these cancers undergoing exenteration is 20 to 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. An exception is \"modified posterior exenteration\", which has been proposed for primary and secondary cytoreduction of ovarian cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/20\">",
"     20",
"    </a>",
"    ]. This operation is an en bloc resection of the pelvic peritoneum, uterus, tubes, ovaries, and a segment of rectosigmoid. It is a supralevator ani resection, useful for dealing with a \"frozen\" pelvis obliterated by ovarian cancer, in which attempting to develop planes between the pelvis and intestinal tract is not feasible. Cytoreductive surgery is performed concurrently. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/48/36618?source=see_link\">",
"     \"Epithelial ovarian cancer: Initial surgical management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is often possible to restore the continuity of the GI tract using modern stapling devices, at the time of modified posterior exenteration for cytoreduction of ovarian cancer. When this is done, some surgeons will do a diverting colostomy to allow the low pelvic anastomosis to heal, while others will not do so if they feel they have a healthy, tension free anastomosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exenteration has also been used for vaginal carcinomas, rhabdomyosarcomas, and other miscellaneous rare tumors. Whenever ultraradical central resection of cancer is feasible, and lesser therapy not feasible, exenteration can be considered. Severe radiation necrosis, rarely seen with modern technology, has also been an indication for exenteration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Palliation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of exenterative surgery for palliation is controversial. Traditionally, the associated morbidity, complications, risk of death, and long hospitalization were considered too high for a palliative procedure. Expert surgical judgment and discretion must be exercised in the selection of those patients who can tolerate the palliative operative procedures without excessive morbidity and who are likely to benefit from the additional survival potentially provided by the operation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Psychological issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;A candidate for pelvic exenteration must be able to accept major changes in body image that will occur despite the surgeon's best efforts at reconstruction. The woman needs a caring family who will support her, intact mental faculties, and access to continued medical care. Extended conversations with other women who have undergone this surgery are also invaluable. Nurses who deal with these patients should have a positive, frank, and understanding manner. The range of complications resulting from surgery must be explained.",
"   </p>",
"   <p>",
"    The patient must understand there is a 3 to 5 percent operative mortality, she will spend several days in the intensive care unit, and likely have a prolonged hospitalization measured in weeks. It is also necessary to discuss the possibility of an aborted procedure, if unresectable or metastatic disease is found. Sexual function will be altered, and she may need to become adept at caring for one or two stoma. Often, a woman will cry and verbalize considerable anguish when these discussions occur. This, however, is preferable to the woman who cheerfully demands that one proceed immediately, and only begins to deal with her emotions postoperatively. The woman in tears is beginning to understand what is proposed. In one sense, this is a terrible operation to offer someone; it is justified by a chance for cure, but must be approached thoughtfully and carefully. The surgeon discussing the procedure with the woman needs to have considerable maturity and experience, and must be able to honestly answer the questions that are asked and relay the uncertainty of the operative result. Finally, she must accept that even after all this, there is no guarantee of cure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Medical evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The woman's general medical condition should be adequate for a prolonged operative procedure (four to eight hours) with probable extensive fluid shifts, transfusion, and nutritional support; potentially fatal coexisting diseases are a contraindication to exenteration. Age over 65 may increase the operative mortality of exenteration, although this probably reflects concurrent medical problems. Biologic age is more important than simple chronological age.",
"   </p>",
"   <p>",
"    Histological confirmation that cancer is present is critical before initiating surgery. The authors rarely, if ever, accept slides from another institution, and never accept only a pathology report. The goal of the medical evaluation (complete history and physical examination, laboratory and imaging studies) is to find evidence of unresectable or metastatic disease; thus, making the woman an unsuitable candidate for exenteration. As an example, unilateral leg swelling and unilateral or bilateral sciatic pain are worrisome, as they suggest metastatic disease to the posterolateral pelvic sidewall. The triad of unilateral leg edema, ipsilateral sciatic pain, and hydronephrosis on intravenous pyelogram (IVP) contraindicates exenteration, as it indicates unresectable cancer metastatic to the posterolateral side wall. Women with one or two of the triad have a high likelihood of metastatic disease, but should not be precluded from exploration if metastasis cannot be documented.",
"   </p>",
"   <p>",
"    Physical examination focuses on looking for evidence of cachexia, palpable supraclavicular or inguinal adenopathy, hepatomegaly, or intra-abdominal masses. Rarely, skin metastasis is found. Routine biopsy of nonpalpable supraclavicular or inguinal lymph nodes is not recommended, as the yield is vanishingly low. Palpable nodes, by contrast, should be biopsied as they almost always represent metastatic disease and preclude exenteration. Aspiration is usually adequate to confirm cancer. Pelvic examination is extremely inaccurate in assessing resectability, since it is not possible to differentiate radiation fibrosis, endometriosis, or igneous cellulitis from cancer. Fixation to the side wall on examination is not a contraindication to exploration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Laboratory and imaging tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate laboratory studies include screening for chronic active hepatitis and human immunodeficiency virus, which probably contraindicate exenteration. Elevated liver enzymes require excluding the possibility of liver metastasis. Additional routine laboratory tests include a complete blood count, platelet count, glucose, electrolytes, urinalysis, urine culture, and renal function tests. Anemia and any bleeding diathesis must be corrected preoperatively, and intercurrent infections cleared, if possible.",
"   </p>",
"   <p>",
"    Preexenteration FDG PET has been reported to have sensitivity and specificity of 100 and 73 percent, respectively, for detecting sites of extra-pelvic metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/22\">",
"     22",
"    </a>",
"    ]. CT-PET is even more accurate and is now a reimbursable modality for assessing cervical cancer. Most surgeons will perform a CT-PET of the abdomen, pelvis, and chest prior to exenteration to evaluate for metastatic disease that would represent a contraindication to performing the surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. &nbsp;If liver lesions or retroperitoneal adenopathy are seen, needle aspiration should be done to confirm cancer spread, which would preclude exenterative surgery. Disease above the pelvic brim is an absolute contraindication to total pelvic exenteration. Any intraperitoneal fluid should be aspirated for cytology. The role of diagnostic laparoscopy with node sampling, peritoneal cytologies, and biopsy as indicated remains undefined, but may aid in selecting patients who are not candidates for exenteration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Absence of fatty planes lateral to tumor on CT imaging should not be used for determining resectability. Neither CT nor magnetic resonance imaging (MRI) are able to assess parametrial or levator extension accurately, as radiation fibrosis, with or without superimposed endometriosis, chronic inflammation, or foreign body reaction, cannot reliably be differentiated from cancer. Ureteral obstruction at the ureteral-vesical junction is resectable; however, obstruction by enlarged pelvic or paraaortic nodes is not. Similarly, ureteral obstruction by extrinsic masses does not influence resectability; only the nature of the mass is important. Bone scans are usually not done unless the woman gives a history of recent onset of bone pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Cystoscopy and sigmoidoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystoscopy and sigmoidoscopy are not necessary unless there are plans to preserve either the bladder or rectum, in which case they must be examined to ensure the absence of occult metastasis. In women undergoing exenteration following radiotherapy for cervical cancer, the bladder is usually removed, as its preservation leads to increased risk of recurrence and urinary tract fistula or stricture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PREOPERATIVE PATIENT PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Informed consent for surgery is obtained before admission. The woman's medical condition should be made optimal. A mechanical bowel preparation is given with intravenous fluids started at the same time to avoid dehydration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/55/39800?source=see_link\">",
"     \"Overview of preoperative evaluation and preparation for gynecologic surgery\"",
"    </a>",
"    .) If the woman is severely malnourished,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN) may be started in advance of surgery. She is taught incentive spirometry preoperatively and given a broad spectrum prophylactic antibiotic (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    1 g IV 30 minutes prior to incision).",
"   </p>",
"   <p>",
"    The sites for stoma are marked by the ostomy team the morning of surgery, and checked when the woman sits, stands, and lies down. Care is taken to avoid skin creases, scars, and the site where the woman normally wears her belt and elastic waistband.",
"   </p>",
"   <p>",
"    Patients may remain NPO (nothing by mouth) for extended periods postoperatively. A central line can be placed in the operating room during the procedure, and TPN started. Central lines with multiple ports facilitate postoperative fluid management. Six units of packed red blood cells are ordered, and incentive spirometry taught preoperatively.",
"   </p>",
"   <p>",
"    Six units of packed red blood cells are ordered, and incentive spirometry taught preoperatively. &nbsp;Preoperatively, if time permits, we correct anemia, begin iron replacement, including parenteral iron therapy if necessary, and will use erythropoietin to raise hemoglobin to 11",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OPERATIVE TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The technique presented here uses an open approach. Laparoscopic pelvic exenteration is performed by some surgeons, but outcomes with this approach require further evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Robot-assisted pelvic exenterations have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The woman is placed in a low dorsal lithotomy position, using stirrups to support the hips, knees, and thighs (",
"    <a class=\"graphic graphic_picture graphicRef79003 \" href=\"mobipreview.htm?43/10/44192\">",
"     picture 1",
"    </a>",
"    ). The assistants can be positioned on each side of the table, as well as between the legs, to allow for a double team approach. The lithotomy position aids in allowing simultaneous abdominal-pelvic examination when the abdomen is open and resectability being assessed and is helpful with the perineal phase of the procedure, or if myocutaneous grafts are planned for reconstruction. The woman is prepared and draped from nipples to knees, and a catheter is placed. Appropriate lines are inserted. The instrument stand is placed over the leg opposite the primary surgeon.",
"   </p>",
"   <p>",
"    Intermittent pneumatic compression devices are applied as prophylaxis for deep vein thrombosis (",
"    <a class=\"graphic graphic_picture graphicRef73950 graphicRef54019 \" href=\"mobipreview.htm?16/24/16774\">",
"     picture 2A-B",
"    </a>",
"    ). Combined epidural and general anesthesia is preferred as maintaining the epidural for 72 hours after surgery gives good pain control while keeping the woman alert and able to comply with respiratory toilet.",
"   </p>",
"   <p>",
"    A midline incision adequate for exploring upper and lower abdomen is made, and extended upward as needed. In a systematic manner, the diaphragm, liver, gallbladder, stomach, spleen, omentum, large and small bowel, and abdominal and pelvic peritoneum are examined for metastatic disease, secondary primary lesions, or unexpected or known incidental pathology (eg, gallstones, hepatic cysts). The pelvis is inspected, looking for evidence of tumor breakthrough into the peritoneal cavity, or metastasis to pelvic peritoneum or adnexae. The retroperitoneum and paraaortic areas are carefully palpated for masses. Any suspicious findings are biopsied and sent for frozen section to confirm unresectability. If no evidence of metastasis outside of the pelvis is found, the peritoneum over the paraaortic area is incised and a paraaortic biopsy obtained and sent for frozen section. If pelvic nodes have not been previously removed, these are dissected and sent for frozen section. If negative, the pelvic exploration begins. Disseminated peritoneal disease is not compatible with cure, but women with limited peritoneal involvement (sigmoid or ileum) have cure rates of 10 to 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not uncommon to encounter small bowel adhesions, which must be lysed to allow adequate exploration of the abdomen. On occasion, a loop of small bowel will be found densely adherent to the uterus and, rarely, there will be actual invasion directly into the loop of small bowel. Although most would resect or bypass the involved loop, reanastomose the bowel, and abort the procedure, there are case reports of patients who underwent exenteration with resection of the small bowel and survived more than five years (6 of 49 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/31\">",
"     31",
"    </a>",
"    ]. Fecal spillage during surgery is handled by copious irrigation and by beginning antibiotics that cover anaerobic and gram-negative organisms.",
"   </p>",
"   <p>",
"    If exenterative surgery is being considered for ovarian cancer, abdominal exploration is aimed at assessing whether disease outside of the pelvis can be cytoreduced to a maximum lesion size of 1 cm or less. If gross disease greater than 2 cms diameter in the upper abdomen cannot be resected, than the patient will be suboptimally cytoreduced, and exenterative surgery would be futile. In this circumstance, should disease in the pelvis obstruct or invade the rectosigmoid, simple diverting colostomy would be preferred.",
"   </p>",
"   <p>",
"    The round ligaments can be divided at the side wall, and the prevesical and pararectal spaces developed. Alternately, the prevesical space can be opened, dissected to the urethra, then extended laterally to both side walls, where the round ligaments can then be divided retroperitoneally, the lateral pelvic peritoneum reflected medially, and the spaces then developed.",
"   </p>",
"   <p>",
"    Biopsy of the pelvic nodes is done if suspicious areas are seen. Routine lymphadenectomy is not done, as it would, at best, be of prognostic value, and of no therapeutic value. However, some gynecologic oncologists routinely perform pelvic lymph node sampling and abort the procedure if the nodes are positive, although some would consider intraoperative radiation therapy (IORT) if there was just limited lymph node involvement, ie, one lymph node positive. In the infrequent event of exenteration being done as primary therapy without prior radiation, lymphadenectomy may be appropriate.",
"   </p>",
"   <p>",
"    The infundibulopelvic ligaments are divided well above the common iliac vessels. The ureters are dissected free for several centimeters past their point of crossing the common iliac vessels. If preoperative studies showed hydronephrosis, the point of obstruction is identified, and biopsies taken to determine if unresectable cancer is causing the blockage. If the ureter is obstructed below the bifurcation of the iliac vessels, but medially, this is not a contraindication to resection and does not need to be dissected, as this area will be included in the major specimen. After resectability is determined, the ureters are divided on an angle to facilitate anastomosis to bowel. There is no point in trying to gain an extra centimeter or two in dividing the ureter; rather, it is important to ensure an adequate margin from cancer. In carefully selected cases, intraoperative radiation therapy contributes to radical salvage of patients with recurrent cervical cancer involving the pelvic wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The spaces lateral to the rectum are sharply developed and carried across the midline, where blunt dissection can be used to develop the potential space posterior to the rectum. At this point, the anterior tissue planes will have been developed down to the levator ani muscles, as will the bilateral perivesical and perirectal spaces, and the rectum will be freed posteriorly down to the sacral curve. This is usually a relatively bloodless dissection.",
"   </p>",
"   <p>",
"    Beginning on the side most likely to contain cancer, the parametrium is sharply divided at the side wall, taking the internal iliac artery just after it crosses the internal iliac vein. This sacrifices the uterine artery, vesicle arteries, and the obliterated umbilical artery. The remainder of the hypogastric artery is left intact. It carries the internal pudendal and inferior hemorrhoidal arteries, which are important to maintain vascularity to the anal canal and lower rectum, a potential site of anastomosis. It also carries the obturator artery, which provides significant blood supply to the gracilis muscle, and is necessarily preserved if planning a gracilis muscle neovagina. The cardinal ligament is divided and ligated at the side wall, and the broad attachments of the rectum to the sacrum are also divided. The vaginal attachments to the tendinous arch are divided and the vaginal arteries and vein are located on the lateral margin of this pedicle. The specimen is now completely mobilized, so that penetration of the rectum and vagina through the pubococcygeus muscle can be identified. A combined abdominal-pelvic examination can be carried out at any point, to identify areas suspicious for cancer, which are biopsied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Intraoperative biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When performing a biopsy to establish resectability, the specimen should be reflected medially, and the biopsy taken from tissue that will be left behind if the exenteration proceeds. The biopsy is meant to tell one what cannot be removed, so it is necessary to have one's planes of dissection well-formed before performing a biopsy. Anterolateral and posterolateral areas where tumor may extend to the side wall along the fascia or muscle fibers of the levator muscles are particularly difficult to biopsy. Kevorkian biopsy forceps, which are excellent for colposcopy, are also superb for biopsy of hard-to-reach areas (eg, diaphragm and liver). Occasionally, troublesome bleeding will be encountered and is best handled with pressure or by placing figure-of-eight sutures.",
"   </p>",
"   <p>",
"    If a biopsy is positive for unresectable metastatic cancer, the procedure is terminated. The planes developed are copiously irrigated, and hemostasis confirmed. No attempt is made to close these planes or to approximate peritoneal edges. Drains are not placed. A bulk closure of the abdomen is used, and the central line left in place for fluid replacement. The surgeon needs to be available to talk with the woman when she awakens. She can usually be returned to the gynecology floor if she is stable in the recovery room.",
"   </p>",
"   <p>",
"    If all biopsies return negative, then the exenterative specimen can begin to be removed. The ureters are now divided and placed into the upper abdomen, and anesthesia is notified that there will no longer be any measurable urine output, and that urine will be mixed with blood loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Anterior exenteration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior exenteration is suitable for lesions confined to the cervix and the anterior upper vagina. The goal is to remove the bladder, urethra, and anterior vagina, but save the posterior vagina and rectum. Bimanual palpation, with the pelvic hand inserting one finger into the vagina and another into the rectum, while the abdominal hand palpates the posterior cul-de-sac (pouch of Douglas) and retracts the rectum posteriorly, will confirm the initial impression that an anterior resection is advisable. If the space posterior to the cervix feels free, then an incision can be made in the cul-de-sac to allow the rectum to drop away with sharp dissection from the upper vagina, leaving at least a 4 cm margin on the vagina. The potential space between the rectum and posterior vagina is developed abdominally, and adequacy of margin confirmed by direct vision vaginally. The posterior vaginal incision is made from below, with the cancer in view, to ensure adequate margin. Biopsies of the vagina, which will be left intact over the rectum, are sent for frozen section if any question remains about cancer involvement. The perineal incision is made, removing the urethra and surrounding soft tissue, but preserving the clitoris and labia. Cautery reduces blood loss while doing this.",
"   </p>",
"   <p>",
"    A pointed clamp such as a long tonsil is passed from the abdomen beneath the pubis and directed out superior to the urethra. The clamp is spread to open the space, and then widened from below with the two index fingers. Clamps are then passed under the pubic arch to allow the pubococcygeal muscles attached to the vagina at the three and nine o'clock positions to be divided. Clamps may also need to be passed from below upward to be sure the whole pedicle is taken. Large suture ligatures are used for hemostasis. The posterior vaginal wall is then separated from the rectum, and this posterior space (which communicates with the cul-de-sac) is joined with the anterior space, thus totally mobilizing the specimen, which can be delivered through the perineal opening. Warm laparotomy pads are placed abdominally into the defect, and pressure applied from above and below. Cautery and ligature are used to obtain hemostasis. The specimen is then carefully inspected to be sure all margins are acceptable. It is often useful to place long sutures into the specimen to aid in orienting the pathologist, who must fix and section this specimen (",
"    <a class=\"graphic graphic_picture graphicRef71158 \" href=\"mobipreview.htm?6/44/6848\">",
"     picture 3",
"    </a>",
"    ). Many surgeons-prefer to be present when the pathologist begins the gross examination of the specimen.",
"   </p>",
"   <p>",
"    If at any time during the exenterative procedure there is difficulty separating the rectum and posterior vagina from the cancer, it is prudent to resect the piece of rectum to ensure an adequate margin.",
"   </p>",
"   <p>",
"    Reconstruction of the vagina is done, if desired. If no vaginal reconstruction is planned, the omentum can be mobilized from the hepatic flexure to the splenic flexure, leaving 3 to 4 cm intact, and then loosely sewn over the pelvic defect. The perineal opening will close rapidly by granulation. Irrigations are usually started after 72 hours to keep the perineum clean, if no reconstruction is done.",
"   </p>",
"   <p>",
"    Urinary diversion is then performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Total exenteration with perineal phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a total exenteration is planned and resectability determined, the sigmoid and descending colon are mobilized, and the sigmoid transected at the pelvic brim after dividing the ureters. The proximal end of the bowel, which will become the stoma, is packed into the upper abdomen. The rectosigmoid is elevated by an assistant and the posterior attachments of the colon freed down to the levator muscles. The sigmoid mesenteric arteries and the superior rectal artery are divided.",
"   </p>",
"   <p>",
"    The perineal phase begins by making an incision sufficient to remove the urethra and entire vagina, and to include the anus. Cautery is used. The subcutaneous tissues are divided around the rectum, and then the urethra and anterior vagina freed as in an anterior exenteration. In addition, the pubococcygeal attachments to the perineal body are identified, as is the anococcygeal ligament, and they are clamped, divided, and suture ligated. The specimen is removed through the perineal defect and hemostasis attained with ligature and cautery (",
"    <a class=\"graphic graphic_picture graphicRef52560 \" href=\"mobipreview.htm?39/6/40032\">",
"     picture 4",
"    </a>",
"    ). This leaves a huge pelvic defect, best filled with myocutaneous flaps of either gracilis or rectus abdominis muscles,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an omental flap. Alternately, after hemostasis has been attained, a large pelvic pack may be placed. A nylon or similar fabric pouch is filled with laparotomy pads and placed with the opening coming out through the perineum, and the pouch is closed with a pursestring suture. The omentum can be mobilized and used to cover the pelvis. It can then be loosely sewn over the pelvic pack, as a floor. The colostomy and urinary diversion can then be constructed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Supralevator total exenteration with low rectal anastomosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with disease extending posteriorly from the cervix onto the vaginal epithelium or into the rectal wall are candidates for this procedure, provided the cancer does not extend to the lower third of the vagina posteriorly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/1,33\">",
"     1,33",
"    </a>",
"    ]. After the bladder, urethra, and anterior vagina are mobilized, as previously described, the posterior vaginal wall incision is made 4 cm below the tumor. The vaginal epithelium is mobilized for 1 to 2 cm away from the rectal muscularis. The hand then encircles the mobilized rectum and pulls it cephalad. The specimen side is clamped to reduce spillage of feces and divided, leaving an anal and rectal stump. The length of the anal rectal stump from the anal sphincter is ideally 6 cm or greater. If less than 6 cm in length, the risk of fistula and incontinence are greater.",
"   </p>",
"   <p>",
"    After mobilization of this lower specimen, the sigmoid colon is divided along with the sigmoidal arteries and the superior rectal artery. Ample mobilization for reanastomosis is accomplished by incising the lateral attachments of the sigmoid and descending colon, mobilizing it, and if necessary, sacrificing some of the sigmoidal vessels. The major blood supply is from the inferior mesenteric artery, which has significant anastomoses between it and the middle colic artery. After the sigmoid and left colon are mobilized, the colon should be observed for adequacy of blood supply and viability while the urinary diversion is done and the flaps for neovaginal construction are harvested. If the appearance of both cut edges is satisfactory, then the anastomosis can be carried out. If there is lack of vascularity to either stump, they should be trimmed back until bleeding is encountered. The anastomosis is accomplished by using 28- or 31-mm diameter circular staplers. Following anastomosis, the omentum is mobilized and brought into the pelvis as an omental graft. It is used to wrap the low rectal anastomosis and to fill the presacral space (",
"    <a class=\"graphic graphic_figure graphicRef77635 \" href=\"mobipreview.htm?19/63/20471\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef64322 \" href=\"mobipreview.htm?10/35/10803\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Neovagina",
"    </span>",
"    &nbsp;&mdash;&nbsp;A neovagina can then be made. The type of neovagina selected depends on the amount of space to be filled and the woman's anatomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6885?source=see_link&amp;anchor=H11#H11\">",
"     \"Vaginectomy\", section on 'Vaginal reconstruction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Posterior exenteration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posterior exenterations are rarely performed, except for primary stage IVA cancers of the cervix invading the rectum. Before planning a posterior exenteration, radiotherapy must be seriously considered. For women who have had recurrence following radiotherapy, a total exenteration with low rectal anastomosis should be the first option.",
"   </p>",
"   <p>",
"    When a cervical cancer recurs after radiotherapy, even if it is confined to the posterior vagina and rectum, one should remove the distal ureters, bladder, and urethra in order to avoid the very significant morbidity and mortality of a urinary tract fistula. The technique of posterior exenteration differs from those described above in that the bladder, anterior vagina, and ureters are preserved. After posterior exenteration, patients have significant bladder dysfunction resulting from the extensive removal of the hypogastric plexus that enervates the bladder. There is a high likelihood of requiring long-term catheter drainage or self-catheterization.",
"   </p>",
"   <p>",
"    The posterior exenteration differs from the low anterior resection of the rectosigmoid performed by general surgeons because the uterus or cardinal ligaments are not removed, and thus the ureters and bladder are not disturbed. It is the radical en bloc excision of the uterus, cardinal ligaments, rectum, and rectal pillars that removes the hypogastric plexus and severely injures bladder function.",
"   </p>",
"   <p>",
"    After dividing the round ligaments and developing the perivesical and perirectal spaces, the peritoneum between bladder and uterus is incised and the bladder reflected as inferiorly as possible with sharp dissection. The ureters are then mobilized and dissected free of their soft tissue attachments, similar to the technique for radical hysterectomy. The uterine arteries are divided at their origin and reflected medially, trying to preserve the other branches of the internal iliac arteries. The cardinal ligaments are then divided laterally, the ureteral dissection completed to the bladder, and the anterior vagina entered. The rectosigmoid is freed posteriorly, the parametrium mobilized medially, and the dissection carried down to the levator muscles, identical to the posterior dissection in a total exenteration. The perineal incision will involve only the posterior aspect of the vulva and anus. An omental flap and small pack can be used to complete management of the defect, and colostomy performed (",
"    <a class=\"graphic graphic_figure graphicRef55699 \" href=\"mobipreview.htm?5/49/5911\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    \"Modified\" posterior exenteration, which does not go below the levator muscles, may be used to complete optimal resection of an ovarian cancer. There is no perineal phase in this operation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Urinary diversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard urinary diversion for several decades was the urinary conduit using a segment of ileum to which the ureters would be anastomosed and a stoma created in the right lower abdomen (",
"    <a class=\"graphic graphic_figure graphicRef65127 \" href=\"mobipreview.htm?28/45/29396\">",
"     figure 5",
"    </a>",
"    ). Currently, the preferred method of urinary diversion is a continent pouch, created from the distal ileum, ascending colon, and a portion of the transverse colon (",
"    <a class=\"graphic graphic_figure graphicRef72883 \" href=\"mobipreview.htm?30/7/30839\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/1,10,34\">",
"     1,10,34",
"    </a>",
"    ]. The ileum is divided 10 to 12 cm proximal to the ileocecal valve, and the transverse colon just distal to the middle colic artery (ie, Miami pouch). An ileotransverse colon enteroenterostomy is performed to restore continuity to the gastrointestinal tract. The isolated segment of bowel is opened with cautery along the tenia. The bowel is then folded on itself in a U shape and the edges closed with staples. This division and closure of the bowel prevents subsequent peristalsis and generation of intermittent high pressures, which would overcome the continence mechanism.",
"   </p>",
"   <p>",
"    The ureters are brought through stab wounds into the bowel reservoir, and the spatulated ends anastomosed mucosa to mucosa. The left ureter is brought through the sigmoid mesentery to reach the reservoir. A 14 French catheter is placed into the ileum, and passed through into the reservoir. Excess ileum is excised from the antimesenteric edge with a stapling device, and three pursestring sutures placed at the ileocecal valve to tighten the ileum. The tapered end of the ileum is brought out as a stoma. The ureters are stented and, with a Malecot catheter, are brought out through the anterior wall of the reservoir and through a separate opening in the abdominal wall. Stents and catheter are removed two weeks postoperatively. The low pressure reservoir can be catheterized as needed.",
"   </p>",
"   <p>",
"    Results have been very encouraging, with most women maintaining continence, and catheterizing their stoma every several hours. The rate of postoperative complications (stricture, stones, fistulae, leakage, urinary infection, difficulty with self-catheterization) can be relatively high (&gt;50 percent), especially in irradiated patients, but most complications have been treated successfully and without reoperation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. The best method of bladder reconstruction has not been determined in controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients, particularly those with intercurrent renal or cardiac disease, will need to be followed in a surgical intensive care unit, with Swan-Ganz catheter monitoring to facilitate administration of blood products, colloid, and crystalloid. This is particularly important in women with a large pelvic defect that will weep serum in large amounts comparable to a burn patient. Concealed hemorrhage and inadequate fluid replacement are constant considerations. It is advisable to keep the hematocrit stable (a level of 30 percent allows a reserve should bleeding occur) and, to keep the prothrombin and partial thromboplastin time values normal with fresh frozen plasma and vitamin K, as needed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/49/793?source=see_link\">",
"     \"Use of blood products in the critically ill\"",
"    </a>",
"    .) Measurement of serum protein levels may help appreciate the magnitude of loss. Frequent blood counts and electrolyte measurements are needed, until the patient is believed to be stable, euvolemic, and has normal clotting parameters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     General care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients can be ambulated or at least out of bed within 48 hours. Adequate pain control must be maintained. Physical therapists are most useful in ensuring good range of motion and gradual increases in physical activity levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Respiratory care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt extubation is preferred, with serial measurements of oxygen saturation used to ensure adequate pulmonary function. A postoperative chest film is needed to ensure that both lungs are expanded, and to exclude pneumothorax from central line insertion. Since delayed pneumothorax can occur, a repeat film at 24 hours is useful. Vigorous respiratory toilet, including use of incentive spirometry and patient positioning, is an integral part of postoperative care. If acute respiratory distress occurs, pulmonary embolus, myocardial infarction, or congestive heart failure should be considered. The intermittent pneumatic compression devices, begun in the operating suite, are continued until discharge, and are removed only when the patient is ambulating.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few hard data on which to base decisions concerning antibiotic usage after exenterative surgery. The source of postoperative fever should be identified, if possible, and appropriate antibiotics initiated; otherwise, antibiotics are begun empirically. Most postoperative febrile episodes remain unexplained and respond to broad spectrum antibiotic therapy. Before assuming that there is no identifiable source, the presence of ureteral obstruction, leaking anastomosis, or pelvic defect abscess should be excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronically malnourished patients can be started on nutritional support in advance of their exenterative surgery. Postoperatively, it is not unusual for patients to go 14 days or longer without adequate oral intake, as ileus is common. There are no data on rapid resumption of oral feeding: we initiate early oral feeding in stable, alert patients. TPN may be started immediately after surgery and continued until the clinician feels the integrity of the bowel is confirmed and oral intake is adequate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Drains",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of drains is unclear. Personal bias and past experience will determine whether closed system, suction drains are placed and when they should be removed. We do not favor use of drains. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10633?source=see_link&amp;anchor=H27#H27\">",
"     \"Principles of abdominal wall closure\", section on 'Drains'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Packs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have a pelvic pack are usually kept at bedrest until it is removed, but the upper body can be elevated to improve respiratory toilet. If a pelvic pack was placed, the pursestring suture is cut after 48 to 72 hours, and one-half of the laparotomy pads removed. The remainder of the pack is removed 24 hours later, and twice daily irrigations begun of the pelvic defect. Warmed saline and peroxide, lactated Ringer's, or similar solutions may be used. Care is taken to ensure that fluid does not collect in the curve of the sacrum. It is usually sufficient to have the woman stand after each irrigation. The entire pelvic defect will slowly granulate in and close over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Bowel and ostomy issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The continent reservoir is irrigated several times a day to remove mucus and clots. The mucus gradually disappears, but irrigations are necessary for up to six weeks. Self-catheterization is taught before discharge, with additional instruction provided by home health care nurses.",
"   </p>",
"   <p>",
"    For women with a low rectal anastomosis, initial stooling will be frequent, since rectal storage capacity is limited. Lomotil and Imodium can be used to decrease peristalsis. The goal is to have the woman pass stools three to six times a day. Gradually, the woman's lower rectum accommodates, and after four to six months, a more normal stooling pattern is usually achieved and antiperistaltic drugs may be discontinued. When anastomoses are less than 6 cm, accommodation is more difficult and incontinence and frequent stooling are more of a problem.",
"   </p>",
"   <p>",
"    Frequent opportunities to speak with other women who have successfully undergone exenteration help keep the woman's spirits high and attitude positive. Stomal therapists and home health care nurses are also important in aiding the patient in the immediate postoperative period and after discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as 50 percent of women suffer a major complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/1,2,14,39-43\">",
"     1,2,14,39-43",
"    </a>",
"    ]. In one review, the most common complications related to the procedure were wound",
"    <span class=\"nowrap\">",
"     disruption/infection",
"    </span>",
"    (39 percent), gastrointestinal fistula (10 percent), genitourinary fistula (8 percent), and",
"    <span class=\"nowrap\">",
"     ileus/small",
"    </span>",
"    bowel obstruction (11 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/42\">",
"     42",
"    </a>",
"    ]. In a large series, complications included infectious morbidity (86 percent), intestinal obstruction (33 percent), and fistulas (23 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/1\">",
"     1",
"    </a>",
"    ]. Death in the perioperative period occurs in fewer than 5 percent of patients, with women over the age of 65 at highest risk. Sepsis, adult respiratory distress syndrome, heart failure, pulmonary embolus, and multiorgan system failure are typical terminal events.",
"   </p>",
"   <p>",
"    Complications relating to prior medical problems and those seen with more commonly performed gynecologic procedures are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/3/24631?source=see_link\">",
"     \"Complications of gynecologic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Intraoperative",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative complications are predominantly related to hemorrhage and problems associated with pelvic reconstruction. Blood loss of 6 units or more is not unusual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/40,41,44\">",
"     40,41,44",
"    </a>",
"    ] and delayed hemorrhage may occur in women with an infected pelvic defect. Delayed hemorrhage is best managed with percutaneous embolization via interventional radiology, as reexploration is extremely morbid. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/18/43305?source=see_link\">",
"     \"Management of hemorrhage in gynecologic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During bowel anastomoses, segments of bowel may turn out to be too short, or ureteral anastomoses may tear. Patience and diligent attention to technique will minimize these occurrences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal complications requiring surgical reexploration are usually attributable to problems with healing of the anastomosis in previously irradiated bowel. Bowel obstruction is managed conservatively, with decompression and fluid replacement. Similarly, fistulas that may be enterocutaneous or through the perineal defect are given a chance to heal, maintaining the patient NPO and continuing TPN. Low output fistulas, in the absence of distal obstruction, occasionally heal. Usually reexploration and surgical correction, with high patient morbidity and mortality, is required. In anterior exenterations, difficult extended dissections to preserve the rectum frequently lead to fistula. In these situations, a total exenteration or low rectal anastomosis may be preferable.",
"   </p>",
"   <p>",
"    Use of colon conduits or reservoirs, thereby avoiding anastomosis in radiated bowel, lessens problems with anastomotic leaks. When leaks are encountered, management with percutaneous stenting and drainage is preferable to reoperation with attempts at reconstruction (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78777 graphicRef58479 \" href=\"mobipreview.htm?37/36/38465\">",
"     image 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/45\">",
"     45",
"    </a>",
"    ]. Percutaneous catheters can also be used to dilate areas of ureteral stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25051010\">",
"    <span class=\"h2\">",
"     Body image and sexual function",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study of 16 women found that sexual function and body image declined during the first three postoperative months and then returned to baseline by 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/46\">",
"     46",
"    </a>",
"    ]. Following pelvic exenteration, patient interest in sexual function and body image is variable. Some women have no interest in sexual activity and others wish to undergo neo-vagina reconstruction with postoperative repeat dilation. The issue is made more complex by the impact of stoma(s) on body image and the occurrence of postoperative complications, which can be slow to resolve. Counseling of the patient regarding postoperative changes in anatomy and body function, and involvement of the patient's sexual partner are important parts of exenterative surgery care. Referral to a gynecologist or other physician or a psychotherapist with expertise in sexual health is often appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Delayed",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed complications include bowel obstruction, bowel or urinary fistula, ureteral obstruction with renal compromise, and stomal stenosis. Recurrent cancer must always be considered. Attempts at conservative management, without surgical exploration, are always wise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival and presumptive cure is possible in approximately one-half of women undergoing exenteration as salvage therapy for pelvic cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31689/abstract/1,47-50\">",
"     1,47-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exenteration refers to an ultraradical surgical procedure in which the female reproductive organs are removed along with en bloc resection of the lower urinary tract and a portion of the rectosigmoid. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It may be offered to women with recurrent or advanced gynecologic cancer with extensive central pelvic disease that cannot be resected with a lesser procedure, and in whom radiation is not an option. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The woman must be counseled thoroughly about the risks and longterm issues related to the procedure. She should undergo a comprehensive evaluation to make sure there is no evidence of unresectable or metastatic disease, thus, making the woman an unsuitable candidate for exenteration. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As many as 50 percent of women suffer a major complication. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Survival is possible in approximately one-half of women undergoing exenteration as salvage therapy for pelvic cancers. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/1\">",
"      Berek JS, Howe C, Lagasse LD, Hacker NF. Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Gynecol Oncol 2005; 99:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/2\">",
"      Goldberg GL, Sukumvanich P, Einstein MH, et al. Total pelvic exenteration: the Albert Einstein College of Medicine/Montefiore Medical Center Experience (1987 to 2003). Gynecol Oncol 2006; 101:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/3\">",
"      BRUNSCHWIG A. Complete excision of pelvic viscera for advanced carcinoma; a one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy. Cancer 1948; 1:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/4\">",
"      Bricker EM. The evolution of the ileal segment bladder substitution operation. Am J Surg 1978; 135:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/5\">",
"      BRICKER EM. Bladder substitution after pelvic evisceration. Surg Clin North Am 1950; 30:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/6\">",
"      Orr JW Jr, Shingleton HM, Hatch KD, et al. Urinary diversion in patients undergoing pelvic exenteration. Am J Obstet Gynecol 1982; 142:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/7\">",
"      Hancock KC, Copeland LJ, Gershenson DM, et al. Urinary conduits in gynecologic oncology. Obstet Gynecol 1986; 67:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/8\">",
"      Kock NG, Nilson AE, Nilsson LO, et al. Urinary diversion via a continent ileal reservoir: clinical results in 12 patients. J Urol 1982; 128:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/9\">",
"      Montie JE, MacGregor PS, Fazio VW, Lavery I. Continent ileal urinary reservoir (Kock pouch). Urol Clin North Am 1986; 13:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/10\">",
"      Penalver MA, Bejany DE, Averette HE, et al. Continent urinary diversion in gynecologic oncology. Gynecol Oncol 1989; 34:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/11\">",
"      Mannel RS, Braly PS, Buller RE. Indiana pouch continent urinary reservoir in patients with previous pelvic irradiation. Obstet Gynecol 1990; 75:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/12\">",
"      Hatch KD, Gelder MS, Soong SJ, et al. Pelvic exenteration with low rectal anastomosis: survival, complications, and prognostic factors. Gynecol Oncol 1990; 38:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/13\">",
"      BARBER HR, BRUNSCHWIG A. PELVIC EXENTERATION FOR EXTENSIVE VISCERAL NECROSIS FOLLOWING RADIATION THERAPY FOR GYNECOLOGIC CANCER. Obstet Gynecol 1965; 25:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/14\">",
"      H&ouml;ckel M, Dornh&ouml;fer N. Pelvic exenteration for gynaecological tumours: achievements and unanswered questions. Lancet Oncol 2006; 7:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/15\">",
"      Phillips B, Buchsbaum HJ, Lifshitz S. Pelvic exenteration for vulvovaginal carcinoma. Am J Obstet Gynecol 1981; 141:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/16\">",
"      Boronow RC, Hickman BT, Reagan MT, et al. Combined therapy as an alternative to exenteration for locally advanced vulvovaginal cancer. II. Results, complications, and dosimetric and surgical considerations. Am J Clin Oncol 1987; 10:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/17\">",
"      Rotmensch J, Rubin SJ, Sutton HG, et al. Preoperative radiotherapy followed by radical vulvectomy with inguinal lymphadenectomy for advanced vulvar carcinomas. Gynecol Oncol 1990; 36:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/18\">",
"      Morris M, Alvarez RD, Kinney WK, Wilson TO. Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Gynecol Oncol 1996; 60:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/19\">",
"      Barakat RR, Goldman NA, Patel DA, et al. Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol 1999; 75:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/20\">",
"      Eisenkop SM, Nalick RH, Teng NN. Modified posterior exenteration for ovarian cancer. Obstet Gynecol 1991; 78:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/21\">",
"      Stanhope CR, Symmonds RE. Palliative exenteration--what, when, and why? Am J Obstet Gynecol 1985; 152:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/22\">",
"      Husain A, Akhurst T, Larson S, et al. A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration. Gynecol Oncol 2007; 106:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/23\">",
"      Belhocine T, Thille A, Fridman V, et al. Contribution of whole-body 18FDG PET imaging in the management of cervical cancer. Gynecol Oncol 2002; 87:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/24\">",
"      Lai CH, Huang KG, See LC, et al. Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-D-glucose positron emission tomography. Cancer 2004; 100:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/25\">",
"      K&ouml;hler C, Tozzi R, Possover M, Schneider A. Explorative laparoscopy prior to exenterative surgery. Gynecol Oncol 2002; 86:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/26\">",
"      Plante M, Roy M. Operative laparoscopy prior to a pelvic exenteration in patients with recurrent cervical cancer. Gynecol Oncol 1998; 69:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/27\">",
"      Schneider A, K&ouml;hler C, Erdemoglu E. Current developments for pelvic exenteration in gynecologic oncology. Curr Opin Obstet Gynecol 2009; 21:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/28\">",
"      Mart&iacute;nez A, Filleron T, Vitse L, et al. Laparoscopic pelvic exenteration for gynaecological malignancy: is there any advantage? Gynecol Oncol 2011; 120:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/29\">",
"      Davis MA, Adams S, Eun D, et al. Robotic-assisted laparoscopic exenteration in recurrent cervical cancer Robotics improved the surgical experience for 2 women with recurrent cervical cancer. Am J Obstet Gynecol 2010; 202:663.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/30\">",
"      Lim PC. Robotic assisted total pelvic exenteration: a case report. Gynecol Oncol 2009; 115:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/31\">",
"      BRUNSCHWIG A, BARBER HR. EXTENDED PELVIC EXENTERATION FOR ADVANCED CANCER OF THE CERVIX. LONG SURVIVALS FOLLOWING ADDED RESECTION OF INVOLVED SMALL BOWEL. Cancer 1964; 17:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/32\">",
"      Stelzer KJ, Koh WJ, Greer BE, et al. The use of intraoperative radiation therapy in radical salvage for recurrent cervical cancer: outcome and toxicity. Am J Obstet Gynecol 1995; 172:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/33\">",
"      Moutardier V, Houvenaeghel G, Lelong B, et al. Colorectal function preservation in posterior and total supralevator exenteration for gynecologic malignancies: an 89-patient series. Gynecol Oncol 2003; 89:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/34\">",
"      Houvenaeghel G, Moutardier V, Karsenty G, et al. Major complications of urinary diversion after pelvic exenteration for gynecologic malignancies: a 23-year mono-institutional experience in 124 patients. Gynecol Oncol 2004; 92:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/35\">",
"      Ramirez PT, Modesitt SC, Morris M, et al. Functional outcomes and complications of continent urinary diversions in patients with gynecologic malignancies. Gynecol Oncol 2002; 85:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/36\">",
"      Karsenty G, Moutardier V, Lelong B, et al. Long-term follow-up of continent urinary diversion after pelvic exenteration for gynecologic malignancies. Gynecol Oncol 2005; 97:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/37\">",
"      Salom EM, Mendez LE, Schey D, et al. Continent ileocolonic urinary reservoir (Miami pouch): the University of Miami experience over 15 years. Am J Obstet Gynecol 2004; 190:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/38\">",
"      Yong SM, Dublin N, Pickard R, et al. Urinary diversion and bladder reconstruction/replacement using intestinal segments for intractable incontinence or following cystectomy. Cochrane Database Syst Rev 2003; :CD003306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/39\">",
"      Rutledge FN, Smith JP, Wharton JT, O'Quinn AG. Pelvic exenteration: analysis of 296 patients. Am J Obstet Gynecol 1977; 129:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/40\">",
"      Soper JT, Berchuck A, Creasman WT, Clarke-Pearson DL. Pelvic exenteration: factors associated with major surgical morbidity. Gynecol Oncol 1989; 35:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/41\">",
"      Morley GW, Hopkins MP, Lindenauer SM, Roberts JA. Pelvic exenteration, University of Michigan: 100 patients at 5 years. Obstet Gynecol 1989; 74:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/42\">",
"      Salom EM, Penalver MA. Pelvic exenteration and reconstruction. Cancer J 2003; 9:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/43\">",
"      Ungar L, Palfalvi L, Novak Z. Primary pelvic exenteration in cervical cancer patients. Gynecol Oncol 2008; 111:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/44\">",
"      Orr JW Jr, Shingleton HM, Hatch KD, et al. Gastrointestinal complications associated with pelvic exenteration. Am J Obstet Gynecol 1983; 145:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/45\">",
"      Bladou F, Houvenaeghel G, Delp&eacute;ro JR, Gu&eacute;rinel G. Incidence and management of major urinary complications after pelvic exenteration for gynecological malignancies. J Surg Oncol 1995; 58:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/46\">",
"      Rezk YA, Hurley KE, Carter J, et al. A prospective study of quality of life in patients undergoing pelvic exenteration: interim results. Gynecol Oncol 2013; 128:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/47\">",
"      Shepherd JH, Ngan HY, Neven P, et al. Multivariate analysis of factors affecting survival in pelvic exenteration. Int J Gynecol Cancer 1994; 4:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/48\">",
"      Numa F, Ogata H, Suminami Y, et al. Pelvic exenteration for the treatment of gynecological malignancies. Arch Gynecol Obstet 1997; 259:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/49\">",
"      Shingleton HM, Soong SJ, Gelder MS, et al. Clinical and histopathologic factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix. Obstet Gynecol 1989; 73:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31689/abstract/50\">",
"      Park JY, Choi HJ, Jeong SY, et al. The role of pelvic exenteration and reconstruction for treatment of advanced or recurrent gynecologic malignancies: Analysis of risk factors predicting recurrence and survival. J Surg Oncol 2007; 96:560.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3190 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-77399545CD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_60_31689=[""].join("\n");
var outline_f30_60_31689=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Vulvar cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ovarian and endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Palliation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Psychological issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Medical evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Laboratory and imaging tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Cystoscopy and sigmoidoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PREOPERATIVE PATIENT PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OPERATIVE TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Intraoperative biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Anterior exenteration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Total exenteration with perineal phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Supralevator total exenteration with low rectal anastomosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Neovagina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Posterior exenteration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Urinary diversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      General care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Respiratory care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Drains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Packs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Bowel and ostomy issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Intraoperative",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25051010\">",
"      Body image and sexual function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Delayed",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3190\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3190|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?7/34/7726\" title=\"algorithm 1\">",
"      Outcome recurrent cervical CA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3190|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?21/61/22495\" title=\"diagnostic image 1A\">",
"      Conduit leak A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?30/12/30926\" title=\"diagnostic image 1B\">",
"      Conduit leak B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3190|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/62/35814\" title=\"figure 1\">",
"      Scope of pelvic exenteration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/63/20471\" title=\"figure 2\">",
"      Rectal anastomosis exenteration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/35/10803\" title=\"figure 3\">",
"      Omental flap for rectal anast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/49/5911\" title=\"figure 4\">",
"      Creating an omental flap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/45/29396\" title=\"figure 5\">",
"      Construction of ileal conduit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/7/30839\" title=\"figure 6\">",
"      Continent colon pouch",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3190|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/10/44192\" title=\"picture 1\">",
"      Patient position for exenteration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/47/16114\" title=\"picture 2A\">",
"      Pneumatic compression boots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/60/1984\" title=\"picture 2B\">",
"      Pneumatic compression boots 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/44/6848\" title=\"picture 3\">",
"      Anterior exenteration specimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/6/40032\" title=\"picture 4\">",
"      Total pelvic exenteration",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/3/24631?source=related_link\">",
"      Complications of gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/18/43305?source=related_link\">",
"      Management of hemorrhage in gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33368?source=related_link\">",
"      Management of recurrent or metastatic cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/55/39800?source=related_link\">",
"      Overview of preoperative evaluation and preparation for gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10633?source=related_link\">",
"      Principles of abdominal wall closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/49/793?source=related_link\">",
"      Use of blood products in the critically ill",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6885?source=related_link\">",
"      Vaginectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9303?source=related_link\">",
"      Vulvar cancer: Clinical manifestations, diagnosis, and pathology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_60_31690="Hepatitis B virus vaccination";
var content_f30_60_31690=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hepatitis B virus vaccination",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/60/31690/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/60/31690/contributors\">",
"     Eng-Kiong Teo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/60/31690/contributors\">",
"     Anna SF Lok, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/60/31690/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/60/31690/contributors\">",
"     Rafael Esteban, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/60/31690/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/60/31690/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/60/31690/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are more than 2 billion individuals with serological evidence of hepatitis B infection worldwide. Of these, 400 million are chronic carriers and 500,000 to 1.2 million will die annually from cirrhosis and hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Despite advances in antiviral therapy, only a minority of patients with chronic hepatitis B will have a sustained response. Thus, primary prevention by vaccination to increase herd immunity remains the main thrust in the control of hepatitis B virus (HBV) infection.",
"   </p>",
"   <p>",
"    Currently available hepatitis B vaccines are extremely safe and have an efficacy of &gt;90 percent and are effective against all HBV serotypes and genotypes. Thus, HBV infection can potentially be eradicated through global vaccination.",
"   </p>",
"   <p>",
"    In its effort to eradicate chronic hepatitis B infection, the World Health Organization (WHO) advocates HBV vaccination. The vaccination coverage is currently measured only after the completion of the third dose of vaccine (HepB3). Globally, the HepB3 rate has increased from 3 percent in 1992 to 75 percent in 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/3\">",
"     3",
"    </a>",
"    ]. In the United States, the vaccine coverage among adults is low, decreasing from 58 percent for those between 18 and 20 years old to 26 percent for those between 41 and 49 years old [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite this suboptimal vaccine coverage, the incidence of acute hepatitis B has decreased by 75 percent (from",
"    <span class=\"nowrap\">",
"     8.5/100,000",
"    </span>",
"    in 1990 to",
"    <span class=\"nowrap\">",
"     2.5/100,000",
"    </span>",
"    in 2004). The biggest decline in incidence was seen in children and adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/5\">",
"     5",
"    </a>",
"    ]. Even in countries that actively advocate universal vaccination, coverage is less than 100 percent. As an example, the vaccine coverage in Taiwan as of 2004 was &gt;90 percent for children younger than 14 years of age but only between 87 to 90 percent among teenagers between 15 and 17 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vaccine coverage is not uniform globally. Coverage in the Eastern Mediterranean, Western Pacific, and America exceed 80 percent, while the HepB3 coverage rate for Europe and Africa is 75 percent. Unfortunately, in areas of high prevalence like South-East Asia, the coverage remains low at approximately 50 percent.",
"   </p>",
"   <p>",
"    While vaccination represents the cornerstone of public health measures to eradicate HBV, 5 to 10 percent of individuals do not respond to currently available vaccines. Thus, other public health measures, including health education and infection control measures, remain important. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4602?source=see_link\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    is considered to be one of the major achievements of modern medicine. Three different classes of hepatitis B vaccine are available based upon how they are derived (from plasma, yeast, or mammalian cells).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first generation HepB vaccine was prepared by concentrating and purifying plasma from HBsAg carriers to produce 22 nm subviral particles, which contain HBsAg alone. Derivation from plasma has left lingering concerns regarding the potential to transmit blood-borne infections, although this vaccine has excellent efficacy and safety [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/7\">",
"       7",
"      </a>",
"      ]. As a result, the plasma-derived vaccine is no longer used in most developed countries. The cost of both the plasma-derived and recombinant HBV vaccine had decreased due to expiration of patent protection and competition. The plasma-derived vaccine has been priced as low as $0.24 per dose for bulk purchase and recombinant vaccine at $0.54 possibly decreasing to $0.30 to $0.40 per dose in the near future. Because the difference in cost is marginal, many countries have switched to the recombinant vaccine. With the decrease in price of vaccine, organizations like the United Nations Children's Fund (UNICEF), the Pan American Health Organization (PAHO), and the Global Alliance for Vaccines and Immunization (GAVI) will be able to assist an increasing number of countries in implementing universal HBV vaccination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Yeast-derived recombinant HepB vaccines were first introduced in the mid 1980s. They are produced by cloning of the HBV S gene in yeast cells. These vaccines contain non-glycosylated HBV small S protein as the envelope antigen which must be released from the yeast during the manufacturing process [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/9\">",
"       9",
"      </a>",
"      ]. These vaccines do not contain antigens of the pre-S regions.",
"      <br/>",
"      <br/>",
"      A concern related to the original versions of the recombinant vaccines is that they contained thimerosal (an organic mercurial) as a preservative. There has been no evidence of harm caused by the level of exposure that children may encounter during existing immunization schedules. Nevertheless, the potential risk of abnormal neurodevelopment prompted a joint statement from the American Academy of Pediatrics and the United States Public Health Service calling for the removal of thimerosal-containing vaccines as soon as possible, and for expeditious replacement with preservative-free vaccine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. However, the joint statement issued interim recommendations highlighting that the risk of not vaccinating children far outweighs the unknown and probably small risk (if any) of cumulative exposure to thimerosal. Two yeast-derived recombinant thimerosal-free vaccines have been developed (Recombivax HB and Engerix-B) and are widely available [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The third class of HepB vaccine is the mammalian cell-derived recombinant vaccine. Three vaccines of this class have been developed. In addition to the S antigen, one of these contain antigen from the pre-S2 region while the other two contain antigens from both the pre-S1 and pre-S2 regions. A controlled trial suggested that this class of vaccine was associated with an enhanced immunologic response compared to Engerix-B in a three-dose regimen and was equally effective in a two-dose regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/13\">",
"       13",
"      </a>",
"      ]. Although vaccines with pre-S antigens may be more immunogenic, they are not widely available.",
"      <br/>",
"      <br/>",
"      A combination vaccine (Twinrix&reg;, GlaxoSmithKline), including Engerix-B and HAVRIX (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/30/44518?source=see_link\">",
"       hepatitis A vaccine",
"      </a>",
"      ), is also available [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/14-16\">",
"       14-16",
"      </a>",
"      ]. It has been approved for use in adults in the United States and Europe, and in children in some countries. Approval was based upon data from 1,551 study participants from 11 clinical trials who received Twinrix&reg; on a 0, 1, and 6-month schedule. An immune response against hepatitis A and B was observed in 99.9 and 98.5 percent of vaccinees, respectively. An accelerated dosing schedule (with doses given at 0, 7, and 21 to 30 days, and a booster at 12 months) has also been approved. Its main potential advantage is convenience and improved compliance for those who require vaccination against both hepatitis viruses.",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"       Hepatitis B vaccine",
"      </a>",
"      is also available as multivalent vaccines in combination with diphtheria, tetanus, pertussis, and Haemophilus influenzae type B [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/17\">",
"       17",
"      </a>",
"      ]. The immunogenicity of these multivalent vaccines is similar to that of the univalent vaccines. The multivalent vaccines are widely used in childhood immunization programs and have greatly facilitated compliance and reduced the cost of delivery.",
"     </li>",
"     <li>",
"      A candidate vaccine has been developed with a novel approach to its administration. It consists of the surface and core antigen of the hepatitis B virus administered as a nasal spray of 125 microliters per nostril at a five-dose schedule of 0, 7, 15, 30, and 60 days. A phase 1 trial reported anti-HBc seroconversion of 100 percent and development of anti-HBs antibodies in 75 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/18\">",
"       18",
"      </a>",
"      ]. Further studies are needed to determine the safety and efficacy of this vaccine. Another development (based upon nanotechnology) to deliver the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      via the mucosal route yielded promising preclinical results [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/19\">",
"       19",
"      </a>",
"      ]. If the results of these initial trials are confirmed, these novel modes of vaccine administration may potentially increase vaccine use in countries where parenteral administration or facilities to maintain the cold chain are not readily available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     Hepatitis B vaccine",
"    </a>",
"    is recommended for all neonates of HBsAg positive mothers, and in many countries is also recommended for neonates of HBsAg negative mothers.",
"   </p>",
"   <p>",
"    Recommendations for screening the adult population have been issued by three major organizations in the United States: the United States Preventive Services Task Force (USPSTF), the Center for Disease Control and Prevention (CDC), and the American Association for the Study of Liver Disease (AASLD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. The USPSTF provides a strong recommendation for screening women during their first prenatal visit.",
"   </p>",
"   <p>",
"    The AASLD supports CDC's recommendation regarding screening of high risk groups and vaccinating those who are not already immune or infected. This includes (in addition to pregnant women) persons born in high or intermediate endemic areas (countries with HBV prevalence rate &gt;2 percent), United States-born persons not vaccinated as infants whose parents were born in regions with high HBV endemicity, persons with chronically elevated aminotransferases, persons needing immunosuppressive therapy, men who have sex with men, persons with multiple sexual partners or history of sexually transmitted disease, inmates of correctional facilities, persons who have ever used injecting drugs, patients on dialysis, HIV or HCV-infected patients, and family members, household members, and sexual contacts of HBV-infected persons. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the management of hepatitis B and case examples\", section on 'Who should be tested'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neonates of HBsAg positive mothers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccination of neonates of HBsAg positive mothers is the most important step toward the eradication of chronic HBV infection. Vaccination of newborns of carrier mothers is extremely cost-effective with an estimated cost per year of life saved of $164 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/23\">",
"     23",
"    </a>",
"    ]. The standard regimen consists of passive and active immunization.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     Hepatitis B vaccine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28437?source=see_link\">",
"     hepatitis B immune globulin",
"    </a>",
"    (HBIG) are given at the same time at two different sites within 12 hours of delivery. The neonates then proceed to two additional doses at months 1 to 2 and months 6 to 12. This regimen has a protective efficacy of 95 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in Taiwan and Hong Kong found that the protective efficacy of vaccine alone was significantly lower (only 75 to 80 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. One study from Thailand found that three doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    without co-administration of HBIG achieved equivalent protective rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/28\">",
"     28",
"    </a>",
"    ]. A similar study was conducted later in the same country to investigate the efficacy of administering the vaccine alone without HBIG to neonates of mothers who were positive for HBeAg. The efficacy of this regimen was between 82 and 87 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data indicate that vaccination alone is insufficient to prevent transmission of HBV infection from HBeAg positive mothers to their infants and vaccination alone should only be considered in countries that cannot afford the cost of HBIG. A statement by the USPSTF noted that the current practice of vaccinating all infants against HBV infection and post exposure prophylaxis with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28437?source=see_link\">",
"     hepatitis B immune globulin",
"    </a>",
"    administered at birth to all HBV infected mothers substantially reduces the risk for acquiring HBV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     All neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Universal vaccination of all newborns regardless of maternal HBsAg status is necessary for global eradication of HBV infection. Experience in the United States demonstrated that vaccination programs targeted at high-risk groups had very little impact on the incidence of HBV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/30\">",
"     30",
"    </a>",
"    ]. Other than healthcare workers, the recognition and recruitment of high-risk individuals have been unrewarding. The Centers for Disease Control and Prevention (CDC) estimated that only 7 percent of high-risk individuals were vaccinated by 1988. In addition, a high proportion of chronic infection acquired during childhood occurred among children born to mothers who are NOT infected with hepatitis B virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1991, the Global Advisory Group of the Expanded Program on Immunization recommended integration of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    into national immunization programs, setting 1995 as a target date for countries with a HBV carrier prevalence of 8 percent or higher, and 1997 as the target date for all other countries. WHO endorsed the recommendation in May 1992, and the World Health Assembly added a disease reduction target for hepatitis B in 1994, calling for an 80 percent decrease in new HBV carrier children by 2001. As of September 2011, 193 countries have introduced hepatitis B vaccine into their national immunization program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/32\">",
"     32",
"    </a>",
"    ]. Countries that have adopted this recommendation have experienced a marked reduction in carrier rates as well as complications from HBV including hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. This has been most evident in regions with a high prevalence of chronic HBV. The reduction in carrier rates ranged from 16 percent before implementation of the program to 0 percent after implementation in Alaska, 7 percent to 0.5 percent in Samoa, and 12 percent to 3 percent in Micronesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/36\">",
"     36",
"    </a>",
"    ]. Universal vaccination of all newborns was recommended in the United States in 1991.",
"   </p>",
"   <p>",
"    Countries that implemented universal hepatitis B vaccination programs early have demonstrated its benefits. In Taiwan, vaccination of newborns of carrier mothers was implemented in July 1984 and extended to all neonates in 1986. The coverage for complete vaccination is between 84 to 94 percent. At the start of the program, the HBV carrier rate among children younger than 15 years of age was 9.8 percent and the incidence of childhood hepatocellular carcinoma (HCC) was 1.02 and 0.48 per 100,000 male and female children, respectively. Twenty years into the program, the HBV carrier rate among children of the same age group decreased to 1.2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/6\">",
"     6",
"    </a>",
"    ]. Almost 30 years later, the prevalence of hepatitis B infection continues to be significantly lower than a comparison cohort before the introduction of universal vaccination of newborns, HBsAg (0.9 versus 10 percent), and anti-HBc (7 versus 28 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/37\">",
"     37",
"    </a>",
"    ]. Most vaccine failures were born to HBsAg positive mothers, suggesting improvement will continue as the population prevalence of HBV declines. The incidence of childhood hepatocellular carcinoma has also decreased by 70 percent among vaccinated children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/35\">",
"     35",
"    </a>",
"    ]. The prevalence of anti-HBc among 15 to 20 year olds (born before the implementation of the vaccination program) was 20.6 percent compared to 2.9 percent among children younger than 15 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings demonstrated that universal vaccination can prevent vertical and horizontal transmission of HBV infection as well as the sequelae of chronic HBV infection. In countries with low endemicity, the benefits of universal neonatal vaccination will not be apparent until two to three decades later because infection in these countries usually occurs among adolescents and young adults through percutaneous or sexual routes.",
"   </p>",
"   <p>",
"    The decrease in the carrier rate in endemic countries with an aggressive vaccination program has already translated into a decline in the incidence of hepatocellular carcinoma. In a landmark study from Taiwan, universal vaccination against hepatitis B was associated with a more than 50 percent decline in the incidence of HCC among children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/38\">",
"     38",
"    </a>",
"    ]. An update showed that this benefit is extended to young adults, in whom the risk of HCC was reduced by approximately 70 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Premature infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to HBV vaccination in premature infants are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/63/37881?source=see_link\">",
"     \"Hepatitis viruses and the newborn: Clinical manifestations and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Catch-up vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catch-up vaccination refers to vaccination of children who were born before universal neonatal vaccination was implemented. Most of these children are school-age. Catch-up vaccination permits these children to be immunized before they reach adolescence when they are at risk of infection through sexual exposure and intravenous drug use. The progress of catch-up vaccination in the United States has been fairly successful. Vaccine coverage among adolescents aged 13 to 15 years reached 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/39\">",
"     39",
"    </a>",
"    ]. In the Alaskan immunization program, catch-up vaccine coverage was 62 percent among susceptible persons aged 11 to 30 years old [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/40\">",
"     40",
"    </a>",
"    ]. However, the coverage was more variable among Asian and Pacific Islander children. In cities with a catch-up vaccination program for these high risk children, the coverage was 51 to 67 percent. In cities without such a program, the coverage was 14 to 18 percent. These results suggest a need for continued focused vaccination program for this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/41\">",
"     41",
"    </a>",
"    ]. As of November 2005, a total of 34 states required vaccination for middle school entry as part of the strategy to extend vaccine coverage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other high-risk groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, in most countries, vaccination targeted only at high-risk groups did not have any impact on the incidence of hepatitis B because most individuals participating in at risk activities do not consider themselves to be at risk. Nevertheless, every effort should still be made to vaccinate high-risk individuals.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sexually active individuals with multiple sex partners and homosexual or bisexual males &mdash; Clinics focusing on sexually transmitted diseases can be strategic for advocating hepatitis B vaccination in this group of patients. In the Sentinel Counties Study of Viral Hepatitis in 1996, 42 percent of patients with acute hepatitis B had been treated for STD in the past [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/42\">",
"       42",
"      </a>",
"      ]. Despite this opportunity, a survey in United States found that of 65 federally funded STD programs, only 47 percent of the project managers thought that hepatitis B vaccination was the responsibility of their programs. Twenty-four percent offered",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      in some or all of their clinics and only 27 percent had policies that provided for vaccination of clients less than 19 years old [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/42\">",
"       42",
"      </a>",
"      ]. Steady sexual partners of individuals with chronic HBV infection should be tested and vaccinated against hepatitis B if found to be seronegative.",
"     </li>",
"     <li>",
"      Household contacts of patients with hepatitis B &mdash; Many countries have listed hepatitis B as a notifiable disease. Household contacts, especially sexual contacts of individuals with chronic HBV infection should be tested and those who are seronegative, should be vaccinated.",
"     </li>",
"     <li>",
"      Intravenous drug users &mdash; Despite warning and education on the harmful effects of intravenous drug use, it is unrealistic to expect a change in habit to have any impact in controlling the transmission of hepatitis B in this group. Vaccination is the best method for primary prevention. Strategic locations to actively promote hepatitis B vaccination include detoxification, counseling and correction centers.",
"     </li>",
"     <li>",
"      Healthcare workers &mdash; Vaccination programs of health care workers have met with the most success. Continued education and enforcement of OSHA guidelines is necessary to ensure that this group is adequately protected. In November 2011, CDC published the updated recommendations of the Advisory Committee on Immunization Practices (ACIP). Among the recommendations were [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/43\">",
"       43",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Healthcare practitioners and trainees and certain high-risk populations should undergo prevaccination serologic testing for previous infection, regardless of vaccination status.",
"     </li>",
"     <li>",
"      Trainees should have their vaccination series completed before they have contact with a patient's blood.",
"     </li>",
"     <li>",
"      Post-vaccination testing and documentation should be performed for all healthcare practitioners at high risk for occupational percutaneous or mucosal exposure to blood or body fluids. The results of the tests are to determine the need for revaccination and post-exposure prophylaxis. For healthcare practitioners with low risks for percutaneous or mucosal exposure to body fluids, post-vaccination testing is not cost-effective. However, these individuals must be informed to seek immediate medical attention upon exposure.",
"     </li>",
"     <li>",
"      Healthcare practitioners with an anti-HBs concentration of less than",
"      <span class=\"nowrap\">",
"       10mIU/mL",
"      </span>",
"      should receive another three appropriately scheduled doses of the vaccine with serological testing performed one to two months after the third dose.",
"     </li>",
"     <li>",
"      Individuals with an anti-HBs level less than 10",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      after the second series should be tested for HBsAg and anti-HBc. Those who are not infected and who had not responded to the vaccine are considered susceptible to HBV infection and must be counseled about prevention and transmission of hepatitis B. These individuals, upon known or likely exposure, should receive HBIG.",
"     </li>",
"     <li>",
"      Individuals who are HBsAg positive should be counseled about prevention of transmission of hepatitis B to others. Those who perform exposure-prone procedures must seek counsel from a review committee regarding procedures they can perform safely. Individuals who are anti-HBc positive and HBsAg negative require no vaccination or treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients on chronic hemodialysis and patients requiring repeated blood or blood product transfusion should also be vaccinated.",
"     </li>",
"     <li>",
"      Patients with chronic liver disease &mdash; Vaccination should be administered as early as possible because response rates to HepB vaccine are low in patients with decompensated cirrhosis (around 36 percent) and those who have undergone liver transplantation (around 8 to 11 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8569?source=see_link\">",
"       \"Immunizations for patients with chronic liver disease\"",
"      </a>",
"      .) There are no data on the role of more immunogenic vaccines containing new adjuvants or additional",
"      <span class=\"nowrap\">",
"       pre-S1/pre-S2",
"      </span>",
"      recombinant antigens in these patients.",
"     </li>",
"     <li>",
"      All unvaccinated persons traveling to areas with intermediate to high levels of endemic HBV infection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=see_link&amp;anchor=H12#H12\">",
"       \"Immunizations for travel\", section on 'Hepatitis B vaccine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with diabetes &mdash; The Advisory Committee on Immunization Practices recommends that HBV vaccination be given to unvaccinated adults with diabetes mellitus who are ages 19 to 59 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/46\">",
"       46",
"      </a>",
"      ]. For older patients with diabetes, vaccination can be administered at the discretion of the treating clinician based on the risk of acquiring HBV and the likelihood of an adequate immune response to vaccination. The recommendation was based on outbreaks of HBV in patients who were undergoing assisted blood glucose monitoring, a subsequent analysis of the risk of acquiring HBV among all diabetics in the United States, and a cost-effectiveness analysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Patients with markers of past infection do not need vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have serologic markers of past HBV infection (anti-HBc and anti-HBs positive) do not need HBV vaccination even if they have low titers of anti-HBs. Such patients will be able to mount an appropriate immune response should they be rechallenged with HBV. Persons with isolated anti-HBc (HBsAg and anti-HBs negative) who have risk factors for HBV infection including having grown up in high endemic areas likely had prior exposure and do not require vaccination. However, persons who are positive only for anti-HBc and who are from a low endemic area with no risk factors for HBV should be given the full series of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PREVACCINATION SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of prevaccination screening is to identify individuals who do not require vaccination and thereby reduce unnecessary vaccination. The need for prevaccination screening should be guided by the likelihood that an individual has been exposed to HBV since the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    to individuals who are infected or immune will not result in any adverse outcome. A report based upon commercial retail rate of the hepatitis B vaccine in the United States suggested that preimmunization testing is cost-effective in populations in which the prevalence of infection exceeds 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In non-endemic areas, prevaccination screening is unnecessary since the costs of screening outweigh that of savings on the vaccine. Exceptions are patients in high-risk groups in whom screening should be performed by testing for anti-HBs antibodies. Additional testing for HBsAg among high risk groups is recommended by the CDC to identify those who might already be infected.",
"     </li>",
"     <li>",
"      In endemic areas, prevaccination screening should be performed in adults since the prevalence of past and current infection may exceed 50 percent. A cost-effectiveness analysis that considered screening and vaccinating Asian and Pacific islanders (groups where HBV is endemic) found that a screen-and-treat strategy had an incremental cost-effectiveness ratio of $36,088 per quality adjusted life-years gained (ie, highly cost-effective) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/48\">",
"       48",
"      </a>",
"      ]. The comparison was a universal vaccination strategy (in which all individuals are given a 3-dose vaccination series). Prevaccination screening in these high risk populations is also important in identifying infected persons who may benefit from treatment.",
"      <br/>",
"      <br/>",
"      In these countries, screening can be performed by a single test for anti-HBc alone, which will detect individuals with past or current infection, or by a combination of tests for HBsAg and anti-HBs. While a single test for anti-HBc may be more economical, it does not differentiate carriers from individuals who have recovered from previous infection. In addition, several studies have found that a significant proportion of individuals who test positive for anti-HBc are negative for HBsAg and anti-HBs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/49\">",
"       49",
"      </a>",
"      ]. Early studies using anti-HBc assays that were less specific found that as many as 80 percent of these individuals with isolated anti-HBc developed a primary anti-HBs response to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      , suggesting that the anti-HBc test result was false positive. Thus, in endemic areas, the combination of HBsAg and anti-HBs testing is preferred. This strategy will also allow the identification of carriers who can be followed and treated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DOSE REGIMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two yeast-derived recombinant hepatitis B vaccines have been licensed in the United States: Engerix-B and Recombivax HB. Engerix-B is formulated to contain 20 mcg",
"    <span class=\"nowrap\">",
"     HBsAg/mL",
"    </span>",
"    while Recombivax HB contains 10 mcg",
"    <span class=\"nowrap\">",
"     HBsAg/mL.",
"    </span>",
"    The vaccine schedules are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/44/41670?source=see_link\">",
"     \"Approach to immunizations in healthy adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=see_link&amp;anchor=H10#H10\">",
"     \"Standard immunizations for children and adolescents\", section on 'Hepatitis B vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are three different manufacturers producing mammalian cell-derived vaccines with pre-S epitopes. Gen Hevac B (Pasteur, France) contains 20",
"    <span class=\"nowrap\">",
"     ug/dose",
"    </span>",
"    of vaccine,",
"    <span class=\"nowrap\">",
"     Bio-Hep-B/",
"    </span>",
"    Sci-B-Vac (Bio-Technology General, Israel) contains 2.5 to 10",
"    <span class=\"nowrap\">",
"     ug/dose",
"    </span>",
"    while AG-3 (Hepagene, Hepacare) (Medeva, UK, Evans UK) contains 10 to 20",
"    <span class=\"nowrap\">",
"     ug/dose",
"    </span>",
"    of vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/50\">",
"     50",
"    </a>",
"    ]. In most countries, the regimen for these mammalian cell-derived recombinant vaccines is similar to the yeast-derived ones; three doses at one and six months apart.",
"   </p>",
"   <p>",
"    Infants born to mothers with unknown or known positive HBsAg status must receive the first dose of vaccine within 12 hours of birth, and the second and third doses at one to two months and at six months, respectively. Administering the birth dose serves as a \"safety net\" to prevent perinatal infection among infants born to HBsAg positive mothers who were not identified because of erroneous maternal HBsAg testing or failure in reporting test results. In addition to providing early protection among infants at risk of perinatal infection, it is also associated with higher rates of on-time completion of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/39\">",
"     39",
"    </a>",
"    ]. Slight flexibility is permitted in the vaccination schedule for infants born to mothers with negative HBsAg status. The first dose should be administered before hospital discharge, the second dose at 1 to 2 months, and the third dose at 6 to 18 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vaccines should be administered intramuscularly since deposition of the vaccine into adipose tissue result in a lower seroconversion rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/51\">",
"     51",
"    </a>",
"    ]. Thus, the deltoid is the preferred site in adults while the vastus lateralis is preferred in infants. Longer needles should be used in overweight individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     What to do about a missed dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Longer than recommended intervals between doses do not reduce final antibody concentrations, although protection might not be attained until the recommended number of doses has been administered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/52-56\">",
"     52-56",
"    </a>",
"    ]. Thus, an interruption in the vaccination schedule does not require restarting the entire series of vaccination or adding extra doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. If the vaccination series is interrupted after the first dose, the second dose should be administered as soon as possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/30\">",
"     30",
"    </a>",
"    ]. The second and third doses should be separated by an interval of at least two months. If only the third dose is delayed, it should be administered when convenient.",
"   </p>",
"   <p>",
"    Although protective anti-HBs titers may be attained in some persons after only one or two doses of vaccine, completion of the full course (three doses) of vaccine is recommended to maximize the anti-HBs titer and duration of protection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     IMMUNIZATION SCHEDULE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunization schedule for hepatitis B is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/44/41670?source=see_link\">",
"     \"Approach to immunizations in healthy adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=see_link&amp;anchor=H10#H10\">",
"     \"Standard immunizations for children and adolescents\", section on 'Hepatitis B vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive immune response to the vaccine is defined as the development of hepatitis B surface antibody (anti-HBs) at a titer of &gt;10",
"    <span class=\"nowrap\">",
"     mIU/mL.",
"    </span>",
"    Although the level of 10",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    was arbitrarily chosen, clinical studies suggest that vaccinees with anti-HBs titer above this level are protected. The significance of this titer was illustrated in a five-year follow-up study of 773 homosexual men vaccinated in 1980; the acute infection rate increased seven times when the anti-HBs titer decreased below the level of 10",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using the definition of &gt;10",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    anti-HBs as a positive response, the overall seroconversion rate is about 95 percent in healthy adults. The rate decreases with increasing age to 86 percent in the fourth decade and 47 percent in the sixth decade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/60\">",
"     60",
"    </a>",
"    ]. The response rate is slightly lower in obese individuals, smokers, and men, and significantly lower in patients with cirrhosis or chronic renal failure, organ transplant recipients, children with celiac disease, and immunosuppressed patients. In patients on chronic hemodialysis, the response rate to recombinant vaccines is 50 to 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/61\">",
"     61",
"    </a>",
"    ]. Despite the lower seroconversion rate, the risk of hepatitis B infection is 70 percent lower in the vaccinated patients when compared with non-vaccinated patients undergoing chronic hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31718?source=see_link\">",
"     \"Evaluation for infection before solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     POSTVACCINATION TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the current hepatitis B vaccines have a response rate of 95 percent. Thus, routine post-vaccination testing to document anti-HBs seroconversion is unnecessary except in health-care workers, patients on chronic hemodialysis, and other individuals (such as spouses or sexual partners of carriers and infants of carrier mothers) who are at risk for recurrent exposure to hepatitis B. Testing should be performed one to two months after completion of the primary vaccination series (except for infants born to HBsAg positive mothers in whom testing should be performed at age 9 to 15 months). Nonresponders should complete a second three-dose vaccine series. The second three-dose course is successful in about 50 to 70 percent of patients. Retesting for anti-HBs should be repeated after the second vaccination series. Non-responders to the second course of vaccine should be tested for HBsAg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Duration of protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although anti-HBs titers decrease with time, the duration of protection is long. Protection has been estimated to persist for up to 22 years after the primary vaccination schedule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/59,63-67\">",
"     59,63-67",
"    </a>",
"    ]. Thus, most studies suggest that routine booster injections are not required (although there have been exceptions) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Protection from clinical disease despite declining (or even undetectable) anti-HBs levels is probably due to the priming of memory cells, which are capable of eliciting anamnestic response when challenged. This is supported by the rapid increases in anti-HBs titers in previously vaccinated individuals who are administered booster injections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/52\">",
"     52",
"    </a>",
"    ]. A spontaneous increase in anti-HBs titer has also been observed in association with anti-HBc seroconversion, indicating a rapid immune response to natural infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the durability of the anamnestic response is incompletely understood. A significant proportion of the vaccinated population loses both the protective levels of anti-HBs and an anamnestic response as illustrated by the following studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/69-72\">",
"     69-72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two reports of adolescents, an anamnestic response to booster vaccination 10 to 15 years after completing a three-dose vaccine series beginning at birth ranged from 48 to 70 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/70,72\">",
"       70,72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, 6156 high school students vaccinated with plasma-derived",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      as infants were screened serologically for sustained immunity after 15 to 18 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/71\">",
"       71",
"      </a>",
"      ]. The authors concluded that approximately 10 percent of the total population had lost their vaccine-conferred immune response.",
"     </li>",
"     <li>",
"      Another study found that approximately 25 percent of college students who were vaccinated at birth and who had undetectable anti-HBs failed to mount an anamnestic response to booster vaccinations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although it is possible that some of those who failed to respond to booster vaccination may be poor responders to the initial vaccination, this decay in immune memory raises questions about the need for surveillance for immunity and booster vaccine among high risk populations. In other studies, protection appeared to extend beyond 15 years in vaccinees who have a high titer anti-HBs response (&gt;100",
"    <span class=\"nowrap\">",
"     mIU/mL)",
"    </span>",
"    after the initial course of vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/63,72-74\">",
"     63,72-74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The need for booster is controversial and the practice varies from country to country. Most health authorities will agree that booster vaccination is recommended for patients on hemodialysis in whom vaccine-induced protection may persist only as long as the antibody level is above 10",
"    <span class=\"nowrap\">",
"     mIU/mL.",
"    </span>",
"    For these patients, the need for booster dose should be assessed annually and booster dose administered if the antibody level declines to &lt;10",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35959?source=see_link\">",
"     \"Immunizations in patients with end-stage renal disease\"",
"    </a>",
"    .) Recommendations for booster vaccination have also been proposed in a European consensus statement (",
"    <a class=\"graphic graphic_table graphicRef67035 \" href=\"mobipreview.htm?27/62/28652\">",
"     table 1",
"    </a>",
"    ). Countries like the Netherlands, Germany, Spain, France and Belgium recommend a booster dose depending on the post-vaccination anti-HBs titer. In the UK, a single booster dose is recommended five years after primary vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the US, a booster dose is not recommended for adults with normal immune status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/76\">",
"     76",
"    </a>",
"    ]. Nevertheless, the loss of an anamnestic response and the possible loss of immunity against hepatitis B after primary vaccination as described above suggest that these individuals may be at risk of acquiring hepatitis B infection. However, the magnitude of risk has not been well defined. As an example, in a study on 493 Alaskan Natives, a protective effect of anti-HBs was demonstrated in 87 percent of individuals 22 years after vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/77\">",
"     77",
"    </a>",
"    ]. Of the remaining 13 percent, none developed acute HBV.",
"   </p>",
"   <p>",
"    However, there is currently only weak evidence supporting the recommendations for booster vaccination. An ongoing study will help determine the durability of HBV vaccination and provide further insight on the utility of HBV booster vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In high-risk individuals (eg, healthcare workers), periodic testing for anti-HBs levels and the administration of a booster vaccine, when appropriate, may be required to maintain immunity. However, more data regarding the actual risk of acquiring hepatitis B infection among individuals who completed a course of vaccination as an infant or child are needed before recommendations on booster dose administration can be formulated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ADVERSE REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common adverse reaction is soreness over the site of injection, which occurs in fewer than 25 percent of the vaccinees. Other adverse reactions reported by 1 to 3 percent of vaccinees include low grade fever, malaise, headache, joint pain and myalgia. These adverse reactions are usually mild and do not result in any serious clinical sequelae. Hepatitis B vaccines have no teratogenic effects and can be administered during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32602?source=see_link\">",
"     \"Immunizations during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several rare adverse events have been described in case reports but the strength of these associations has not been clear.",
"   </p>",
"   <p>",
"    A series of reports on a possible association between hepatitis B vaccination and multiple sclerosis prompted the French Government in October 1998 to suspend routine school-based vaccination for hepatitis B. However, at least six subsequent studies from the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/81-86\">",
"     81-86",
"    </a>",
"    ] failed to show a statistically significant temporal or causal association between hepatitis B vaccination and multiple sclerosis. Based upon the current evidence and the proven benefit of the vaccine, the World Health Organization recommended that all countries should continue to have universal infant",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adolescent hepatitis B immunization programs and to immunize adults at risk of hepatitis B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF NONRESPONDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three main groups of vaccine nonresponders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with underlying medical conditions such as chronic kidney disease and immunosuppressed states. In patients undergoing hemodialysis, response rate to the standard dose of vaccine is between 50 and 60 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/61\">",
"       61",
"      </a>",
"      ]. This can be improved to above 70 percent by doubling the dose of the vaccine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/87\">",
"       87",
"      </a>",
"      ]. The response rate can also be improved by intradermal administration of the vaccine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/61\">",
"       61",
"      </a>",
"      ]. However, intradermal injections are technically difficult and inadvertent subcutaneous injections can result in diminished efficacy. The current policy for patients with chronic renal failure is to vaccinate them before commencement of hemodialysis. In the United States, higher doses of vaccine are recommended for patients who are already on hemodialysis or who are immunocompromised. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=see_link\">",
"       \"Treatment of hepatitis B in the HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The second group of nonresponders consists of healthy individuals in whom the lack of response appears to be genetically determined. Immunogenetics studies have demonstrated that these individuals lack a dominant response gene that controls the production of anti-HBs. The absence of this gene may be marked by two extended HLA haplotypes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/88\">",
"       88",
"      </a>",
"      ]. In a study from the United States, an increased incidence of individuals homozygous for the extended HLA haplotype -B8, SC01, DR3 was found among nonresponders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/88\">",
"       88",
"      </a>",
"      ]. Among the responders, individuals homozygous for this haplotype developed a lower antibody level compared to heterozygotes. In another study of 52 non-responders from Sweden, the HLA haplotype (DQB1*0604; DQA1*0102DRB1*1302) was more frequent in nonresponders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/89\">",
"       89",
"      </a>",
"      ]. However, the same HLA haplotypes could be found among responders and nonresponders suggesting that factors other than immunogenetics may be related to nonresponse to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      Individuals with celiac disease also appear to have a diminished response to HBV vaccination, possibly because of HLA haplotypes that predispose to both celiac disease and HepB vaccine nonresponse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/90,91\">",
"       90,91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The third group of nonresponders consists of individuals who failed to respond as a result of technical errors including intra-gluteal injection or inappropriate storage conditions such as inadvertent freezing of vaccines during shipment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current recommendation for all healthy individuals who have no or inadequate anti-HBs response to the primary vaccine series is to administer one or more additional doses. An adequate antibody response is seen in 15 to 25 percent after one additional dose and in 50 percent after three additional doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/30\">",
"     30",
"    </a>",
"    ]. As a result, it may be reasonable to repeat a three-dose schedule, retesting two to three months after the third dose. Individuals who fail to respond after three additional doses of vaccine have been appropriately administered are unlikely to benefit from further vaccination. However, these individuals may still mount an adequate immune response and recover from HBV infection. Individuals who fail to respond after two courses of HepB vaccine should be tested for HBsAg, particularly in countries where pre-vaccination testing is not performed or performed using anti-HBs test only.",
"   </p>",
"   <p>",
"    Additional strategies for vaccinating nonresponders continue to be studied. In a report that included 48 HepB vaccine nonresponders, vaccination with a double dose of the combined hepatitis A and B vaccine (Twinrix) at 0, 1, and 6 months led to protective anti-HBs levels in 59 and 95 percent after the first and third dose, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/92\">",
"     92",
"    </a>",
"    ]. These results support that nonresponders should receive a second course of HepB vaccine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     VACCINE-INDUCED HBV S ESCAPE MUTANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBV S gene mutants have been described in infants who were infected with hepatitis B despite an adequate anti-HBs response to hepatitis B vaccination. These mutants have been observed in many parts of the world including China, Singapore, Taiwan, Japan, Italy, and Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/93-98\">",
"     93-98",
"    </a>",
"    ].The most common mutation involves a glycine to arginine substitution at codon 145 in the \"a\" determinant of HBsAg. This mutation decreases binding of HBsAg to anti-HBs and may explain why these infants develop \"escape\" infection. The G145R mutation has also been observed in liver transplant recipients who developed recurrent HBV infection despite HBIG prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. Other mutations in the \"a\" determinant have also been described, but are of unclear significance.",
"   </p>",
"   <p>",
"    Most reports found that the HBV S mutations were not detected in the maternal carriers, suggesting that the mutations were selected by immune pressure (vaccine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    HBIG). A study from Taiwan demonstrated these mutants in infants who received HepB vaccine without HBIG indicating that the vaccine alone was sufficient to select the mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/101\">",
"     101",
"    </a>",
"    ]. These mutants can be detected in less than 5 percent of all infants who have received HBV vaccination and only 10 to 40 percent of the vaccine failures can be attributed to HBV S mutants. Experiments in chimpanzees confirmed that these mutants are infectious.",
"   </p>",
"   <p>",
"    There are concerns that the vaccine escape mutants have become more prevalent over time, causing acute infections in individuals who were previously vaccinated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/102\">",
"     102",
"    </a>",
"    ]. However, long-term follow-up of vaccination programs have not observed a progressive decline in the efficacy of HepB vaccines. A report from Taiwan found that the prevalence of HBV S mutants in HBV DNA positive children increased from 8 percent (8 of 103) in 1984 to 19.6 percent (10 of 51) in 1989, peaked at 28 percent (9 of 32) in 1994, and remained at 23 percent (3 of 13) in 1999 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/101\">",
"     101",
"    </a>",
"    ]. However, long-term follow-up of vaccination programs have not observed a progressive decline in the efficacy of HepB vaccines or an increase in the prevalence of HBV S mutants among the pediatric population. A report from Taiwan found that the prevalence of HBV S mutants among children &lt;15 years surveyed in 1984 and 2004 decreased from 0.67 to 0.10 percent, and prevalence of HBsAg decreased from 9.6 to 0.5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon available data, the benefits of conventional HepB vaccine far outweigh the concerns of HBV S escape mutants and vaccination programs should not be deterred because of these concerns. However, continued monitoring is necessary to determine if the prevalence of these mutants is increasing and if the protective efficacy of conventional vaccines is maintained. There is clearly a need for further research to develop vaccines that are more effective and which are capable of circumventing these mutations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     VACCINATION FROM A GLOBAL PERSPECTIVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, Hepatitis B vaccination can prevent HBV infection and its complications and is extremely cost-effective. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Indications'",
"    </a>",
"    above.) Nevertheless, many countries have not yet implemented universal vaccination. In Europe, as of March 2009, six countries (the United Kingdom, and the five Nordic countries) have not implemented universal vaccination because of the belief that hepatitis B is a limited public health problem that does not justify the expense and other efforts of universal vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/104\">",
"     104",
"    </a>",
"    ]. In developing and under-developed nations, health policies concentrate on more pressing needs such as food, clean water supply and sanitation. The high cost of hepatitis B vaccines and the lack of infrastructure to deliver the vaccines further impede the implementation of universal vaccination programs.",
"   </p>",
"   <p>",
"    The cost of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    has decreased due to economies of scale, local production of vaccines, competition among vaccine manufacturers, and bulk discounts obtained by the World Health Organization permitting many developing countries to initiate hepatitis B vaccine programs. The World Bank's 1993 Development Report stated that the addition of hepatitis B is the most cost-effective intervention in preventive care in developing countries. To further the cause of disease prevention through immunization, the Global Alliance for Vaccination and Immunization (GAVI) was launched in 2000 to harness the strength and experience of multiple partners in immunization. The Vaccine Fund, GAVI's financing arm listed hepatitis B vaccine as one of the vaccines that support may be provided for based on the country's proposal. Since its inception, GAVI has prevented more than 670,000 deaths by improving the delivery of vaccines to children in the poorest countries. Since 1999, the Vaccine Fund has raised more than $2.3 billion. However, WHO estimates that $8 to $12 billion will be needed from 2005 to 2010 to immunize children in the poorest countries, hence the call for donors, both private and public to step up the effort to close the immunization gap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the recognized benefit on public health, children in the poorest countries who depend upon donated vaccines continue to be denied hepatitis vaccine. In these countries, addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    to other childhood vaccines (such as BCG, DTP, polio, and measles) would double or triple the budget of the donors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/106\">",
"     106",
"    </a>",
"    ]. With the effort from GAVI, 42 million more children have been vaccinated with hepatitis B vaccine from 2001 to 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the concerted efforts of WHO, GAVI, and other public and private organizations, the coverage for hepatitis B vaccination has improved significantly. As of December 2007, 171 countries have incorporated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    into their national infant immunization programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/107\">",
"     107",
"    </a>",
"    ]. This is a significant increase from 151 countries in 2002. Of the 171 countries, 139 (72 percent) achieved &gt;80 percent third dose coverage. Thirty-one countries (16 percent) mainly in South-East Asia and Central Africa achieved &lt;80 percent third dose coverage. Globally, the third dose coverage of the vaccine for infants has reached 65 percent. The coverage is highest in North America (approximately 90 percent) but decreases to about 30 percent in South-East Asia where the disease prevalence is high.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     NEW DEVELOPMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for multiple dosing, the observation that 5 to 10 percent of vaccinees are non-responders, and reports of vaccine escape HBV S gene mutants remain a challenge for the production of a better vaccine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Ways to improve the application of the vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measures that can decrease the cost of manufacturing and delivery of vaccines are particularly important in under-developed countries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Combination vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     Hepatitis B vaccine",
"    </a>",
"    has been successfully combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/30/44518?source=see_link\">",
"     Hepatitis A vaccine",
"    </a>",
"    and with diphtheria, tetanus and acellular pertussis and inactivated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/58/35749?source=see_link\">",
"     poliovirus vaccine",
"    </a>",
"    without reducing its efficacy. These combination vaccines reduce the number of injections resulting in higher compliance. Known as the 4:3:1:3:3 vaccine series, it consists of &ge;4 doses of",
"    <span class=\"nowrap\">",
"     DTP/DT/DTaP,",
"    </span>",
"    &ge;3 doses of poliovirus vaccine, &ge;1 dose of any measles-containing vaccine, &ge;3 doses of Hib vaccine, and &ge;3 doses of hepatitis B vaccine. In the Healthy People 2010 goal, the coverage of this vaccine series was set at 80 percent. The coverage of this vaccine series has been steadily increasing in the United States among children age 19 to 35 months, from 73 percent in 2000 to 81 percent in 2004. This is significant as the goal set for Healthy People 2010 has already been achieved. However, the coverage varies from 89 percent in Massachusetts to 68 percent in Nevada. In areas with low coverage, continued effort to increase coverage is important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Single dose vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single dose vaccine has been developed in which HBsAg has been encapsulated in microparticles prepared from polylactide-co-glycolide and polylactide polymers. Both small (&lt;10 microns) and large (10 to 100 microns) particles are obtained with 80 percent of the particles encapsulated. Upon inoculation, the combination of small, large, encapsulated, and unencapsulated HBsAg particles are released at different times simulating multiple dosing. In a study in mice, a single injection of this compound vaccine induced comparable anti-HBs titers at one year compared to mice inoculated with three doses of the conventional vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/108\">",
"     108",
"    </a>",
"    ]. This vaccine remains to be tested in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Oral vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gene coding for HBsAg has been inserted into a virulent strain of recombinant Salmonella, which can be administered orally. The Salmonella produces HBsAg, which is presented to mucosal macrophages leading to the production of anti-HBs. This live vaccine has been successful in inducing an anti-HBs response in mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/109\">",
"     109",
"    </a>",
"    ]. However, concerns that the virulence of the recombinant Salmonella may be reversible have slowed the development of this vaccine. More recently, genetically engineered plants such as bananas and potatoes expressing HBsAg have been developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/110\">",
"     110",
"    </a>",
"    ]. One report described successful immunization of mice using an oral recombinant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    encapsulated in alginate chitosan nanoparticles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Inhaled vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intratracheal administration of a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    made with tetradecyl-beta-maltoside elicited a strong positive immune response in rodents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/112\">",
"     112",
"    </a>",
"    ]. An intranasal vaccine showed promise in a phase 1 study in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The oral and nasal routes of administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    require further evaluation but have the potential to increase the coverage of hepatitis B vaccination, especially in regions where facilities for parenteral administration are limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Ways to enhance immunogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of methods have been proposed to reduce the non-response rate of conventional vaccines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Intradermal inoculation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intradermal inoculation appears to be more immunogenic than intramuscular injections, but is technically more difficult to administer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/61,113,114\">",
"     61,113,114",
"    </a>",
"    ]. Several studies have evaluated intradermal versus intramuscular vaccination in patients with chronic kidney disease on dialysis (a group that generally has a suboptimal response to vaccination). A meta-analysis of 12 studies concluded that an initial response was more likely with the intradermal approach but the difference was no longer significant with follow-up (6 to 60 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In other studies, the increased efficacy of intradermal inoculation was also evident in intramuscular vaccine nonresponders. In one study, for example, 50 hemodialysis patients were revaccinated either intradermally or intramuscularly with a total dose of 80 mcg of recombinant vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/116\">",
"     116",
"    </a>",
"    ]. Seroconversion rates at 20 months were much higher in the group vaccinated intradermally (54 versus 0 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/116\">",
"     116",
"    </a>",
"    ]. Frequent low dose intradermal administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    may maintain protective anti-HBs levels in hemodialyzed patients who did not have an adequate immune response to hepatitis B vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/114\">",
"     114",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35959?source=see_link\">",
"     \"Immunizations in patients with end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     New adjuvants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concomitant administration of interferon alpha, interferon gamma, or interleukin-2 with conventional",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    augmented the immune response in patients undergoing hemodialysis in some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/117\">",
"     117",
"    </a>",
"    ], but discordant data have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/118\">",
"     118",
"    </a>",
"    ]. Other vaccines have incorporated more immunogenic adjuvants such as non-alum based monophosphoryl lipid A and MF-59 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/119,120\">",
"     119,120",
"    </a>",
"    ]. Preliminary studies suggest that these vaccines can induce higher titers of anti-HBs, but further studies are needed to confirm these results.",
"   </p>",
"   <p>",
"    Another vaccine combined HBsAg with an adjuvant containing 3'-deacylated monophosphoryl lipid A and alum (AS04) to enhance the immunogenicity. In a study involving 105 non-responders to commercially available",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    , aged 20 to 60 years,",
"    <span class=\"nowrap\">",
"     HBsAg/AS04",
"    </span>",
"    vaccine was compared against revaccination with commercially available hepatitis B vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/121\">",
"     121",
"    </a>",
"    ]. After three doses, the response rate was 98 percent compared to 68 percent among those inoculated with the conventional vaccine. The geometric mean anti-HBs titers (GMT) were also significantly higher than the group that received conventional vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/121\">",
"     121",
"    </a>",
"    ]. Other studies have reported a two dose regimen for this vaccine with superior GMTs compared to three doses of conventional vaccine. It is anticipated that a simpler vaccination schedule may increase compliance with completion of the vaccination regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/122,123\">",
"     122,123",
"    </a>",
"    ]. This vaccine is currently approved in Europe for patients older than 15 years of age with renal insufficiency, including those who are pre-hemodialysis and those on hemodialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Live recombinant vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results of studies using live recombinant vaccinia virus that express the HBV S gene in chimpanzees have been promising but more refinements are needed to ensure their safety in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     DNA vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccines that contain naked DNA (plasmids that contain the HBV S gene) can be injected intramuscularly. HBsAg is expressed in the muscle cells. The intracellular production of HBsAg stimulates production of anti-HBs. In addition, the newly synthesized HBsAg may be degraded within the muscle cells to form peptides, which are expressed on the cell surface together with HLA class I molecule stimulating the production of cytotoxic T-cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/124\">",
"     124",
"    </a>",
"    ]. The protective efficacy of the HBV DNA vaccine was demonstrated in two chimpanzees that were vaccinated at birth and boosted at 6 and 24 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/125\">",
"     125",
"    </a>",
"    ]. Although the production of anti-HBs was transient, both animals developed an anamnestic antibody response when challenged with an inoculum containing infectious doses of HBV at 33 weeks, and did not develop any markers of HBV infection. Data from human trials are not yet available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Pre-S vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HBV encodes three envelope proteins. The large S protein includes the pre-S1, pre-S2 and S regions, the middle S protein includes the pre-S2 and S regions, and the small S protein encodes the S region only. All three regions contain immunogenic T and B cell epitopes. Studies in mice found that addition of pre-S1 or pre-S2 regions may circumvent non-responsiveness to HBsAg. Preliminary clinical studies found that addition of pre-S2 region to conventional vaccine did not reduce the non-response rate in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/126\">",
"     126",
"    </a>",
"    ]. However, a study on 100 non-responders found that revaccination with a vaccine that contain pre-S1, pre-S2 and S regions induced higher rates of response than revaccination with another course of conventional vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/127\">",
"     127",
"    </a>",
"    ]. Sixty-nine percent of the vaccinees seroconverted after one single dose of the vaccine and one vaccinee seroconverted after a booster dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/127\">",
"     127",
"    </a>",
"    ]. These encouraging results remain to be confirmed in other studies. Another study reported positive response among the majority of non-responders to yeast-derived, single epitope recombinant vaccine after two doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    containing pre-S2 epitopes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/128\">",
"     128",
"    </a>",
"    ]. A third study showed a response rate of 71 percent after four doses of this vaccine among patients with chronic renal disease of whom about 75 percent were on chronic dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/129\">",
"     129",
"    </a>",
"    ]. In addition to its potential use in conventional vaccine non-responders, there were reports that this new class of vaccine resulted in high mean titers of anti-HBs earlier in the course of vaccination. This suggests higher immunogenicity for this class of vaccines compared to conventional yeast-derived recombinant vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/130,131\">",
"     130,131",
"    </a>",
"    ]. Currently, these vaccines are licensed for use in Israel, Western Europe and some Asian countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/60/31690/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     NEEDLE STICK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to HBV management after a needle stick exposure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23416?source=see_link\">",
"     \"Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/41/26258?source=see_link\">",
"       \"Patient information: Hepatitis B (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/45/31447?source=see_link\">",
"       \"Patient information: Hepatitis B (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no doubt that the development of hepatitis B vaccines is a major accomplishment in modern medicine.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     Hepatitis B vaccine",
"    </a>",
"    is effective not only in preventing HBV infection but also in preventing the sequelae of chronic HBV infection. It is the first example that cancer can be prevented by vaccination. Nevertheless, much work remains to achieve the goal of global eradication of HBV infection. Clearly, the costs of vaccines have to be reduced and the infrastructure for their delivery has to be simplified. As with other areas of medicine, new challenges frequently arise as old problems are solved.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/1\">",
"      McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005; 25 Suppl 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/2\">",
"      Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11:97.",
"     </a>",
"    </li>",
"    <li>",
"     WHO/UNICEF coverage estimates 2010 revision. July 2011: 193 WHO Member States",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/4\">",
"      Centers for Disease Control and Prevention (CDC). Hepatitis B vaccination coverage among adults--United States, 2004. MMWR Morb Mortal Wkly Rep 2006; 55:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/5\">",
"      Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan. MMWR 2005; 54:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/6\">",
"      Ni YH, Huang LM, Chang MH, et al. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology 2007; 132:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/7\">",
"      Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980; 303:833.",
"     </a>",
"    </li>",
"    <li>",
"     Immunization financing in developing countries and the international vaccine market: Trends and issues www.who.int/immunization_delivery/new_vaccines/14.immunization_financingindevelopingcountries.pdf (Accessed on October 17, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/9\">",
"      Stephenne J. Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. Vaccine 1990; 8 Suppl:S69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service. MMWR Morb Mortal Wkly Rep 1999; 48:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Recommendations regarding the use of vaccines that contain thimerosal as a preservative. MMWR Morb Mortal Wkly Rep 1999; 48:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/12\">",
"      Centers for Disease Control and Prevention (CDC). Availability of hepatitis B vaccine that does not contain thimerosal as a preservative. MMWR Morb Mortal Wkly Rep 1999; 48:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/13\">",
"      Young MD, Schneider DL, Zuckerman AJ, et al. Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine. Hepatology 2001; 34:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/14\">",
"      Rendi-Wagner P, Kundi M, Stemberger H, et al. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine 2001; 19:2055.",
"     </a>",
"    </li>",
"    <li>",
"     Blatter M, Joines R, Resinger K, et al. An open, randomized, controlled study to evaluate the safety and immunogenicity of SmithKline Beecham Biologicals' combined hepatitis A/hepatitis B (Twinrix&reg;) vaccine in adults (abstract 1629). In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco), American Society for Microbiology, Washington, DC 1999. p.394.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/16\">",
"      Abraham B, Parenti D. Antibody production in response to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine. J Infect Dis 2000; 182:1005.",
"     </a>",
"    </li>",
"    <li>",
"     Vaccine Names and Abbreviations www.immunization-sd.org/docs/iz78.pdf (Accessed on October 22, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/18\">",
"      Betancourt AA, Delgado CA, Est&eacute;vez ZC, et al. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int J Infect Dis 2007; 11:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/19\">",
"      Makidon PE, Bielinska AU, Nigavekar SS, et al. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS One 2008; 3:e2954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/20\">",
"      Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     US. Preventive Services Task Force. Screening for Hepatitis B infection. Recommendation statement 2004. Agency for Healthcare Research and Quality. Rockville, MD www.ahrq.gov/clinic/uspstf/uspshepb.htm (Accessed on March 01, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/22\">",
"      Lok AS, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/23\">",
"      Margolis HS, Coleman PJ, Brown RE, et al. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 1995; 274:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/24\">",
"      Stevens CE, Toy PT, Tong MJ, et al. Perinatal hepatitis B virus transmission in the United States. Prevention by passive-active immunization. JAMA 1985; 253:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/25\">",
"      Lee C, Gong Y, Brok J, et al. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev 2006; :CD004790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/26\">",
"      Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983; 2:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/27\">",
"      Wong VC, Ip HM, Reesink HW, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet 1984; 1:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/28\">",
"      Poovorawan Y, Sanpavat S, Pongpunlert W, et al. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA 1989; 261:3278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/29\">",
"      Lolekha S, Warachit B, Hirunyachote A, et al. Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand. Vaccine 2002; 20:3739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/30\">",
"      Hoofnagle JH. Toward universal vaccination against hepatitis B virus. N Engl J Med 1989; 321:1333.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Immunization, Vaccines and Biologicals. Hepatitis B vaccine www.who.int/vaccines/en/hepatitisb.shtml (Accessed on May 01, 2006).",
"    </li>",
"    <li>",
"     www.apps.who.int/immunization_monitoring/en/globalsummary/timeseries/tscove (Accessed on January 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/33\">",
"      Poovorawan Y, Chongsrisawat V, Theamboonlers A, et al. Long-term benefit of hepatitis B vaccination among children in Thailand with transient hepatitis B virus infection who were born to hepatitis B surface antigen-positive mothers. J Infect Dis 2009; 200:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/34\">",
"      Liang X, Bi S, Yang W, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis 2009; 200:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/35\">",
"      Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009; 101:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/36\">",
"      Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999; 12:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/37\">",
"      Ni YH, Chang MH, Wu JF, et al. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol 2012; 57:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/38\">",
"      Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/39\">",
"      Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/40\">",
"      Harpaz R, McMahon BJ, Margolis HS, et al. Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. J Infect Dis 2000; 181:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/41\">",
"      Centers for Disease Control and Prevention (CDC). Hepatitis B vaccination coverage among Asian and Pacific Islander children--United States, 1998. MMWR Morb Mortal Wkly Rep 2000; 49:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/42\">",
"      Mast EE, Williams IT, Alter MJ, Margolis HS. Hepatitis B vaccination of adolescent and adult high-risk groups in the United States. Vaccine 1998; 16 Suppl:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/43\">",
"      Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/44\">",
"      Kher A, Samama MM. Low-molecular-weight heparins: weeks or months instead of days of treatment. Clin Appl Thromb Hemost 2001; 7:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/45\">",
"      Horlander JC, Boyle N, Manam R, et al. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci 1999; 318:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/46\">",
"      Centers for Disease Control and Prevention (CDC). Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011; 60:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/47\">",
"      Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997; 336:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/48\">",
"      Hutton DW, Tan D, So SK, Brandeau ML. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med 2007; 147:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/49\">",
"      Lok AS, Lai CL, Wu PC. Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: implications in hepatitis B vaccination programs. Hepatology 1988; 8:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/50\">",
"      Shouval D. Hepatitis B vaccines. J Hepatol 2003; 39 Suppl 1:S70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/51\">",
"      Shaw FE Jr, Guess HA, Roets JM, et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 1989; 7:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/52\">",
"      Wistr&ouml;m J, Ahlm C, Lundberg S, et al. Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose. Vaccine 1999; 17:2162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/53\">",
"      Zechowy R, Rubin LG. Effect of the time interval between the first and second doses of hepatitis B vaccine on the antibody titer achieved after the third dose. Child Hos Q 1997; 9:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/54\">",
"      Middleman AB, Kozinetz CA, Robertson LM, et al. The effect of late doses on the achievement of seroprotection and antibody titer levels with hepatitis b immunization among adolescents. Pediatrics 2001; 107:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/55\">",
"      Halsey NA, Moulton LH, O'Donovan JC, et al. Hepatitis B vaccine administered to children and adolescents at yearly intervals. Pediatrics 1999; 103:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/56\">",
"      Heron LG, Chant KG, Jalaludin BB. A novel hepatitis B vaccination regimen for adolescents: two doses 12 months apart. Vaccine 2002; 20:3472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/57\">",
"      Saito K. Introductory remark of Dr. Rokuzo Kobayashi's achievements. Keio J Med 2002; 51 Suppl 2:2.",
"     </a>",
"    </li>",
"    <li>",
"     Hepatitis B vaccine: What you need to know. Available at: www.cdc.gov/vaccines/pubs/vis/downloads/vis-hep-b.pdf (Accessed on October 20, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/59\">",
"      Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/60\">",
"      Poland GA. Hepatitis B immunization in health care workers. Dealing with vaccine nonresponse. Am J Prev Med 1998; 15:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/61\">",
"      Propst T, Propst A, Lhotta K, et al. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am J Kidney Dis 1998; 32:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/62\">",
"      Miller ER, Alter MJ, Tokars JI. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis 1999; 33:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/63\">",
"      Liao SS, Li RC, Li H, et al. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine 1999; 17:2661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/64\">",
"      Lin HH, Wang LY, Hu CT, et al. Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan. J Med Virol 2003; 69:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/65\">",
"      Yuen MF, Lim WL, Chan AO, et al. 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clin Gastroenterol Hepatol 2004; 2:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/66\">",
"      McMahon BJ, Bruden DL, Petersen KM, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005; 142:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/67\">",
"      Zanetti AR, Mariano A, Roman&ograve; L, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/68\">",
"      Lu CY, Chiang BL, Chi WK, et al. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 2004; 40:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/69\">",
"      Jan CF, Huang KC, Chien YC, et al. Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology 2010; 51:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/70\">",
"      Bialek SR, Bower WA, Novak R, et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J 2008; 27:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/71\">",
"      Lu CY, Ni YH, Chiang BL, et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008; 197:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/72\">",
"      Chaves SS, Fischer G, Groeger J, et al. Persistence of long-term immunity to hepatitis B among adolescents immunized at birth. Vaccine 2012; 30:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/73\">",
"      Wainwright RB, McMahon BJ, Bulkow LR, et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA 1989; 261:2362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/74\">",
"      West DJ, Watson B, Lichtman J, et al. Persistence of immunologic memory for twelve years in children given hepatitis B vaccine in infancy. Pediatr Infect Dis J 1994; 13:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/75\">",
"      Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 2000; 355:561.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/vaccines/pubs/pinkbook/hepb.html (Accessed on April 24, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/77\">",
"      McMahon BJ, Dentinger CM, Bruden D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009; 200:1390.",
"     </a>",
"    </li>",
"    <li>",
"     file://clinicaltrial.gov/ct2/show/NCT01182311 (Accessed on January 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/79\">",
"      Ayoola EA, Johnson AO. Hepatitis B vaccine in pregnancy: immunogenicity, safety and transfer of antibodies to infants. Int J Gynaecol Obstet 1987; 25:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/80\">",
"      Levy M, Koren G. Hepatitis B vaccine in pregnancy: maternal and fetal safety. Am J Perinatol 1991; 8:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/81\">",
"      Shaw FE Jr, Graham DJ, Guess HA, et al. Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years. Am J Epidemiol 1988; 127:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/82\">",
"      McMahon BJ, Helminiak C, Wainwright RB, et al. Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons. Am J Med 1992; 92:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/83\">",
"      Niu MT, Davis DM, Ellenberg S. Recombinant hepatitis B vaccination of neonates and infants: emerging safety data from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 1996; 15:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/84\">",
"      Ascherio A, Zhang SM, Hern&aacute;n MA, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001; 344:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/85\">",
"      Hall A, Kane M, Roure C, Meheus A. Multiple sclerosis and hepatitis B vaccine? Vaccine 1999; 17:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/86\">",
"      Confavreux C, Suissa S, Saddier P, et al. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 2001; 344:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/87\">",
"      Peces R, de la Torre M, Alc&aacute;zar R, Urra JM. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am J Kidney Dis 1997; 29:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/88\">",
"      Alper CA, Kruskall MS, Marcus-Bagley D, et al. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 1989; 321:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/89\">",
"      Lang&ouml;-Warensj&ouml; A, Cardell K, Lindblom B. Haplotypes comprising subtypes of the DQB1*06 allele direct the antibody response after immunisation with hepatitis B surface antigen. Tissue Antigens 1998; 52:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/90\">",
"      Noh KW, Poland GA, Murray JA. Hepatitis B vaccine nonresponse and celiac disease. Am J Gastroenterol 2003; 98:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/91\">",
"      Park SD, Markowitz J, Pettei M, et al. Failure to respond to hepatitis B vaccine in children with celiac disease. J Pediatr Gastroenterol Nutr 2007; 44:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/92\">",
"      Cardell K, Akerlind B, S&auml;llberg M, Fryd&eacute;n A. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. J Infect Dis 2008; 198:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/93\">",
"      He JW, Lu Q, Zhu QR, et al. Mutations in the 'a' determinant of hepatitis B surface antigen among Chinese infants receiving active postexposure hepatitis B immunization. Vaccine 1998; 16:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/94\">",
"      Zuckerman AJ, Harrison TJ, Oon CJ. Mutations in S region of hepatitis B virus. Lancet 1994; 343:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/95\">",
"      Hsu HY, Chang MH, Ni YH, et al. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology 1997; 26:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/96\">",
"      Okamoto H, Yano K, Nozaki Y, et al. Mutations within the S gene of hepatitis B virus transmitted from mothers to babies immunized with hepatitis B immune globulin and vaccine. Pediatr Res 1992; 32:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/97\">",
"      Carman WF, Zanetti AR, Karayiannis P, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/98\">",
"      Fortuin M, Karthigesu V, Allison L, et al. Breakthrough infections and identification of a viral variant in Gambian children immunized with hepatitis B vaccine. J Infect Dis 1994; 169:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/99\">",
"      Ghany MG, Ayola B, Villamil FG, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/100\">",
"      Carman WF, Trautwein C, van Deursen FJ, et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996; 24:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/101\">",
"      Hsu HY, Chang MH, Ni YH, Chen HL. Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. Gut 2004; 53:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/102\">",
"      Kajiwara E, Tanaka Y, Ohashi T, et al. Hepatitis B caused by a hepatitis B surface antigen escape mutant. J Gastroenterol 2008; 43:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/103\">",
"      Hsu HY, Chang MH, Ni YH, et al. No increase in prevalence of hepatitis B surface antigen mutant in a population of children and adolescents who were fully covered by universal infant immunization. J Infect Dis 2010; 201:1192.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.euro.who.int/vaccine/diseases/20090127_15 (Accessed on May 23, 2010).",
"    </li>",
"    <li>",
"     Announcements-Bill and Melinda Gates Foundation file://www.gatesfoundation.org/globalhealth/pri_diseases/vaccines/announcements (Accessed on January 25, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/106\">",
"      Kane MA. Global status of hepatitis B immunisation. Lancet 1996; 348:696.",
"     </a>",
"    </li>",
"    <li>",
"     www.who.int/immunization_monitoring/diseases/hepatitis/en/index.html (Accessed on January 03, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/108\">",
"      Singh M, Li XM, McGee JP, et al. Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice. Vaccine 1997; 15:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/109\">",
"      Sch&ouml;del F, Milich DR, Will H. Hepatitis B virus nucleocapsid/pre-S2 fusion proteins expressed in attenuated Salmonella for oral vaccination. J Immunol 1990; 145:4317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/110\">",
"      Mason HS, Lam DM, Arntzen CJ. Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci U S A 1992; 89:11745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/111\">",
"      Borges O, Tavares J, de Sousa A, et al. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. Eur J Pharm Sci 2007; 32:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/112\">",
"      Thomas C, Rawat A, Bai S, Ahsan F. Feasibility study of inhaled hepatitis B vaccine formulated with tetradecylmaltoside. J Pharm Sci 2008; 97:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/113\">",
"      Rahman F, Dahmen A, Herzog-Hauff S, et al. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology 2000; 31:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/114\">",
"      Rault R, Freed B, Nespor S, Bender F. Efficacy of different hepatitis B vaccination strategies in patients receiving hemodialysis. ASAIO J 1995; 41:M717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/115\">",
"      Fabrizi F, Dixit V, Magnini M, et al. Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. Aliment Pharmacol Ther 2006; 24:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/116\">",
"      Fabrizi F, Andrulli S, Bacchini G, et al. Intradermal versus intramuscular hepatitis b re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. Nephrol Dial Transplant 1997; 12:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/117\">",
"      Quiroga JA, Carre&ntilde;o V. Interferon and hepatitis B vaccine in haemodialysis patients. Lancet 1989; 1:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/118\">",
"      Jungers P, Devillier P, Salomon H, et al. Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet 1994; 344:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/119\">",
"      Thoelen S, Van Damme P, Mathei C, et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 1998; 16:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/120\">",
"      Traquina P, Morandi M, Contorni M, Van Nest G. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J Infect Dis 1996; 174:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/121\">",
"      Jacques P, Moens G, Desombere I, et al. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine 2002; 20:3644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/122\">",
"      Levie K, Gjorup I, Skinh&oslash;j P, Stoffel M. A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults. Scand J Infect Dis 2002; 34:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/123\">",
"      Boland G, Beran J, Lievens M, et al. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 2004; 23:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/124\">",
"      Moss B, Smith GL, Gerin JL, Purcell RH. Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature 1984; 311:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/125\">",
"      Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/126\">",
"      Milich DR, Thornton GB, Neurath AR, et al. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 1985; 228:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/127\">",
"      Zuckerman JN, Sabin C, Craig FM, et al. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study. BMJ 1997; 314:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/128\">",
"      Suzuki H, Iino S, Shiraki K, et al. Safety and efficacy of a recombinant yeast-derived pre-S2 + S-containing hepatitis B vaccine (TGP-943): phase 1, 2 and 3 clinical testing. Vaccine 1994; 12:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/129\">",
"      Haubitz M, Ehlerding G, Beigel A, et al. Clinical experience with a new recombinant hepatitis-B vaccine in previous non-responders with chronic renal insufficiency. Clin Nephrol 1996; 45:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/130\">",
"      Yap I, Guan R, Chan SH. Study on the comparative immunogenicity of a recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein with non pre-S containing vaccines. J Gastroenterol Hepatol 1995; 10:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/60/31690/abstract/131\">",
"      Shapira MY, Zeira E, Adler R, Shouval D. Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine. J Hepatol 2001; 34:123.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3641 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-FA3CAE7412-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_60_31690=[""].join("\n");
var outline_f30_60_31690=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF VACCINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neonates of HBsAg positive mothers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      All neonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Premature infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Catch-up vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other high-risk groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Patients with markers of past infection do not need vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PREVACCINATION SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DOSE REGIMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      What to do about a missed dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      IMMUNIZATION SCHEDULE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      POSTVACCINATION TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Duration of protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ADVERSE REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MANAGEMENT OF NONRESPONDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      VACCINE-INDUCED HBV S ESCAPE MUTANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      VACCINATION FROM A GLOBAL PERSPECTIVE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      NEW DEVELOPMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Ways to improve the application of the vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Combination vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Single dose vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Oral vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Inhaled vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Ways to enhance immunogenicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Intradermal inoculation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - New adjuvants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Live recombinant vaccines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - DNA vaccines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Pre-S vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      NEEDLE STICK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3641\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3641|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/62/28652\" title=\"table 1\">",
"      Booster vaccination for HBV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/44/41670?source=related_link\">",
"      Approach to immunizations in healthy adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4602?source=related_link\">",
"      Epidemiology, transmission, and prevention of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31718?source=related_link\">",
"      Evaluation for infection before solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/63/37881?source=related_link\">",
"      Hepatitis viruses and the newborn: Clinical manifestations and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8569?source=related_link\">",
"      Immunizations for patients with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=related_link\">",
"      Immunizations for travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35959?source=related_link\">",
"      Immunizations in patients with end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23416?source=related_link\">",
"      Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/45/31447?source=related_link\">",
"      Patient information: Hepatitis B (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/41/26258?source=related_link\">",
"      Patient information: Hepatitis B (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_60_31691="Monitoring MEN2 FMTC";
var content_f30_60_31691=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F77855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F77855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Periodic clinical monitoring of carriers of an MEN2 or FMTC mutation depends on specific mutation in the RET gene",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Medullary thyroid carcinoma (MTC)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Preceding and after total thyroidectomy: annual utrasound of the neck",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Annual basal serum calcitonin and CEA level; if elevated at least biannual",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Pheochromocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Codons 634, 918",
"       </td>",
"       <td>",
"        From the age of&nbsp;five annually at least: serum fractionated metanephrines and/or normetanephrine / metanephrine in 24-hour urine collection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Codons 533, 609, 611, 618, 620, 630, 633, 666, 768, 790, 791, 804, 891",
"       </td>",
"       <td>",
"        From the age of 10 biennial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Hyperparathyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Codon 634",
"       </td>",
"       <td>",
"        Annual calcium, PTH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Codons 609, 611, 618, 620, 790, 791",
"       </td>",
"       <td>",
"        From the age of 10 biennial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Codons 768, 804, 891",
"       </td>",
"       <td>",
"        Hyperparathyroidism occurs infrequently",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Codons 883, 918, 922 (MEN2B)",
"       </td>",
"       <td>",
"        Hyperparathyroidism is not a feature",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_60_31691=[""].join("\n");
var outline_f30_60_31691=null;
var title_f30_60_31692="Zoonoses from Cats A";
var content_f30_60_31692=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Zoonoses cats",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Transmission",
"       </td>",
"       <td class=\"subtitle1\">",
"        Organism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Human symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Feline symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Geographic distribution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Infectious saliva",
"       </td>",
"       <td>",
"        Bartonella henselae",
"       </td>",
"       <td>",
"        Cat scratch disease, lymphadenopathy",
"       </td>",
"       <td>",
"        Asymptomatic even with bacteremia",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pasteurella",
"       </td>",
"       <td>",
"        Skin and soft-tissue infections, septic arthritis, osteomyelitis",
"       </td>",
"       <td>",
"        Asymptomatic",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rabies",
"       </td>",
"       <td>",
"        Acute progressive encephalitis",
"       </td>",
"       <td>",
"        Stages: prodromal, furious, and paralytic",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capnocytophaga",
"       </td>",
"       <td>",
"        Skin and soft-tissue infections, sepsis, meningitis",
"       </td>",
"       <td>",
"        Asymptomatic",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cowpox",
"       </td>",
"       <td>",
"        Painful, hemorrhagic pustules or black eschars",
"       </td>",
"       <td>",
"        Ulcerated, crusted focal skin lesions; systemic illness possible",
"       </td>",
"       <td>",
"        Europe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"6\">",
"        Fecal",
"       </td>",
"       <td>",
"        Salmonella Campylobacter Cryptosporidium Giardia",
"       </td>",
"       <td>",
"        Asymptomatic or gastroenteritis",
"       </td>",
"       <td>",
"        Asymptomatic or gastroenteritis",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxocara cati",
"       </td>",
"       <td>",
"        Visceral larva migrans and ocular larva migrans",
"       </td>",
"       <td>",
"        Asymptomatic",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ancylostoma caninum",
"       </td>",
"       <td>",
"        Cutaneous larva migrans",
"       </td>",
"       <td>",
"        Hookworm",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echinococcus granulosus",
"       </td>",
"       <td>",
"        Hydatid cysts, echinococcosis",
"       </td>",
"       <td>",
"        Hydatid cysts, echinococcosis",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxoplasma gondii",
"       </td>",
"       <td>",
"        Lymphadenopathy, cerebral, congenital infection",
"       </td>",
"       <td>",
"        Asymptomatic, may be associated with co-infection with feline leukemia virus or feline immuno- deficiency virus",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dipylidium caninum",
"       </td>",
"       <td>",
"        Asymptomatic to abdominal pain, diarrhea, pruritus ani, and urticaria",
"       </td>",
"       <td>",
"        Tapeworm",
"       </td>",
"       <td>",
"        Most common in ranching areas of the Mediterranean, South America, and Australia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_60_31692=[""].join("\n");
var outline_f30_60_31692=null;
var title_f30_60_31693="Contents: Dissociative disorders";
var content_f30_60_31693=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?41/24/42381\">",
"       Psychiatry",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Dissociative disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Dissociative disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/7/32888\">",
"           Depersonalization disorder: Epidemiology, pathogenesis, clinical manifestations, course, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/32/522\">",
"           Dissociative aspects of posttraumatic stress disorder: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/56/11146\">",
"           Dissociative identity disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/55/21367\">",
"           Treatment of depersonalization disorder",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-7537527282-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f30_60_31693=[""].join("\n");
var outline_f30_60_31693=null;
var title_f30_60_31694="Megakaryocyte number and volume";
var content_f30_60_31694=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F57865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F57865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Megakaryocyte number and volume in megakaryocyte disorders",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 264px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow analysis was performed in normal subjects and patients with a variety of hematological conditions: hypoplastic bone marrow states (Hypo), B12 deficiency (B12 def), congestive splenomegaly (Congest), immune thrombocytopenia (ITP), chronic inflammation (Inflam), and essential thrombocythemia (ET). Left panel: The number of megakaryocytes was reduced below normal only in hypoplastic bone marrow states and was variably increased in all other conditions examined. Right panel: Megakaryocyte volume was reduced below normal only in B12 deficiency and chronic inflammation, and was variably elevated in all other conditions. Megakaryocyte volume and ploidy are directly related to each other and are proportional to the amount of thrombopoietin present, except in essential thrombocythemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Harker LA, Finch CA. J Clin Invest 1969; 48:963.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_60_31694=[""].join("\n");
var outline_f30_60_31694=null;
var title_f30_60_31695="Motility medium Shigella";
var content_f30_60_31695=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60548%7EID%2F52747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60548%7EID%2F52747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Motility testing on nonlactose fermenting gram negative rods",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 221px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left tube: The nonmotile Shigella does not migrate away from the central stab line in the agar. Right tube: Motile Proteus produces visible opacification of the agar away from the central stab line. The color difference between the two samples is unrelated to the motility test.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael S Glickman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Shigella versus urease positive gram-negative rods on urea slant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 258px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urea slant shows the positive (pink) and negative (yellow) reactions that differentiate Proteus (left) from Shigella (right).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael S Glickman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_60_31695=[""].join("\n");
var outline_f30_60_31695=null;
